

=> fil reg

FILE 'REGISTRY' ENTERED AT 11:19:02 ON 13 APR 2012

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2012 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 APR 2012 HIGHEST RN 1367421-69-9

DICTIONARY FILE UPDATES: 12 APR 2012 HIGHEST RN 1367421-69-9

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH DECEMBER 23, 2011


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que 138

L5 STR



G3 17

VAR G1=1/6

VAR G2=O/N/S

VAR G3=8/12

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

L7 28963 SEA FILE=REGISTRY SSS FUL L5

L10 STR



A @13

REP G1=(1-20) 13

NODE ATTRIBUTES:

NSPEC IS RC AT 13

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 11




STEREO ATTRIBUTES: NONE

L12 797 SEA FILE=REGISTRY SUB=L7 SSS FUL L10

L33 STR



A @13



REP G1=(1-20) 13

VAR G2=15/18/21/COOH/SO3H

NODE ATTRIBUTES:

NSPEC IS RC AT 13

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

L35 24 SEA FILE=REGISTRY SUB=L12 SSS FUL L33

L37 8 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L35

L38 3 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L37 AND (1802-2003  
)/PRY,AY,PY

=> d 138 1-3 ibib ed abs hitstr hitind  
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:n

=> fil hcap  
FILE 'HCAPLUS' ENTERED AT 11:19:19 ON 13 APR 2012  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2012 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Apr 2012 VOL 156 ISS 17  
FILE LAST UPDATED: 12 Apr 2012 (20120412/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2011  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2011

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2011.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 138 1-3 ibib ed abs hitstr hitind

L38 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2012 ACS on STN  
ACCESSION NUMBER: 2005:568976 HCAPLUS Full-text  
DOCUMENT NUMBER: 143:83603  
TITLE: One-part self-etching, self-priming dental  
adhesive composition  
INVENTOR(S): Klee, Joachim E.; Lehmann, Uwe; Walz, Uwe  
PATENT ASSIGNEE(S): Dentsply Detrey GmbH, Germany  
SOURCE: Eur. Pat. Appl., 30 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 1548021	A1	20050629	EP 2003-29824	20031223
			<--	

EP 1548021 B1 20070321  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,  
 PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 AT 357450 T 20070415 AT 2003-29824 20031223  
 <--  
 CA 2551228 A1 20050714 CA 2004-2551228 20041215  
 <--  
 WO 2005063778 A1 20050714 WO 2004-EP14307 20041215  
 <--  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,  
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
 GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,  
 KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
 MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,  
 SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
 VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,  
 DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC,  
 NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,  
 GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 JP 2007520465 T 20070726 JP 2006-545998 20041215  
 <--  
 US 20070293642 A1 20071220 US 2007-596747 20070508  
 <--  
 PRIORITY APPLN. INFO.: EP 2003-29824 A 20031223  
 <--  
 WO 2004-EP14307 W 20041215

## ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

ED Entered STN: 01 Jul 2005


AB One-part self-etching, self-priming dental adhesive compn. having a pH of at most 2 comprises (a) a polymerizable acidic phosphoric acid ester monomer; (b) one or more polymerizable acidic monomers; (c) a polymerizable N-substituted alkylacrylic or acrylic acid amide monomer; (d) an org. and/or inorg. acid; (e) an org. water sol. solvent and/or water; and (f) polymn. initiator, inhibitor and stabilizer. An adhesive polymer was prepd. from 2-acrylamido-2-methyl-propane-sulfonic acid, 3,(4),8,(9)-bis(acrylamido methyl) tricyclo-5.2.1.02,6 decane, Et 2-[13-dihydrogen phosphoryl-13,2-dioxatridecyl]acrylate, and N,N'-bisacrylamido-N,N'-diethyl-1,3-propane.

IT 752234-98-3P 752235-00-0P 855894-56-3P

(one-part self-etching, self-priming dental adhesive compn.)


RN 752234-98-3 HCAPLUS

CN 2-Propenoic acid, 2-[[[10-(phosphonooxy)decyl]oxy]methyl]-, 1-ethyl ester (CA INDEX NAME)




RN 752235-00-0 HCAPLUS

CN 2-Propenoic acid, 2-[[2-(phosphonooxy)ethoxy]methyl]-, 1-ethyl ester (CA INDEX NAME)



RN 855894-56-3 HCAPLUS

CN 2-Propenoic acid, 2-[[2-(phosphonooxy)ethoxy)methyl]- (CA INDEX NAME)



IT 855894-57-4P, 2-Acrylamido-2-methyl-propane-sulfonic acid-3, (4), 8, (9)-bis(acrylamido methyl) tricyclo-5.2.1.02,6 decane-Ethyl 2-[13-dihydrogen phosphoryl-13,2-dioxatridecyl]acrylate-N,N'-Bisacrylamido-N,N'-diethyl-1,3-propane copolymer 855894-58-5P

(one-part self-etching, self-priming dental adhesive compn.)

RN 855894-57-4 HCAPLUS



CN 2-Propenoic acid, 2-[[[10-(phosphonooxy)decyl]oxy)methyl]-, 1-ethyl ester, polymer with 2-methyl-2-[(1-oxo-2-propen-1-yl)amino]-1-propanesulfonic acid, N,N-[[octahydro-4,7-methano-1H-indene-1,5(1,6 or 2,5)diyl]bis(methylene)]bis[2-propenamide] and N,N'-1,3-propanediylbis[N-ethyl-2-propenamide] (CA INDEX NAME)

CM 1

CRN 855532-00-2

CMF C18 H26 N2 O2


CCI IDS



CM 2

CRN 752234-98-3


CMF C16 H31 O7 P



CM 3

CRN 442200-41-1


CMF C13 H22 N2 O2



CM 4

CRN 15214-89-8

CMF C7 H13 N O4 S



RN 855894-58-5 HCAPLUS

CN 2-Propenoic acid, 2-[[2-(phosphonoxy)ethoxy)methyl]-, 1-ethyl ester, polymer with 2-methyl-2-[(1-oxo-2-propen-1-yl)amino]-1-propanesulfonic acid, N,N-[[octahydro-4,7-methano-1H-indene-1,5(1,6 or 2,5)diyl]bis(methylene)]bis[2-propenamide] and N,N'-1,3-propanediylbis[N-ethyl-2-propenamide] (CA INDEX NAME)



CM 1

CRN 855532-00-2

CMF C18 H26 N2 O2

CCI IDS


10/596,747



CM 2

CRN 752235-00-0


CMF C8 H15 O7 P



CM 3

CRN 442200-41-1


CMF C13 H22 N2 O2



CM 4

CRN 15214-89-8

CMF C7 H13 N O4 S



IPCI C07F0009-00 [I,C]; A61K0006-00 [I,C]; A61K0006-02 [I,C]; C08F0030-00

[I,C]; C07F0009-09 [I,A]; A61K0006-00 [I,A]; A61K0006-083 [I,A];  
C08F0030-02 [I,A]  
IPCR A61K0006-00 [I,A]; A61K0006-083 [I,A]; C07F0009-09 [I,A]; C08F0030-02  
[I,A]  
CC 63-8 (Pharmaceuticals)  
IT 752234-97-2P 752234-98-3P 752234-99-4P  
752235-00-0P 855894-56-3P  
(one-part self-etching, self-priming dental adhesive compn.)  
IT 855894-57-4P, 2-Acrylamido-2-methyl-propane-sulfonic  
acid-3, (4), 8, (9)-bis(acrylamido methyl) tricyclo-5.2.1.02,6  
decane-Ethyl 2-[13-dihydrogen phosphoryl-13,2-dioxatridecyl]acrylate-  
N,N'-Bisacrylamido-N,N'-diethyl-1,3-propane copolymer  
855894-58-5P  
(one-part self-etching, self-priming dental adhesive compn.)  
OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS  
RECORD (7 CITINGS)  
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
RE FORMAT

L38 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2012 ACS on STN  
ACCESSION NUMBER: 2005:182218 HCAPLUS Full-text  
DOCUMENT NUMBER: 142:287808  
TITLE: Lithographic printing plate precursor for direct  
imaging from a digital data and developing in a  
printing machine without passing through a  
development step  
INVENTOR(S): Yamasaki, Sumiaki; Makino, Naonori; Inno,  
Toshifumi  
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan  
SOURCE: U.S. Pat. Appl. Publ., 50 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050048398	A1	20050303	US 2004-896070	20040722
			<--	
US 7183038	B2	20070227		
EP 1500498	A2	20050126	EP 2004-17306	20040722
			<--	
EP 1500498	A3	20051012		
EP 1500498	B1	20101215		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2005238816	A	20050908	JP 2004-214190	20040722
			<--	
AT 491968	T	20110115	AT 2004-17306	20040722
			<--	
PRIORITY APPLN. INFO.:			JP 2003-277448	A 20030722
			<--	
			JP 2004-652	A 20040105



10/596,747

JP 2004-17599 A 20040126


JP 2004-214190 A 20040722

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 142:287808

ED Entered STN: 04 Mar 2005

GI



AB A lithog. printing plate precursor is described for recording an image directly from a digital data and development in a printing machine without passing through a development step. The precursor provides lithog. printing plates with improved press life and stain resistance. Thus, the precursor coating compn. comprises an image-forming layer contg. a polymn. initiator and a polymerizable compd., and a hydrophilic support. The compn. includes a compd. contg. at least one functional group interacting with a surface of the hydrophilic support. This compd. is one of a phosphonic acid and a phosphoric acid amide.


IT 847226-71-5

(lithog. printing plate precursor for direct imaging from digital data and in-press development)

RN 847226-71-5 HCAPLUS

CN 2-Propenoic acid, 2-(15,15-dihydroxy-15-oxido-2,5,8,11,14-pentaoxa-15-phosphapentadec-1-yl)-, 1-ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




IT 847204-83-5 847204-84-6

(phosphonic deriv.; lithog. printing plate precursor for direct imaging from digital data and in-press development)

RN 847204-83-5 HCAPLUS


CN	2-Propenoic acid, 2-(9,9-dihydroxy-9-oxido-2,5,8-trioxa-9-phosphanon-1-yl)-, 1-methyl ester (CA INDEX NAME)
----	---



RN 847204-84-6 HCAPLUS

CN 2-Propenoic acid, 2-(15,15-dihydroxy-15-oxido-2,5,8,11,14-pentaoxa-15-phosphapentadec-1-yl)-, 1-methyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

$$-\text{OPO}_3\text{H}_2$$

INCL 430270100

IPCI G03C0001-77 [I,A]; G03C0001-91 [I,A]; G03F0007-028 [I,A]; G03F0007-038 [I,A]; G03F0007-09 [I,A]

IPCR G03F0007-027 [I,A]; B41C0001-10 [I,A]; B41N0001-08 [I,A]; B41N0001-14 [I,A]; B41N0003-03 [I,A]; G03F0007-00 [I,A]; G03C0001-77 [I,A]; G03C0001-91 [I,A]; G03F0007-028 [I,A]; G03F0007-038 [I,A]; G03F0007-09 [I,A]

NCL 430/270.100; 430/271.100; 101/456.000; 101/457.000; 101/459.000;  
101/467.000; 430/278.100; 430/281.100; 430/302.000; 430/325.000;  
430/944.000

CC 74-5 (Radiation Chemistry, Photochemistry, and Photographic and Other Reprographic Processes)

IT	847204-87-9	847204-88-0	847204-89-1	847204-90-4	847204-91-5
----	-------------	-------------	-------------	-------------	-------------

(lithog. printing plate precursor for direct imaging from digital data and in-press development)

IT	80730-17-2	223681-84-3	847204-73-3	847204-74-4	847204-75-5
	847204-76-6	847204-77-7	847204-78-8	847204-82-4	
	<del>847204-83-5</del>	<del>847204-84-6</del>	847204-85-7		
	847232-64-8				

(phosphonic deriv.; lithog. printing plate precursor for direct imaging from digital data and in-press development)

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS

REFERENCE COUNT: 25 RECORD (8 CITINGS)  
THERE ARE 25 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
RE FORMAT

L38 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2012 ACS on STN  
ACCESSION NUMBER: 2004:732258 HCAPLUS Full-text  
DOCUMENT NUMBER: 141:243056  
TITLE: Polymerizable phosphoric acid ester derivatives  
for dental compositions  
INVENTOR(S): Klee, Joachim E.; Lehmann, Uwe; Walz, Uwe; Liu,  
Huaibing  
PATENT ASSIGNEE(S): Dentsply Detrey GmbH, Germany  
SOURCE: Eur. Pat. Appl., 20 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1454911	A1	20040908	EP 2003-5174	20030307
<--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CA 2518202	A1	20040916	CA 2004-2518202	20040305
<--				
WO 2004078100	A2	20040916	WO 2004-EP2289	20040305
<--				
WO 2004078100	A3	20041028		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1601679	A2	20051207	EP 2004-717576	20040305
<--				
EP 1601679	B1	20110511		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2006520344	T	20060907	JP 2006-504563	20040305
<--				
JP 4594297	B2	20101208		
US 20060246017	A1	20061102	US 2006-548362	20060626
<--				
PRIORITY APPLN. INFO.:			EP 2003-5174	A 20030307
<--				
			WO 2004-EP2289	W 20040305


ED Entered STN: 09 Sep 2004

AB The present invention provides a polymerizable phosphoric acid ester deriv. for use in dental compns. E.g.,  
 2,2,2-tris(2,6-dioxa-4-methylene-5-oxo-octyl)ethanol phosphoric acid ester was prepd. from pentaerythritol, Et chloromethyacrylate, and then treatment with the product with POCl<sub>3</sub> and hydrolyzed.

IT 752234-96-1P 752234-98-3P 752235-00-0P  
 (polymerizable phosphoric acid ester derivs. for dental compns.)


RN 752234-96-1 HCAPLUS

CN 2-Propenoic acid, 2,2'-[[2-[[[2-(ethoxycarbonyl)-2-propenyl]oxy]methyl]-2-[(phosphonooxy)methyl]-1,3-propanediyl]bis(oxymethylene)]bis-, 1,1'-diethyl ester (9CI) (CA INDEX NAME)




RN 752234-98-3 HCAPLUS

CN 2-Propenoic acid, 2-[[[10-(phosphonooxy)decyl]oxy]methyl]-, 1-ethyl ester (CA INDEX NAME)



RN 752235-00-0 HCAPLUS

CN 2-Propenoic acid, 2-[[2-(phosphonooxy)ethoxy]methyl]-, 1-ethyl ester (CA INDEX NAME)



IPCI C07F0009-09 [ICM,7]; A61K0006-08 [ICS,7]; C08F0030-02 [ICS,7]  
 IPCR A61K0006-00 [I,A]; A61K0006-08 [I,A]; A61K0006-083 [I,A]; C07F0009-09 [I,A]; C08F0030-02 [I,A]  
 CC 23-17 (Aliphatic Compounds)  
 Section cross-reference(s): 63

IT 752234-96-1P 752234-98-3P 752235-00-0P  
 (polymerizable phosphoric acid ester derivs. for dental compns.)

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE




10/596,747

RE FORMAT

=&gt; d que 139

L5 STR

SO3H @6 G1 7



G3 17

VAR G1=1/6

VAR G2=O/N/S

VAR G3=8/12

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

L7 28963 SEA FILE=REGISTRY SSS FUL L5

L10 STR



REP G1=(1-20) 13

NODE ATTRIBUTES:

NSPEC IS RC AT 13

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:



RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

L12 797 SEA FILE=REGISTRY SUB=L7 SSS FUL L10

L16 STR



A @19

REP G1=(1-20) 19

VAR G2=6/16

NODE ATTRIBUTES:

NSPEC IS RC AT 19

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED





GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L18 13442 SEA FILE=REGISTRY SUB=L7 SSS FUL L16  
 L20 14 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L12 AND L18  
 L21 8 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L20  
 L22 400 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L12  
 L23 13991 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L18  
 L27 37 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L22 AND L23  
 L28 20 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L27 AND (1802-2003  
 ) /PRY,AY,PY  
 L29 2 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L21 AND (1802-2003  
 ) /PRY,AY,PY  
 L30 20 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L28 OR L29  
 L33 STR



REP G1=(1-20) 13

VAR G2=15/18/21/COOH/SO3H

NODE ATTRIBUTES:

NSPEC IS RC AT 13

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

L35 24 SEA FILE=REGISTRY SUB=L12 SSS FUL L33  
L37 8 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L35  
L38 3 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L37 AND (1802-2003  
)/PRY,AY,PY  
L39 19 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L30 NOT L38

=> d l39 1-19 ibib ed abs hitstr hitind

L39 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2005:33579 HCAPLUS Full-text

DOCUMENT NUMBER: 142:115528

TITLE: Ethylene-vinyl acetate copolymer emulsions, their  
manufacture, and adhesive compositions thereof  
with balanced heat resistance and low-temperature  
properties

INVENTOR(S): Yako, Manabu; Yamamoto, Hiroki

PATENT ASSIGNEE(S): Denki Kagaku Kogyo Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
JP 2005008718	A	20050113	JP 2003-172880	20030618
			<--	
JP 4041534	B2	20080130		
PRIORITY APPLN. INFO.:			JP 2003-172880	20030618
			<--	

OTHER SOURCE(S): MARPAT 142:115528

ED Entered STN: 14 Jan 2005

AB The emulsions have av. particle size .gtoreq.3 .mu.m and nonvolatile fraction .gtoreq.70% and are manufd. by using 0.2-3.0 parts/100 parts vinyl acetate (I) of reactive surfactants having structures H2C:CHCH2OCOCH(SO3Na)CH2CO2R (R = H, alkyl), H2C:CHCH2OCH2CH(CH2OC6H4R) (OCH2CH2)nOX (n = 1-50; X = H, SO3NH4; R = C5-12 alkyl), or [H2C:CHCH2O(CH2CH2MeO)n]mP(O)(OH)3-m (n = 1-50; m = 1-2) and 0.5-4.0 parts/100 parts I of vinyl alc. polymer (PVA) with sapon. degree 60-85 mol% and av. d.p. 100-500 as emulsifiers in polymn. Thus, 70 parts I and 25 parts ethylene were polyimd. in an aq. soln. contg. 3 parts PVA (UMR 10H; sapon. degree 80 mol%, d.p. 400), 1 part sulfosuccinate-type reactive emulsifier (Elemiol JS 2), nonionic surfactants (Emulgen 913, Emulgen 950), NaOAc, Rongalit, FeSO4.7H2O, EDTA.4Na, and ammonium persulfate, then 30 parts I was added dropwise to the soln. and polyimd. to give an EVA emulsion showing nonvolatile fraction 71.1%, av. particle size 5.1 .mu.m, viscosity 1800 mPa-s at 30.degree. and 30 rpm, and PhMe-insol. fraction 42%.

IT 820213-85-2F

(manuf. of ethylene-vinyl acetate polymer emulsions by using  
reactive emulsifier and poly(vinyl alc.) for cold- and  
heat-resistant adhesives)

RN 820213-85-2 HCAPLUS



CN Acetic acid ethenyl ester, polymer with ethene and  
 .alpha.-sulfo-.omega.-[1-[(nonylphenoxy)methyl]-2-(2-  
 propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt, graft (9CI)  
 (CA INDEX NAME)

CM 1


CRN 113405-85-9

CMF (C2 H4 O)<sub>n</sub> C21 H34 O6 S . H3 N

CCI IDS, PMS




D1-(CH<sub>2</sub>)<sub>8</sub>-Me



CM 2

CRN 108-05-4


CMF C4 H6 O2



CM 3

CRN 74-85-1

CMF C2 H4




IT 86271-46-7, Allyl sodium sulfosuccinate  
 220308-52-1, Polypropylene glycol monoallyl ether, phosphate

(reactive emulsifier; manuf. of ethylene-vinyl acetate polymer emulsions by using reactive emulsifier and poly(vinyl alc.) for cold- and heat-resistant adhesives)


RN 86271-46-7 HCAPLUS

CN Butanedioic acid, 2-sulfo-, 1-(2-propen-1-yl) ester, sodium salt (1:1)  
(CA INDEX NAME)



RN 220308-52-1 HCAPLUS

CN Poly[oxy(methyl-1,2-ethanediyl)],  
.alpha.-phosphono-.omega.-(2-propen-1-yloxy)- (CA INDEX NAME)



IPCI C08F0210-00 [I,A]; C08F0218-08 [I,A]; C08F0002-24 [I,A]; C09J0131-04 [I,A]; C09J0011-08 [I,A]

IPCR C08F0002-24 [I,A]; C08F0010-00 [I,A]; C09J0011-08 [I,A]; C09J0131-04 [I,A]; C08F0210-00 [I,A]; C08F0218-08 [I,A]

CC 38-3 (Plastics Fabrication and Uses)

IT 820213-84-1P, Eleminol JS 2-ethylene-vinyl acetate copolymer  
820213-85-2P 820233-84-9P

(manuf. of ethylene-vinyl acetate polymer emulsions by using reactive emulsifier and poly(vinyl alc.) for cold- and heat-resistant adhesives)

IT 86271-46-7, Allyl sodium sulfosuccinate

220308-52-1, Polypropylene glycol monoallyl ether, phosphate  
(reactive emulsifier; manuf. of ethylene-vinyl acetate polymer emulsions by using reactive emulsifier and poly(vinyl alc.) for cold- and heat-resistant adhesives)

L39 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2004:856797 HCAPLUS Full-text

DOCUMENT NUMBER: 141:350862

TITLE: Reactive liquid polymer crosslinking agent and process for preparation

INVENTOR(S): Lazar, Warren G.; Clark, James A.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. Ser. No. 13,164, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20040200993	A1	20041014	US 2004-833816	20040427
			<--	
US 20030168629	A1	20030911	US 2001-13164	20011210
			<--	
PRIORITY APPLN. INFO.:			US 2001-13164	B2 20011210
			<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


ED Entered STN: 18 Oct 2004

AB A reactive liq. crosslinking agent for use in the prepn. of polymeric substances. The crosslinking agent comprises a substituted 1,3,5-triazine reacted with H<sub>2</sub>O, an acid alkyl sulfonate and/or phosphonate and a solidifying modifier contg. an hydroxyl functional group to form a substituted 1,3,5-triazine hydrate. The reactive liq. polymer crosslinking agent has a solids content between 20-99% solids. The reactive liq. crosslinking agents (RLPC's) are useful as modifiers in the prepn. of polymeric compds. which are suitable for 1-component self-crosslinking adhesives, coatings and polymers used in optics, textiles, composites, casting and molding. RLPC systems contg. from 1-30% RLPC provide fast single package thermosetting polymeric compds. with enhanced properties such as chem., heat and abrasion resistance.

IT 15214-89-8D, 2-Acrylamido-2-methylpropanesulfonic acid, reaction products with triazine and polyethylene glycol  
111083-74-0D, reaction products with triazine and diol  
(reactive liq. polymer crosslinking agent)


RN 15214-89-8 HCAPLUS

CN 1-Propanesulfonic acid, 2-methyl-2-[(1-oxo-2-propen-1-yl)amino]- (CA INDEX NAME)



RN 111083-74-0 HCAPLUS

CN Titanate(3-), [2,2-bis[(2-propen-1-yloxy)methyl]-1-butanolato-.kappa.O][P,P-diocetyl diphosphato(2-)-.kappa.O''']bis[P,P-diocetyl diphosphato(2-)-.kappa.O'',.kappa.O''']-, hydrogen (1:3) (CA INDEX NAME)



● 3 H<sup>+</sup>

INCL 252182130  
 IPCI C09K0003-00 [ICM,7]  
 IPCR C08F0008-30 [I,A]; C09D0167-00 [I,A]; C09J0167-00 [I,A]  
 NCL 252/182.130  
 CC 37-6 (Plastics Manufacture and Processing)  
 IT 57-50-1D, Sucrose, alkylglycosides, reaction products with triazine and sulfonylzirconate 98-11-3D, Phenylsulfonic acid, reaction products with triazine and diethylene glycol 107-21-1D, Ethylene glycol, reaction products with triazine and sulfonyltitanate 108-78-1D, 2,4,6-Triamino-1,3,5-triazine, reaction products with phenylphosphoric acid 110-63-4D, 1,4-Butanediol, reaction products with triazine and phosphatotitanate 111-46-6D, Diethylene glycol, reaction products with phenylsulfonic acid and triazine 504-63-2D, 1,3-Propylene glycol, reaction products with triazine and sulfonate 629-11-8D, 1,6-Hexanediol, reaction products with triazine and phosphatotitanate 1571-33-1D, Phenylphosphonic acid, reaction products with triazine 5606-17-7D, reaction products with sulfonate and propylene glycol 5606-19-9D, reaction products with polypropylene glycol and sulfate ester 15214-89-8D, 2-Acrylamido-2-methylpropanesulfonic acid, reaction products with triazine and polyethylene glycol 25322-68-3D, Polyethylene glycol, reaction products with triazine and sulfonate 25322-69-4D, Polypropylene glycol, reaction products with triazine and sulfate ester 89619-91-0D, reaction products with alkylglycosides and sulfonylzirconate 103406-74-2D, reaction products with triazine and ethylene glycol 109766-35-0D, reaction products with triazine and alkylglycosides 111083-74-0D, reaction products with triazine and diol 544651-50-5D, reaction products with sulfonate and polyethylene glycol 544651-51-6D, reaction products with phosphate

ester and polyethylene glycol 544651-52-7D, reaction products with  
phosphotitanate and diol  
(reactive liq. polymer crosslinking agent)

L39 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN  
ACCESSION NUMBER: 2004:467829 HCAPLUS Full-text  
DOCUMENT NUMBER: 141:27260  
TITLE: Defoaming agent for cementitious composition  
INVENTOR(S): Lorenz, Klaus; Yaguchi, Minoru; Sugiyama, Tomomi;  
Albrecht, Gerhard  
PATENT ASSIGNEE(S): Die Construction Research & Technology G.m.b.H.,  
Germany  
SOURCE: PCT Int. Appl., 22 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048293	A1	20040610	WO 2002-EP13328	20021125
<--				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506950	A1	20040610	CA 2002-2506950	20021125
<--				
CA 2506950	C	20100601		
AU 2002365282	A1	20040618	AU 2002-365282	20021125
<--				
EP 1565416	A1	20050824	EP 2002-808177	20021125
<--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20060148976	A1	20060706	US 2006-534606	20060222
<--				
US 7662882	B2	20100216		
PRIORITY APPLN. INFO.:			WO 2002-EP13328	W 20021125
<--				

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


ED Entered STN: 10 Jun 2004

AB A defoaming agent, for cementitious compns., has an excellent defoaming performance and does not segregate when mixed with a high performance air entraining AE water-reducing agent to form a single admixt. or when dild. in H2O at the desired concn., and which has excellent long term storage properties. The defoaming agent is obtained by mixing .gtoreq.1 polyethylene oxide deriv. and a nonionic defoaming agent, where the polyethylene oxide deriv. has at one end a hydrophobic group with a branched structure and/or an unsatd. bond and at the other end an anionic group.


IT 136931-77-6P 478019-97-5P 478019-98-6P  
 478020-00-7P 478020-01-8P 478020-02-9P  
 (antifoaming agents for cement compns. contg. nonionic antifoaming  
 agents and polyethylene oxide derivs.)  
 RN 136931-77-6 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(4-  
 nonylphenoxy)methyl]-2-(2-propen-1-yloxy)ethoxy]-, ammonium salt (1:1)  
 (CA INDEX NAME)




RN 478019-97-5 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[[3-phenyl-2-  
 propenyl]oxy]methyl]-2-(2-propenyloxy)ethoxy]-, ammonium salt (9CI)  
 (CA INDEX NAME)




RN 478019-98-6 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(1-  
 naphthalenyloxy)methyl]-2-(2-propenyloxy)ethoxy]-, ammonium salt (9CI)  
 (CA INDEX NAME)




RN 478020-00-7 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-phenyl-2-(2-propenyloxy)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)



RN 478020-01-8 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1,2-diphenyl-2-(2-propenyloxy)ethoxy]-, disodium salt (9CI) (CA INDEX NAME)



RN 478020-02-9 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(2-propenyloxy)methyl]-2-[(2-propenyl)phenoxy]ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)



IPCI C04B0040-00 [ICM,7]; C04B0024-32 [ICS,7]; C04B0024-16 [ICS,7]  
 IPCR C04B0024-16 [I,A]; C04B0024-24 [I,A]; C04B0024-32 [I,A]; C04B0040-00 [I,A]  
 CC 58-1 (Cement, Concrete, and Related Building Materials)  
 Section cross-reference(s): 38

IT 31691-97-1P 59764-60-2P 136931-77-6P 171407-73-1P  
 478019-97-5P 478019-98-6P 478019-99-7P  
 478020-00-7P 478020-01-8P 478020-02-9P  
 478020-04-1P

(antifoaming agents for cement compns. contg. nonionic antifoaming agents and polyethylene oxide derivs.)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2003:472494 HCAPLUS Full-text

DOCUMENT NUMBER: 139:53794

TITLE: Reactive liquid polymer crosslinking agent and preparation

INVENTOR(S): Lazar, Warren G.; Clark, James A.

PATENT ASSIGNEE(S): LCB Worldwide Inc., USA

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003050094	A1	20030619	WO 2002-US38058	20021126
<--				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030168629	A1	20030911	US 2001-13164	20011210
<--				
AU 2002366570	A1	20030623	AU 2002-366570	20021126
<--				
PRIORITY APPLN. INFO.:			US 2001-13164	A 20011210
<--				
			WO 2002-US38058	W 20021126
<--				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

ED Entered STN: 20 Jun 2003

AB A reactive liq. crosslinking agent for use in the prepn. of polymeric substances. The crosslinking agent comprises a substituted (e.g. butylated) 1,3,5-triazine reacted with H2O, an acid alkyl sulfonate and/or phosphonate and a solidifying modifier contg. an hydroxyl functional group. The reactive liq. polymer crosslinking agent has a solids content 20-99% solids. The reactive liq. crosslinking agents (RLPC's) are useful as modifiers in the prepn. of polymeric compds. which are suitable for 1-component self-crosslinking adhesives, coatings and polymers used in optics, textiles, composites, casting and molding. Systems




contg. 1-30% RLPC provide fast single package thermosetting polymeric compds. with enhanced properties such as chem., heat and abrasion resistance.

```


IT      15214-89-8D, 2-Acrylamido-2-methylpropanesulfonic acid,
        reaction products with triazine and polyethylene glycol
        111083-74-0D, reaction products with triazine and diol
        (reactive liq. polymer crosslinking agent reaction product of
        substituted triazine, water, sulfonate or phosphonate, and hydroxy
        compd.)
RN      15214-89-8   HCAPLUS
CN      1-Propanesulfonic acid, 2-methyl-2-[(1-oxo-2-propen-1-yl)amino]-  (CA
        INDEX NAME)

```



RN	111083-74-0	HCAPLUS
CN	Titanate(3-), [2,2-bis[(2-propen-1-yloxy)methyl]-1-butanolato-.kappa.O][P,P-dioctyl diphosphato(2-)-.kappa.O''']bis[P,P-dioctyl diphosphato(2-)-.kappa.O''',.kappa.O''''']-, hydrogen (1:3) (CA INDEX NAME)	

PAGE 1-A



PAGE 2-A

IPCI C07D0251-54 [ICM,7]; C07D0251-66 [ICS,7]; C09K0003-00 [ICS,7]  
 IPCR C08F0008-30 [I,A]; C09D0167-00 [I,A]; C09J0167-00 [I,A]  
 CC 37-6 (Plastics Manufacture and Processing)  
 IT 57-50-1D, Sucrose, alkylglycosides, reaction products with triazine and sulfonylzirconate 98-11-3D, Phenylsulfonic acid, reaction products with triazine and diethylene glycol 107-21-1D, Ethylene glycol, reaction products with triazine and sulfonyltitanate 108-78-1D, 2,4,6-Triamino-1,3,5-triazine, reaction products with phenylphosphoric acid 110-63-4D, Butane-1,4-diol, reaction products with triazine and phosphatotitanate 111-46-6D, Diethylene glycol, reaction products with phenylsulfonic acid and triazine 504-63-2D, 1,3-Propylene glycol, reaction products with triazine and sulfonate 629-11-8D, Hexane-1,6-diol, reaction products with triazine and phosphatotitanate 1571-33-1D, Phenylphosphonic acid, reaction products with triazine 5606-17-7D, reaction products with sulfonate and propylene glycol 5606-19-9D, reaction products with polypropylene glycol and sulfate ester 15214-89-8D, 2-Acrylamido-2-methylpropanesulfonic acid, reaction products with triazine and polyethylene glycol 25322-68-3D, Polyethylene glycol, reaction products with triazine and sulfonate 25322-69-4D, Polypropylene glycol, reaction products with triazine and sulfate ester 89619-91-0D, reaction products with alkylglycosides and sulfonylzirconate 103406-74-2D, reaction products with triazine and ethylene glycol 109766-35-0D, reaction products with triazine and alkylglycosides 111083-74-0D, reaction products with triazine and diol 544651-50-5D, reaction products with sulfonate and polyethylene glycol 544651-51-6D, reaction products with phosphate ester and polyethylene glycol 544651-52-7D, reaction products with phosphotitanate and diol  
 (reactive liq. polymer crosslinking agent reaction product of substituted triazine, water, sulfonate or phosphonate, and hydroxy compd.)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 2003:222046 HCAPLUS Full-text  
 DOCUMENT NUMBER: 138:260046  
 TITLE: Method for controlling scale formation and deposition in aqueous systems  
 INVENTOR(S): Buentello, Kristin E.; Kessler, Stephen M.; May, Roger C.; Kaechelin, Julie A.; Chen, Fu; Kolson, Natalie A.  
 PATENT ASSIGNEE(S): Betzdearborn Inc., USA  
 SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. 6,444,747.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20030052303	A1	20030320	US 2001-878646	20010611

```

                                <--
US 6641754          B2      20031104
US 6444747          B1      20020903      US 2001-808679      20010315
                                <--
CA 2440435          A1      20021010      CA 2002-2440435      20020301
                                <--
CA 2440435          C       20100608
WO 2002079106       A1      20021010      WO 2002-US6370      20020301
                                <--
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
    CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
    GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
    LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
    NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
    TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
    CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
    SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
    SN, TD, TG
AU 2002314719       A1      20021015      AU 2002-314719      20020301
                                <--
AU 2002314719       B2      20070426
EP 1379475          A1      20040114      EP 2002-741643      20020301
                                <--
EP 1379475          B1      20090708
R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
    PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
HU 2003003535       A2      20040128      HU 2003-3535      20020301
                                <--
HU 2003003535       A3      20080328
BR 2002008127       A       20040323      BR 2002-8127      20020301
                                <--
CN 1496338          A       20040512      CN 2002-806631      20020301
                                <--
CN 1262489          C       20060705
JP 2004528439       T       20040916      JP 2002-577740      20020301
                                <--
NZ 528038           A       20050527      NZ 2002-528038      20020301
                                <--
AT 435839           T       20090715      AT 2002-741643      20020301
                                <--
PT 1379475          E       20090901      PT 2002-741643      20020301
                                <--
ES 2326960          T3      20091022      ES 2002-741643      20020301
                                <--
PL 204918           B1      20100226      PL 2002-363968      20020301
                                <--
TW 300060           B       20080821      TW 2002-104266      20020307
                                <--
IN 2003KN00910      A       20050708      IN 2003-KN910      20030715
                                <--
US 20040039144      A1      20040226      US 2003-646278      20030822
                                <--
US 7094852          B2      20060822
KR 904789           B1      20090625      KR 2003-7011900      20030909
                                <--



```

NO 2003004049	A	20031104	NO 2003-4049	20030912
			<--	
MX 2003008342	A	20041015	MX 2003-8342	20030912
			<--	
AU 2007202743	A1	20070705	AU 2007-202743	20070613
			<--	
AU 2007202743	B2	20081120		
PRIORITY APPLN. INFO.:			US 2001-808679	A2 20010315
			<--	
			US 2001-806679	A 20010315
			<--	
			US 2001-878646	A 20010611
			<--	
			AU 2002-314719	A3 20020301
			<--	
			WO 2002-US6370	W 20020301
			<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

ED Entered STN: 21 Mar 2003

GI




AB A method for inhibiting the formation and deposition of scale forming moieties in aq. systems by adding water-sol. or water-dispersible polymers is disclosed. The method comprises adding to an aq. system a polymer having repeat units characterized by I, wherein E is the repeat unit remaining after polymn. of an ethylenically unsatd. compd.; preferably, a carboxylic acid, sulfonic acid, phosphonic acid, or amide form thereof or mixts. thereof, R1 is H or lower (C1-C4) alkyl, G is -CH2- or -CHCH3-; R2 is CH2-CH2-On or CH2-CHCH3-n where n ranges from about 1 to 100, preferably about 1 to 20, X is an anionic radical selected from the group consisting

of SO<sub>3</sub>, PO<sub>3</sub>, or COO; Z is H or hydrogens or any water sol. cationic moiety which counterbalances the valence of the anionic radical X, including but not limited to Na, K, Ca, or NH<sub>4</sub>, F, when present, is a repeat unit having the structure of II, wherein X and Z are the same as in Formula I. R<sub>4</sub> is H or lower (C<sub>1</sub>-C<sub>4</sub>) alkyl, R<sub>5</sub> is hydroxy substituted alkyl or alkylene having from about 1 to 6 of carbon atoms.

IT 171439-08-0P 330666-77-8P 452311-66-9P  
 452311-67-0P 452311-68-1P 452311-69-2P  
 452311-70-5P 502546-09-0P, Acrylic acid-ethylene  
 oxide-allyloxy-2-hydroxypropane-3-sulfonic acid graft terpolymer,  
 ammonium sulfate 502546-11-4P  
 (method for controlling scale formation and deposition in aq.  
 systems)

RN 171439-08-0 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-(2-propen-1-yloxy)-  
 (CA INDEX NAME)



RN 330666-77-8 HCAPLUS


CN 2-Propenoic acid, polymer with  
 .alpha.-sulfo-.omega.-(2-propen-1-yloxy)poly(oxy-1,2-ethanediyl)  
 ammonium salt (1:1) (CA INDEX NAME)

CM 1

CRN 55866-85-8

CMF (C2 H4 O)<sub>n</sub> C3 H6 O4 S . H3 N


CCI PMS



CM 2

CRN 79-10-7


CMF C3 H4 O2



RN 452311-66-9 HCAPLUS  
 CN 2-Propenoic acid, polymer with  
 2-hydroxy-3-(2-propen-1-yloxy)-1-propanesulfonic acid and  
 .alpha.-sulfo-.omega.-(2-propen-1-yloxy)poly(oxy-1,2-ethanediyl)  
 ammonium salt (1:1) (CA INDEX NAME)


CM 1

CRN 94928-31-1  
 CMF C6 H12 O5 S




CM 2

CRN 55866-85-8  
 CMF (C2 H4 O)n C3 H6 O4 S . H3 N  
 CCI PMS



CM 3

CRN 79-10-7  
 CMF C3 H4 O2




RN 452311-67-0 HCAPLUS  
 CN 2-Propenoic acid, 2-methyl-, polymer with 2-propenoic acid and  
 .alpha.-sulfo-.omega.-(2-propen-1-yloxy)poly(oxy-1,2-ethanediyl)  
 ammonium salt (1:1) (CA INDEX NAME)

CM 1


10/596,747

CRN 55866-85-8  
 CMF (C2 H4 O)<sub>n</sub> C3 H6 O4 S . H3 N  
 CCI PMS




CM 2

CRN 79-41-4  
 CMF C4 H6 O2



CM 3


CRN 79-10-7  
 CMF C3 H4 O2



RN 452311-68-1 HCAPLUS  
 CN 2-Propenoic acid, polymer with  
 2-methyl-2-[(1-oxo-2-propen-1-yl)amino]-1-propanesulfonic acid and  
 .alpha.-sulfo-.omega.-(2-propen-1-yloxy)poly(oxy-1,2-ethanediyl)  
 ammonium salt (1:1) (CA INDEX NAME)

CM 1


CRN 55866-85-8  
 CMF (C2 H4 O)<sub>n</sub> C3 H6 O4 S . H3 N  
 CCI PMS



CM 2

CRN 15214-89-8


CMF C7 H13 N O4 S



CM 3

CRN 79-10-7

CMF C3 H4 O2



RN 452311-69-2 HCAPLUS


CN 2-Propenoic acid, polymer with  
 .alpha.-phosphono-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl)  
 (9CI) (CA INDEX NAME)

CM 1

CRN 171439-08-0

CMF (C2 H4 O)<sub>n</sub> C3 H7 O4 P


CCI PMS





CM 2


CRN 79-10-7  
CMF C3 H4 O2



RN 452311-70-5 HCAPLUS  
CN 2-Propenoic acid, polymer with  
.alpha.-sulfo-.omega.-(2-propen-1-yloxy)poly(oxy-1,2-ethanediyl) (CA  
INDEX NAME)


CM 1

CRN 201605-73-4  
CMF (C2 H4 O)<sub>n</sub> C3 H6 O4 S  
CCI PMS



CM 2


CRN 79-10-7  
CMF C3 H4 O2



RN 502546-09-0 HCAPLUS  
CN 2-Propenoic acid, polymer with  
2-hydroxy-3-(2-propenyloxy)-1-propanesulfonic acid and oxirane,  
hydrogen sulfate, graft, ammonium salt (9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9  
CMF H2 O4 S



CM 2

CRN 502546-08-9


CMF (C6 H12 O5 S . C3 H4 O2 . C2 H4 O) x

CCI PMS

CM 3

CRN 94928-31-1


CMF C6 H12 O5 S



CM 4

CRN 79-10-7

CMF C3 H4 O2



CM 5

CRN 75-21-8

CMF C2 H4 O



RN 502546-11-4 HCAPLUS

CN 2-Propenoic acid, polymer with


10/596,747

2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid and  
oxirane, hydrogen sulfate (ester), graft, ammonium salt (9CI) (CA  
INDEX NAME)

CM 1

CRN 7664-93-9

CMF H2 O4 S



CM 2

CRN 164578-98-7


CMF (C7 H13 N O4 S . C3 H4 O2 . C2 H4 O) x

CCI PMS

CM 3

CRN 15214-89-8


CMF C7 H13 N O4 S



CM 4

CRN 79-10-7

CMF C3 H4 O2



CM 5

CRN 75-21-8  
CMF C2 H4 O



INCL 252175000  
IPCI C02F0005-02 [ICM,7]  
IPCR F25D0017-02 [I,A]; C02F0005-00 [I,A]; C02F0005-10 [I,A]; C02F0005-12 [I,A]; C02F0005-14 [I,A]; C08F0216-14 [I,A]; C23F0011-16 [I,A]; C23F0011-167 [I,A]  
NCL 252/175.000; 252/180.000; 252/181.000; 524/807.000; 526/287.000  
CC 61-8 (Water)  
IT 171439-08-0P 330666-77-8P 452311-66-9P  
452311-67-0P 452311-68-1P 452311-69-2P  
452311-70-5P 502546-07-8P, Acrylic acid-ethylene oxide graft copolymer, ammonium sulfate 502546-09-0P, Acrylic acid-ethylene oxide-allyloxy-2-hydroxypropane-3-sulfonic acid graft terpolymer, ammonium sulfate 502546-11-4P 502546-12-5P 502546-13-6P  
(method for controlling scale formation and deposition in aq. systems)

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L39 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN  
ACCESSION NUMBER: 2002:945818 HCAPLUS Full-text  
DOCUMENT NUMBER: 138:28220  
TITLE: Antifoaming agents for cement compositions showing segregation resistance when being mixed with high-performance air entraining water reducing agents or water  
INVENTOR(S): Lorentz, Claus; Yaguchi, Minoru; Sugiyama, Tomomi; Albrecht, Gerhard  
PATENT ASSIGNEE(S): NMB K. K., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
JP 2002356356	A	20021213	JP 2001-164388	20010531
			<--	
PRIORITY APPLN. INFO.:			JP 2001-164388	20010531
			<--	

ED Entered STN: 13 Dec 2002


AB The antifoaming agents contain nonionic antifoaming agents and polyethylene oxide derivs. having one anionic terminals and branched and/or unsatd. hydrophobic terminals on the other end.

IT 136931-77-6P 478019-97-5P 478019-98-6P  
478020-00-7P 478020-01-8P 478020-02-9P

(antifoaming agents for cement compns. contg. nonionic antifoaming agents and polyethylene oxide derivs.)


RN 136931-77-6 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(4-nonylphenoxy)methyl]-2-(2-propen-1-yloxy)ethoxy]-, ammonium salt (1:1)  
(CA INDEX NAME)




RN 478019-97-5 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(3-phenyl-2-propenyl)oxy]methyl]-2-(2-propenyloxy)ethoxy]-, ammonium salt (9CI)  
(CA INDEX NAME)




RN 478019-98-6 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(1-naphthalenyloxy)methyl]-2-(2-propenyloxy)ethoxy]-, ammonium salt (9CI)  
(CA INDEX NAME)




RN 478020-00-7 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-phenyl-2-(2-propenyloxy)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 478020-01-8 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1,2-diphenyl-2-(2-propenyloxy)ethoxy]-, disodium salt (9CI) (CA INDEX NAME)



RN 478020-02-9 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(2-propenyloxy)methyl]-2-[(2-propenyl)phenoxy]ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)



● NH<sub>3</sub>

IPCI C04B0024-28 [ICM,7]; B01D0019-04 [ICS,7]; C04B0024-32 [ICS,7];  
 C08G0065-338 [ICS,7]; C04B0103-50 [ICS,7]  
 IPCR B01D0019-04 [I,A]; C04B0024-28 [I,A]; C04B0024-32 [I,A]; C04B0103-50  
 [N,A]; C08G0065-338 [I,A]  
 CC 58-1 (Cement, Concrete, and Related Building Materials)  
 Section cross-reference(s): 38  
 IT 31691-97-1P 59764-60-2P 136931-77-6P 171407-73-1P  
 478019-97-5P 478019-98-6P 478019-99-7P  
 478020-00-7P 478020-01-8P 478020-02-9P  
 478020-04-1P  
 (antifoaming agents for cement compns. contg. nonionic antifoaming  
 agents and polyethylene oxide derivs.)

L39 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 2002:777854 HCAPLUS Full-text  
 DOCUMENT NUMBER: 137:299503  
 TITLE: Method for controlling scale formation and  
 deposition in aqueous systems  
 INVENTOR(S): Chen, Fu; Kolson, Natalie A.; Buentello, Kristin  
 E.; Kaechel, Julie A.; Kessler, Stephen M.; May,  
 Roger C.  
 PATENT ASSIGNEE(S): Betzdearborn Inc., USA  
 SOURCE: PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002079106	A1	20021010	WO 2002-US6370	20020301

<--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
 NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
 TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,  
 CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,  
 SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

10/596,747

US 6444747	B1	20020903	US 2001-808679	20010315
			<--	
US 20030052303	A1	20030320	US 2001-878646	20010611
			<--	
US 6641754	B2	20031104		
CA 2440435	A1	20021010	CA 2002-2440435	20020301
			<--	
CA 2440435	C	20100608		
AU 2002314719	A1	20021015	AU 2002-314719	20020301
			<--	
AU 2002314719	B2	20070426		
EP 1379475	A1	20040114	EP 2002-741643	20020301
			<--	
EP 1379475	B1	20090708		
			R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,	
			PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
HU 2003003535	A2	20040128	HU 2003-3535	20020301
			<--	
HU 2003003535	A3	20080328		
BR 2002008127	A	20040323	BR 2002-8127	20020301
			<--	
JP 2004528439	T	20040916	JP 2002-577740	20020301
			<--	
NZ 528038	A	20050527	NZ 2002-528038	20020301
			<--	
AT 435839	T	20090715	AT 2002-741643	20020301
			<--	
IN 2003KN00910	A	20050708	IN 2003-KN910	20030715
			<--	
KR 904789	B1	20090625	KR 2003-7011900	20030909
			<--	
NO 2003004049	A	20031104	NO 2003-4049	20030912
			<--	
MX 2003008342	A	20041015	MX 2003-8342	20030912
			<--	
AU 2007202743	A1	20070705	AU 2007-202743	20070613
			<--	
AU 2007202743	B2	20081120		
PRIORITY APPLN. INFO.:			US 2001-806679	A 20010315
			<--	
			US 2001-808679	A 20010315
			<--	
			US 2001-878646	A 20010611
			<--	
			AU 2002-314719	A3 20020301
			<--	
			WO 2002-US6370	W 20020301
			<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


ED Entered STN: 11 Oct 2002

AB A water sol. or water dispersible polymer compn., useful as scale and/or corrosion inhibitors in aq. systems has the formula [E]<sub>c</sub>[CH<sub>2</sub>CR<sub>1</sub>(GOR<sub>2</sub>XZ)]<sub>d</sub>[F]<sub>e</sub> wherein E is the repeating unit remaining after polymn. of an ethylenically unsatd. compd., preferably, a carboxylic acid, sulfonic acid, phosphonic acid, or amide form thereof or mixts. thereof; R<sub>1</sub> is H or lower C1-4 alkyl; G is CH<sub>2</sub> or CHMe; R<sub>2</sub> is (CH<sub>2</sub>CH<sub>2</sub>O)<sub>n</sub> or (CH<sub>2</sub>CHMeO)<sub>m</sub> where n and m range from about 1 to 100, preferably n




is greater than 10 and m ranges from about 1 to 20; X is an anionic radical selected from the group consisting of SO<sub>3</sub>, PO<sub>3</sub>, or CO<sub>2</sub>; Z is H or hydrogens or any water sol. cationic moiety which counterbalances the valence of the anionic radical X, including but not limited to Na, K, Ca, or NH<sub>4</sub>; F, when present, is a repeating unit having the structure of formula [CH<sub>2</sub>CR<sub>4</sub>(CH<sub>2</sub>OR<sub>5</sub>XZ)] wherein X and Z are the same as above, R<sub>4</sub> is H or a lower C1-4 alkyl, and R<sub>5</sub> is a hydroxy-substituted alkyl or alkylene having from about 1 to 6 carbon atoms. This water sol. or water dispersible polymer compn. is useful: as scale deposit control and corrosion inhibition agents in water treatment or gas scrubbing processes, in pulp and paper manufg. processes, in pretreating of metals; as rheol. modifiers for concrete and cement additives; as cleaning agents for membranes; and as hydrophilic modifier components in personal care, cosmetic and pharmaceutical formulations.

- IT 171439-08-0P, Poly(oxy-1,2-ethanediyl),  
.alpha.-phosphono-.omega.-(2-propenyloxy)- 330666-77-8P,  
2-Propenoic acid, polymer with  
.alpha.-sulfo-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl) ammonium  
salt 452311-66-9P, 2-Propenoic acid, polymer with  
2-hydroxy-3-(2-propenyloxy)-1-propanesulfonic acid and  
.alpha.-sulfo-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl) ammonium  
salt 452311-67-0P, 2-Propenoic acid, 2-methyl-, polymer  
with 2-propenoic acid and .alpha.-sulfo-.omega.-(2-  
propenyloxy)poly(oxy-1,2-ethanediyl) ammonium salt  
452311-68-1P, 2-Propenoic acid, polymer with  
2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid and  
.alpha.-sulfo-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl) ammonium  
salt 452311-69-2P, 2-Propenoic acid, polymer with  
.alpha.-phosphono-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl)  
452311-70-5P, 2-Propenoic acid, polymer with  
.alpha.-sulfo-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl)  
452311-71-6P  
(water sol. or water dispersible polymers as scale and/or corrosion  
inhibitors in aq. systems)
- RN 171439-08-0 HCAPLUS
- CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-(2-propen-1-yloxy)-  
(CA INDEX NAME)




- RN 330666-77-8 HCAPLUS
- CN 2-Propenoic acid, polymer with  
.alpha.-sulfo-.omega.-(2-propen-1-yloxy)poly(oxy-1,2-ethanediyl)  
ammonium salt (1:1) (CA INDEX NAME)
- CM 1
- CRN 55866-85-8
- CMF (C2 H4 O)<sub>n</sub> C3 H6 O4 S . H3 N
- CCI PMS



CM 2

CRN 79-10-7  
CMF C3 H4 O2




RN 452311-66-9 HCAPLUS

CN 2-Propenoic acid, polymer with  
2-hydroxy-3-(2-propen-1-yloxy)-1-propanesulfonic acid and  
.alpha.-sulfo-.omega.-(2-propen-1-yloxy)poly(oxy-1,2-ethanediyl)  
ammonium salt (1:1) (CA INDEX NAME)


CM 1

CRN 94928-31-1  
CMF C6 H12 O5 S




CM 2

CRN 55866-85-8  
CMF (C2 H4 O)n C3 H6 O4 S . H3 N  
CCI PMS



CM 3

CRN 79-10-7  
 CMF C3 H4 O2




RN 452311-67-0 HCAPLUS

CN 2-Propenoic acid, 2-methyl-, polymer with 2-propenoic acid and  
 .alpha.-sulfo-.omega.-(2-propen-1-yloxy)poly(oxy-1,2-ethanediyl)  
 ammonium salt (1:1) (CA INDEX NAME)


CM 1

CRN 55866-85-8  
 CMF (C2 H4 O)<sub>n</sub> C3 H6 O4 S . H3 N  
 CCI PMS




CM 2

CRN 79-41-4  
 CMF C4 H6 O2



CM 3

CRN 79-10-7  
 CMF C3 H4 O2




RN 452311-68-1 HCAPLUS  
 CN 2-Propenoic acid, polymer with  
 2-methyl-2-[(1-oxo-2-propen-1-yl)amino]-1-propanesulfonic acid and  
 .alpha.-sulfo-.omega.-(2-propen-1-yloxy)poly(oxy-1,2-ethanediyl)  
 ammonium salt (1:1) (CA INDEX NAME)

CM 1

CRN 55866-85-8

CMF (C2 H4 O)<sub>n</sub> C3 H6 O4 S . H3 N


CCI PMS



CM 2

CRN 15214-89-8


CMF C7 H13 N O4 S



CM 3

CRN 79-10-7


CMF C3 H4 O2



RN 452311-69-2 HCAPLUS  
 CN 2-Propenoic acid, polymer with  
 .alpha.-phosphono-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl)  
 (9CI) (CA INDEX NAME)


CM 1

CRN 171439-08-0  
 CMF (C2 H4 O)<sub>n</sub> C3 H7 O4 P  
 CCI PMS



CM 2


CRN 79-10-7  
 CMF C3 H4 O2



RN 452311-70-5 HCAPLUS  
 CN 2-Propenoic acid, polymer with  
 .alpha.-sulfo-.omega.-(2-propen-1-yloxy)poly(oxy-1,2-ethanediyl) (CA  
 INDEX NAME)


CM 1

CRN 201605-73-4  
 CMF (C2 H4 O)<sub>n</sub> C3 H6 O4 S  
 CCI PMS




CM 2


CRN 79-10-7  
 CMF C3 H4 O2



RN 452311-71-6 HCAPLUS  
 CN 2-Propenoic acid, 2-methyl-, polymer with  
 .alpha.-sulfo-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl) ammonium  
 salt (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 55866-85-8  
 CMF (C2 H4 O)n C3 H6 O4 S . H3 N  
 CCI PMS



CM 2  
 CRN 79-41-4  
 CMF C4 H6 O2



IPCI C02F0005-10 [ICM,7]; C08F0216-14 [ICS,7]  
 IPCR F25D0017-02 [I,A]; C02F0005-00 [I,A]; C02F0005-10 [I,A]; C02F0005-12  
 [I,A]; C02F0005-14 [I,A]; C08F0216-14 [I,A]; C23F0011-16 [I,A];  
 C23F0011-167 [I,A]  
 CC 61-8 (Water)  
 Section cross-reference(s): 35, 43, 58, 59, 62, 63  
 IT 171439-08-0P, Poly(oxy-1,2-ethanediyl),  
 .alpha.-phosphono-.omega.-(2-propenyloxy)- 330666-77-8P,  
 2-Propenoic acid, polymer with  
 .alpha.-sulfo-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl) ammonium  
 salt 452311-66-9P, 2-Propenoic acid, polymer with  
 2-hydroxy-3-(2-propenyloxy)-1-propanesulfonic acid and  
 .alpha.-sulfo-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl) ammonium  
 salt 452311-67-0P, 2-Propenoic acid, 2-methyl-, polymer

with 2-propenoic acid and .alpha.-sulfo-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl) ammonium salt  
 452311-68-1P, 2-Propenoic acid, polymer with  
 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid and  
 .alpha.-sulfo-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl) ammonium  
 salt 452311-69-2P, 2-Propenoic acid, polymer with  
 .alpha.-phosphono-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl)  
 452311-70-5P, 2-Propenoic acid, polymer with  
 .alpha.-sulfo-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl)  
 452311-71-6P

(water sol. or water dispersible polymers as scale and/or corrosion  
 inhibitors in aq. systems)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS  
 RECORD (1 CITINGS)  
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
 RE FORMAT

L39 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 2002:669688 HCAPLUS Full-text  
 DOCUMENT NUMBER: 137:202027  
 TITLE: Water soluble polymers  
 INVENTOR(S): Chen, Fu; Kolson, Natalie A.  
 PATENT ASSIGNEE(S): Betzdearborn Inc., USA  
 SOURCE: U.S., 7 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6444747	B1	20020903	US 2001-808679	20010315
			<--	
US 20030052303	A1	20030320	US 2001-878646	20010611
			<--	
US 6641754	B2	20031104		
CA 2440435	A1	20021010	CA 2002-2440435	20020301
			<--	
CA 2440435	C	20100608		
WO 2002079106	A1	20021010	WO 2002-US6370	20020301
			<--	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002314719	A1	20021015	AU 2002-314719	20020301
			<--	
AU 2002314719	B2	20070426		

10/596,747



EP 1379475	A1	20040114	EP 2002-741643	20020301
			<--	
EP 1379475	B1	20090708		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,				
PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003003535	A2	20040128	HU 2003-3535	20020301
			<--	
HU 2003003535	A3	20080328		
CN 1496338	A	20040512	CN 2002-806631	20020301
			<--	
CN 1262489	C	20060705		
JP 2004528439	T	20040916	JP 2002-577740	20020301
			<--	
NZ 528038	A	20050527	NZ 2002-528038	20020301
			<--	
AT 435839	T	20090715	AT 2002-741643	20020301
			<--	
PT 1379475	E	20090901	PT 2002-741643	20020301
			<--	
ES 2326960	T3	20091022	ES 2002-741643	20020301
			<--	
PL 204918	B1	20100226	PL 2002-363968	20020301
			<--	
TW 300060	B	20080821	TW 2002-104266	20020307
			<--	
IN 2003KN00910	A	20050708	IN 2003-KN910	20030715
			<--	
US 20040039144	A1	20040226	US 2003-646278	20030822
			<--	
US 7094852	B2	20060822		
KR 904789	B1	20090625	KR 2003-7011900	20030909
			<--	
NO 2003004049	A	20031104	NO 2003-4049	20030912
			<--	
MX 2003008342	A	20041015	MX 2003-8342	20030912
			<--	
AU 2007202743	A1	20070705	AU 2007-202743	20070613
			<--	
AU 2007202743	B2	20081120		
PRIORITY APPLN. INFO.:			US 2001-806679	A 20010315
			<--	
			US 2001-808679	A2 20010315
			<--	
			US 2001-878646	A 20010611
			<--	
			AU 2002-314719	A3 20020301
			<--	
			WO 2002-US6370	W 20020301
			<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

ED Entered STN: 05 Sep 2002

GI





AB A water sol. or water dispersible polymer compn., useful as deposit control and corrosion inhibition agents in water treatment, pulp and paper manufg. processes, and in pretreating of metals; as rheol. modifiers for concrete and cement additives; as cleaning agents for membranes; and as hydrophilic modifier components in personal care, cosmetic and pharmaceutical formulations, has the repeat units of I: Wherein E is the repeat unit remaining after polymn. of an ethylenically unsatd. compd.; preferably, a carboxylic acid, sulfonic acid, phosphonic acid, or amide thereof or mixts. thereof; R<sup>1</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl; G is -CH<sub>2</sub>- or -CHCH<sub>3</sub>-; R<sup>2</sup> is polyoxyethylene or polyoxypropylene where n is 1-100, preferably 1-20; X is an anionic radical selected from the group consisting of SO<sub>3</sub>, PO<sub>3</sub>, or CO<sub>2</sub>; Z is H or hydrogens or any water sol. cationic moiety which counterbalances the valence of the anionic radical X, including but not limited to Na, K, Ca, or NH<sub>4</sub>; F, when present, is a repeat unit having the structure of II: wherein X and Z are the same as in I; R<sup>4</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl; R<sup>5</sup> is hydroxy substituted alkyl or C<sub>1</sub>-C<sub>6</sub> alkylene.

IT 330666-77-8P 452311-66-9P 452311-67-0P  
452311-68-1P 452311-69-2P 452311-70-5P

(water sol. polymers)

RN 330666-77-8 HCAPLUS


CN 2-Propenoic acid, polymer with  
.alpha.-sulfo-.omega.-(2-propen-1-yloxy)poly(oxy-1,2-ethanediyl)  
ammonium salt (1:1) (CA INDEX NAME)

CM 1

CRN 55866-85-8


CMF (C2 H4 O)<sub>n</sub> C3 H6 O4 S . H3 N

CCI PMS



CM 2


CRN 79-10-7  
 CMF C3 H4 O2



RN 452311-66-9 HCAPLUS  
 CN 2-Propenoic acid, polymer with  
 2-hydroxy-3-(2-propen-1-yloxy)-1-propanesulfonic acid and  
 .alpha.-sulfo-.omega.-(2-propen-1-yloxy)poly(oxy-1,2-ethanediyl)  
 ammonium salt (1:1) (CA INDEX NAME)


CM 1

CRN 94928-31-1  
 CMF C6 H12 O5 S




CM 2

CRN 55866-85-8  
 CMF (C2 H4 O)<sub>n</sub> C3 H6 O4 S . H3 N  
 CCI PMS



CM 3

CRN 79-10-7  
 CMF C3 H4 O2



RN 452311-67-0 HCAPLUS


CN 2-Propenoic acid, 2-methyl-, polymer with 2-propenoic acid and  
.alpha.-sulfo-.omega.-(2-propen-1-yloxy)poly(oxy-1,2-ethanediyl)  
ammonium salt (1:1) (CA INDEX NAME)

CM 1

CRN 55866-85-8

CMF (C2 H4 O)n C3 H6 O4 S . H3 N


CCI PMS



CM 2

CRN 79-41-4


CMF C4 H6 O2



CM 3

CRN 79-10-7

CMF C3 H4 O2



RN 452311-68-1 HCAPLUS


CN 2-Propenoic acid, polymer with  
2-methyl-2-[(1-oxo-2-propen-1-yl)amino]-1-propanesulfonic acid and  
.alpha.-sulfo-.omega.-(2-propen-1-yloxy)poly(oxy-1,2-ethanediyl)  
ammonium salt (1:1) (CA INDEX NAME)

CM 1

CRN 55866-85-8

CMF (C2 H4 O)n C3 H6 O4 S . H3 N


CCI PMS



CM 2

CRN 15214-89-8


CMF C7 H13 N O4 S



CM 3

CRN 79-10-7

CMF C3 H4 O2



RN 452311-69-2 HCAPLUS


CN 2-Propenoic acid, polymer with  
.alpha.-phosphono-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl)  
(9CI) (CA INDEX NAME)

CM 1

CRN 171439-08-0

CMF (C2 H4 O)<sub>n</sub> C3 H7 O4 P


CCI PMS



CM 2

CRN 79-10-7

CMF C3 H4 O2



RN 452311-70-5 HCAPLUS


CN 2-Propenoic acid, polymer with  
 .alpha.-sulfo-.omega.-(2-propen-1-yloxy)poly(oxy-1,2-ethanediyl) (CA  
 INDEX NAME)

CM 1

CRN 201605-73-4

CMF (C2 H4 O)<sub>n</sub> C3 H6 O4 S


CCI PMS




CM 2

CRN 79-10-7


CMF C3 H4 O2




IT 452311-71-6  
 (water sol. polymers)  
 RN 452311-71-6 HCAPLUS  
 CN 2-Propenoic acid, 2-methyl-, polymer with  
 .alpha.-sulfo-.omega.-(2-propenyloxy)poly(oxy-1,2-ethanediyl) ammonium  
 salt (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 55866-85-8  
 CMF (C2 H4 O)n C3 H6 O4 S . H3 N  
 CCI PMS



CM 2  
 CRN 79-41-4  
 CMF C4 H6 O2



IT 171439-08-0P  
 (water sol. polymers)  
 RN 171439-08-0 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-(2-propen-1-yloxy)-  
 (CA INDEX NAME)



INCL 524807000  
 IPCI C08L0041-00 [ICM,7]; C08L0043-00 [ICS,7]; C08F0220-04 [ICS,7];  
 C08F0220-64 [ICS,7]; C08F0228-02 [ICS,7]  
 IPCR C02F0005-10 [I,A]; C02F0005-12 [I,A]; C02F0005-14 [I,A]; C08F0216-14  
 [I,A]  
 NCL 524/807.000; 524/817.000; 524/832.000; 526/287.000; 526/318.410;

526/320.000  
 CC 37-3 (Plastics Manufacture and Processing)  
 Section cross-reference(s): 43, 58, 62, 63  
 IT 330666-77-8P 452311-66-9P 452311-67-0P  
 452311-68-1P 452311-69-2P 452311-70-5P  
 (water sol. polymers)  
 IT 452311-71-6  
 (water sol. polymers)  
 IT 171439-08-0P  
 (water sol. polymers)  
 OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS  
 RECORD (4 CITINGS)  
 REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
 RE FORMAT

L39 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 2001:603583 HCAPLUS Full-text  
 DOCUMENT NUMBER: 135:167504  
 TITLE: Reactive surfactant compositions and manufacture  
 of polymer emulsions using them  
 INVENTOR(S): Ishikawa, Yoshinobu; Sawada, Hiroki; Ishii, Yasuo  
 PATENT ASSIGNEE(S): Kao Corp., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001226439	A	20010821	JP 2000-33804	20000210
			<--	
JP 3420733	B2	20030630		
EP 1129770	A1	20010905	EP 2001-102796	20010209
			<--	
EP 1129770	B1	20041222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 20010020064	A1	20010906	US 2001-779314	20010209
			<--	
ES 2230186	T3	20050501	ES 2001-102796	20010209
			<--	
PRIORITY APPLN. INFO.:			JP 2000-33804	A 20000210
			<--	

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

ED Entered STN: 21 Aug 2001

AB The comps. essentially contain reactive surfactants (a) [crit. micelle concn. (CMC) 0.007-0.4 mol/L] having one reactive group selected from CHR1:CR2(Y)p (R1, R2 = H, CH2X; X = H, substituent; Y = CO, CH2; p = 0, 1) and one anionic hydrophilic group and reactive surfactants (b) (CMC 1 .times. 10<sup>-5</sup>-0.007 mol/L) having one reactive group above mentioned and one anionic hydrophilic group [a/b = 5/95 to 60/40 (by mol)]. Thus, a polymer emulsion prepd. from 71.5 g H2O, 1g of a compn. contg. a 12.9:87.1 mixt. of CH2:C(CO2K)CH2CO2-n-C6H13 and

CH<sub>2</sub>:C(CO<sub>2</sub>K)CH<sub>2</sub>CO<sub>2</sub>-n-C<sub>12</sub>H<sub>25</sub>, 50g styrene, and 7.5g 2% aq. soln. of K<sub>2</sub>S<sub>2</sub>O<sub>8</sub> showed good polymn. stability and av. particle size 85.1 nm.

IT 354552-66-2P 354552-68-4P 354583-13-4P  
 354583-14-5P 354583-15-6P 354583-16-7P  
 354583-17-8P 354583-18-9P

(reactive surfactant compns. with controlled CMC for polymer emulsions)


RN 354552-66-2 HCAPLUS

CN 2-Propenoic acid, butyl ester, polymer with dodecyl  
 2-hydroxy-3-(2-propenyloxy)propyl hydrogen phosphate monosodium salt  
 and .alpha.-sulfo-.omega.-[1-[[4-(1,1-dimethylethyl)phenoxy]methyl]-2-  
 (2-propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI)  
 (CA INDEX NAME)

CM 1

CRN 354552-65-1

CMF C18 H37 O6 P . Na




● Na

CM 2

CRN 354552-64-0

CMF (C<sub>2</sub> H<sub>4</sub> O)<sub>n</sub> C<sub>16</sub> H<sub>24</sub> O<sub>6</sub> S . H<sub>3</sub> N

CCI PMS




● NH<sub>3</sub>

CM 3

CRN 141-32-2

CMF C<sub>7</sub> H<sub>12</sub> O<sub>2</sub>






RN 354552-68-4 HCAPLUS

CN 2-Propenoic acid, butyl ester, polymer with dodecyl  
2-hydroxy-3-(2-propenyloxy)propyl hydrogen phosphate monosodium salt  
and 2-hydroxy-3-(2-propenyloxy)propyl octyl hydrogen phosphate  
monosodium salt (9CI) (CA INDEX NAME)

CM 1

CRN 354552-67-3

CMF C14 H29 O6 P . Na




● Na

CM 2

CRN 354552-65-1

CMF C18 H37 O6 P . Na




● Na

CM 3

CRN 141-32-2

CMF C7 H12 O2



RN 354583-13-4 HCAPLUS


CN Butanedioic acid, sulfo-, C-[2-hydroxy-3-(2-propenyloxy)propyl]  
C-octyl ester, monosodium salt, polymer with butyl 2-propenoate,  
methyl 2-methyl-2-propenoate, 2-propenoic acid and  
.alpha.-sulfo-.omega.-[1-[(4-isononylphenoxy)methyl]-2-(2-  
propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI) (CA  
INDEX NAME)

CM 1

CRN 354583-12-3

CMF (C2 H4 O)<sub>n</sub> C21 H34 O6 S . H3 N


CCI IDS, PMS



CM 2

CRN 141-32-2


CMF C7 H12 O2



CM 3


CRN 80-62-6

CMF C5 H8 O2



CM 4

CRN 79-10-7  
 CMF C3 H4 O2




CM 5

CRN 354583-08-7  
 CMF C18 H32 O9 S . Na  
 CCI IDS


CM 6

CRN 5138-18-1  
 CMF C4 H6 O7 S




CM 7

CRN 123-34-2  
 CMF C6 H12 O3



CM 8

CRN 111-87-5  
 CMF C8 H18 O




RN 354583-14-5 HCAPLUS  
 CN Butanedioic acid, sulfo-, C-dodecyl  
 C-[2-hydroxy-3-(2-propenyloxy)propyl] ester, monosodium salt, polymer  
 with butyl 2-propenoate, methyl 2-methyl-2-propenoate, 2-propenoic  
 acid and .alpha.-sulfo-.omega.-[1-[[4-(1,1-  
 dimethylethyl)phenoxy]methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-  
 ethanediyl) ammonium salt (9CI) (CA INDEX NAME)

CM 1

CRN 354552-64-0

CMF (C2 H4 O)n C16 H24 O6 S . H3 N


CCI PMS



CM 2

CRN 141-32-2


CMF C7 H12 O2



CM 3


CRN 80-62-6

CMF C5 H8 O2



CM 4

CRN 79-10-7  
CMF C3 H4 O2




CM 5

CRN 119588-64-6  
CMF C22 H40 O9 S . Na  
CCI IDS


CM 6

CRN 5138-18-1  
CMF C4 H6 O7 S




CM 7

CRN 123-34-2  
CMF C6 H12 O3



CM 8

CRN 112-53-8  
CMF C12 H26 O



RN 354583-15-6 HCAPLUS


CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with butyl  
 2-propenoate, 2-propenoic acid,  
 .alpha.-sulfo-.omega.-[1-[[4-(1,1-dimethylethyl)phenoxy]methyl]-2-(2-  
 propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt and  
 .alpha.-sulfo-.omega.-[4-isononyl(1-propenyl)phenoxy]poly(oxy-1,2-  
 ethanediyl) ammonium salt (9CI) (CA INDEX NAME)

CM 1

CRN 354583-10-1

CMF (C2 H4 O)<sub>n</sub> C18 H28 O4 S . H3 N

CCI IDS, PMS




CM 2

CRN 354552-64-0

CMF (C2 H4 O)<sub>n</sub> C16 H24 O6 S . H3 N


CCI PMS



CM 3


CRN 141-32-2

CMF C7 H12 O2




CM 4

CRN 80-62-6  
CMF C5 H8 O2



CM 5

CRN 79-10-7  
CMF C3 H4 O2




RN 354583-16-7 HCAPLUS

CN Butanedioic acid, sulfo-, C-[2-hydroxy-3-(2-propenyloxy)propyl]  
C-octyl ester, monosodium salt, polymer with butyl 2-propenoate,  
methyl 2-methyl-2-propenoate, 2-propenoic acid and  
.alpha.-sulfo-.omega.-[1-[(dodecyloxy)methyl]-2-(2-  
propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI) (CA  
INDEX NAME)


CM 1

CRN 113377-37-0  
CMF (C2 H4 O)<sub>n</sub> C18 H36 O6 S . H3 N  
CCI PMS




CM 2

CRN 141-32-2  
CMF C7 H12 O2




CM 3

CRN 80-62-6  
CMF C5 H8 O2



CM 4

CRN 79-10-7  
CMF C3 H4 O2




CM 5

CRN 354583-08-7  
CMF C18 H32 O9 S . Na  
CCI IDS

CM 6

CRN 5138-18-1  
CMF C4 H6 O7 S









10/596,747

CRN 354552-67-3  
CMF C14 H29 O6 P . Na



CM 3



CRN 141-32-2  
CMF C7 H12 O2



RN 354583-18-9 HCAPLUS  
CN 2-Propenoic acid, butyl ester, polymer with  
2-hydroxy-3-(2-propenyloxy)propyl octyl hydrogen phosphate monosodium  
salt and .alpha.-sulfo-.omega.-[4-isononyl(1-propenyl)phenoxy]poly(oxy-  
1,2-ethanediyl) ammonium salt (9CI) (CA INDEX NAME)


CM 1

CRN 354583-10-1  
CMF (C2 H4 O)<sub>n</sub> C18 H28 O4 S . H3 N  
CCI IDS, PMS



CM 2


CRN 354552-67-3  
 CMF C14 H29 O6 P . Na



● Na

CM 3

CRN 141-32-2  
 CMF C7 H12 O2



IPCI C08F0222-16 [ICM,7]; B01F0017-52 [ICS,7]; C08F0002-24 [ICS,7];  
 C08F0012-04 [ICS,7]; C08F0216-12 [ICS,7]; C08F0220-04 [ICS,7]  
 IPCR B01F0017-00 [I,A]; B01F0017-52 [I,A]; C08F0002-16 [I,A]; C08F0002-24  
 [I,A]; C08F0002-26 [I,A]; C08F0004-00 [I,A]; C08F0012-04 [I,A];  
 C08F0020-12 [I,A]; C08F0216-12 [I,A]; C08F0220-04 [I,A]; C08F0222-16  
 [I,A]  
 CC 37-3 (Plastics Manufacture and Processing)  
 IT 354552-58-2P 354552-59-3P 354552-61-7P 354552-62-8P  
 354552-66-2P 354552-68-4P 354583-09-8P  
 354583-11-2P 354583-13-4P 354583-14-5P  
 354583-15-6P 354583-16-7P 354583-17-8P  
 354583-18-9P

(reactive surfactant compns. with controlled CMC for polymer emulsions)

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L39 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 2001:289987 HCAPLUS Full-text  
 DOCUMENT NUMBER: 134:281635  
 TITLE: Hydrophilic allylic crosslinking agents for water-absorbing polymers  
 INVENTOR(S): Nakamura, Shinichiro; Shimizu, Yasumi; Matsutomi, Toru  
 PATENT ASSIGNEE(S): Daiso Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent

LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2001114840	A	20010424	JP 1999-299551	19991021

PRIORITY APPLN. INFO.: JP 1999-299551 19991021  
 <--


ED Entered STN: 24 Apr 2001

AB The agents have 2 allyl groups and .gtoreq.1 hydrophilic group chosen from OSO<sub>3</sub>Y, SO<sub>3</sub>Y, and OP(O)(OY)<sub>2</sub> (Y = H, alkali metal, ammonium, alk. earth metal). Thus, pentaerythritol triallyl ether (I) was treated with HSO<sub>3</sub>Cl followed by NaOH to give I sulfate Na salt, which showed 2.21 w/v% soly. in acrylic acid. Acrylic acid was polymd. with I sulfate Na salt to give a polymer showing 46 g/g water absorption.

IT 333718-49-3P 333718-50-6P  
 (hydrophilic allylic crosslinking agents for water-absorbing polymers)

RN 333718-49-3 HCAPLUS


CN 1-Propanol, 3-(2-propen-1-yloxy)-2,2-bis[(2-propen-1-yloxy)methyl]-, 1-(hydrogen sulfate), sodium salt (1:1) (CA INDEX NAME)



● Na

RN 333718-50-6 HCAPLUS

CN 1-Propanol, 3-(2-propenyloxy)-2,2-bis[(2-propenyloxy)methyl]-, dihydrogen phosphate, disodium salt (9CI) (CA INDEX NAME)



●<sub>2</sub> Na


IT 333718-51-7P 333718-52-8P 333718-53-9P  
 (hydrophilic allylic crosslinking agents for water-absorbing polymers)

RN 333718-51-7 HCAPLUS

CN 2-Propenoic acid, polymer with sodium  
 3-(2-propenyloxy)-2,2-bis[(2-propenyloxy)methyl]propyl sulfate (9CI)  
 (CA INDEX NAME)


CM 1

CRN 333718-49-3  
 CMF C14 H24 O7 S . Na



CM 2



CRN 79-10-7  
 CMF C3 H4 O2



RN 333718-52-8 HCAPLUS  
 CN 2-Propenoic acid, polymer with disodium  
 3-(2-propenyloxy)-2,2-bis[(2-propenyloxy)methyl]propyl phosphate (9CI)  
 (CA INDEX NAME)


CM 1

CRN 333718-50-6  
 CMF C14 H25 O7 P . 2 Na



CM 2

CRN 79-10-7  
 CMF C3 H4 O2




RN 333718-53-9 HCAPLUS  
 CN 2-Propenoic acid, polymer with sodium  
 3-(2-propenyloxy)-2,2-bis[(2-propenyloxy)methyl]propyl sulfate, sodium  
 salt (9CI) (CA INDEX NAME)

CM 1

CRN 333718-51-7  
 CMF (C14 H24 O7 S . C3 H4 O2 . Na)x  
 CCI PMS


CM 2

CRN 333718-49-3  
 CMF C14 H24 O7 S . Na



CM 3

CRN 79-10-7  
 CMF C3 H4 O2



IPCI C08F0228-02 [ICM,7]; C08F0002-44 [ICS,7]; C08F0230-02 [ICS,7];  
 C08F0291-00 [ICS,7]; C08J0003-24 [ICS,7]; C08L0101-14 [ICS,7]  
 IPCR C08J0003-24 [I,A]; C08F0002-44 [I,A]; C08F0228-02 [I,A]; C08F0230-02  
 [I,A]; C08F0291-00 [I,A]; C08L0101-14 [I,A]  
 CC 37-6 (Plastics Manufacture and Processing)  
 Section cross-reference(s): 23  
 IT 333718-49-3P 333718-50-6P  
 (hydrophilic allylic crosslinking agents for water-absorbing  
 polymers)  
 IT 333718-51-7P 333718-52-8P 333718-53-9P  
 (hydrophilic allylic crosslinking agents for water-absorbing  
 polymers)  
 OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS  
 RECORD (1 CITINGS)

L39 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 1997:533603 HCAPLUS Full-text  
 DOCUMENT NUMBER: 127:191884  
 ORIGINAL REFERENCE NO.: 127:37207a,37210a  
 TITLE: Compounds and surfactants for emulsifiers for  
 polymerization and fiber finishing  
 INVENTOR(S): Komiya, Kaoru; Kawamata, Hiromasa; Umezawa, Shohei  
 PATENT ASSIGNEE(S): Asahi Denka Kogyo K.K., Japan  
 SOURCE: PCT Int. Appl., 35 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9728111	A1	19970807	WO 1997-JP186	19970128
			<--	
W: JP, KR, US				
RW: DE, FR, GB, NL				
EP 825167	A1	19980225	EP 1997-900791	19970128
			<--	
EP 825167	B1	20011004		
R: DE, FR, GB, NL				
JP 4031831	B2	20080109	JP 1997-527481	19970128
			<--	
US 5929290	A	19990727	US 1997-913856	19970929
			<--	
JP 2008024942	A	20080207	JP 2007-203331	20070803
			<--	
JP 4824646	B2	20111130		
PRIORITY APPLN. INFO.:			JP 1996-14441	A 19960130
			<--	
			JP 1996-23908	A 19960209
			<--	
			JP 1997-527481	A3 19970128
			<--	
			WO 1997-JP186	W 19970128
			<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

ED Entered STN: 21 Aug 1997

AB Reactive surfactants  $R_fO(AO)_mCH_2CH[O(AO')_{m'}X]CH_2OCH_2CR_1:CH_2$  are prepd., where  $R_1 = H$  or  $Me$ ,  $R_f$  is a hydrocarbon group or acyl in which  $\geq 1$  H is replaced by F, AO and AO' represent groups selected among C2-4 oxyalkylenes or styrene oxide residues;  $m, m' = 0$  or  $1-1,000$ ; and  $X = H$  or a hydrophilic group. Thus,  $C_6F_{13}OCH_2CH[O(CH_2CH_2O)_{30}H]CH_2OCH_2CH:CH_2$  was prepd. and used as an emulsifier for the polymn. of acrylonitrile, butadiene, and styrene.

IT 194295-78-8P 194295-91-5P 194296-01-0P  
(antifogging and antistatic polymers)

RN 194295-78-8 HCAPLUS


CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(2-propenyloxy)methyl]-2-[(tridecafluorohexyl)oxy]ethoxy]-, potassium salt, polymer with 1-propene, graft (9CI) (CA INDEX NAME)

CM 1

CRN 194294-93-4

CMF (C2 H4 O) $_n$  C12 H11 F13 O6 S . K

CCI PMS



CM 2

CRN 115-07-1

CMF C3 H6



RN 194295-91-5 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[[2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluorononyl)oxy]methyl]-2-(2-propenyloxy)ethoxy]-.omega.-hydroxy-, ammonium salt, polymer with 1-propene, graft (9CI) (CA INDEX NAME)

CM 1


CRN 194295-11-9

CMF (C2 H4 O) $_n$  C15 H14 F16 O6 S . H3 N

CCI PMS




10/596,747



CM 2

CRN 115-07-1

CMF C3 H6



RN 194296-01-0 HCAPLUS


CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-  
 [[(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15  
 ,16,16,17,17,18,18,19,19,19-heptatriacontafluoro-1-  
 oxononadecyl)oxy]methyl]-2-[(2-methyl-2-propenyl)oxy]ethoxy]-,  
 disodium salt, polymer with 1-propene, graft (9CI) (CA INDEX NAME)

CM 1

CRN 194294-99-0

CMF (C2 H4 O)n C26 H14 F37 O7 P . 2 Na


CCI PMS




CM 2

CRN 115-07-1


CMF C3 H6



IT 194296-31-6P 194296-39-4P 194296-45-2P  
 (antistatic and antifogging polymers)  
 RN 194296-31-6 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(2-propenyloxy)methyl]-2-[(tridecafluorohexyl)oxy]ethoxy]-, potassium salt, polymer with ethenylbenzene, graft (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 194294-93-4  
 CMF (C2 H4 O)n C12 H11 F13 O6 S . K  
 CCI PMS




CM 2  
 CRN 100-42-5  
 CMF C8 H8



RN 194296-39-4 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[[[(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluorononyl)oxy]methyl]-2-(2-propenyloxy)ethoxy]-, ammonium salt, polymer with ethenylbenzene, graft (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 194295-11-9  
 CMF (C2 H4 O)n C15 H14 F16 O6 S . H3 N  
 CCI PMS


10/596,747



CM 2

CRN 100-42-5

CMF C8 H8



RN 194296-45-2 HCAPLUS


CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-  
 [(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15  
 ,16,16,17,17,18,18,19,19,19-heptatriacontafluoro-1-  
 oxononadecyl)oxy]methyl]-2-[(2-methyl-2-propenyl)oxy]ethoxy]-,  
 disodium salt, polymer with ethenylbenzene, graft (9CI) (CA INDEX  
 NAME)

CM 1

CRN 194294-99-0

CMF (C2 H4 O)<sub>n</sub> C26 H14 F37 O7 P . 2 Na


CCI PMS




CM 2

CRN 100-42-5


CMF C8 H8




IT 194296-09-8P 194296-18-9P 194296-25-8P  
 (fibers; antisoiling fabrics)  
 RN 194296-09-8 HCAPLUS  
 CN 1,4-Benzenedicarboxylic acid, polymer with 1,2-ethanediol and  
 .alpha.-sulfo-.omega.-[1-[(2-propenyloxy)methyl]-2-  
 [(tridecafluorohexyl)oxy]ethoxy]poly(oxy-1,2-ethanediyl) potassium  
 salt, graft (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 194294-93-4  
 CMF (C2 H4 O)n C12 H11 F13 O6 S . K  
 CCI PMS



CM 2  
 CRN 107-21-1  
 CMF C2 H6 O2




CM 3  
 CRN 100-21-0  
 CMF C8 H6 O4



RN 194296-18-9 HCAPLUS  
 CN 1,4-Benzenedicarboxylic acid, polymer with 1,2-ethanediol and  
 .alpha.-sulfo-.omega.-[1-[[ (2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-  
 hexadecafluorononyl)oxy)methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-  
 ethanediyl) ammonium salt, graft (9CI) (CA INDEX NAME)


CM 1

CRN 194295-11-9  
 CMF (C2 H4 O)<sub>n</sub> C15 H14 F16 O6 S . H3 N  
 CCI PMS




CM 2

CRN 107-21-1  
 CMF C2 H6 O2



CM 3

CRN 100-21-0  
 CMF C8 H6 O4



RN 194296-25-8 HCAPLUS  
 CN 1,4-Benzenedicarboxylic acid, polymer with 1,2-ethanediol and  
 .alpha.-phosphono-.omega.-[1-  
 [[ (2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15,  
 ,16,16,17,17,18,18,19,19,19-heptatriacontafluoro-1-  
 oxononadecyl)oxy)methyl]-2-[(1-methyl-2-propenyl)oxy]ethoxy]poly(oxy-

10/596,747


1,2-ethanediyl) disodium salt, graft (9CI) (CA INDEX NAME)

CM 1

CRN 194294-99-0

CMF (C2 H4 O)n C26 H14 F37 O7 P . 2 Na

CCI PMS




● 2 Na

CM 2

CRN 107-21-1


CMF C2 H6 O2



CM 3

CRN 100-21-0

CMF C8 H6 O4



IT 194295-16-4P 194295-20-0P 194295-23-3P  
 194295-26-6P 194295-30-2P 194295-33-5P  
 194295-36-8P 194295-40-4P 194295-43-7P

(manuf. and reactive surfactants as emulsifiers for)

RN 194295-16-4 HCAPLUS

CN 2-Propenenitrile, polymer with 1,3-butadiene, ethenylbenzene and  
 .alpha.-sulfo-.omega.-[1-[(2-propenyloxy)methyl]-2-  
 [(tridecafluorohexyl)oxy]ethoxy]poly(oxy-1,2-ethanediyl) potassium  
 salt (9CI) (CA INDEX NAME)


10/596,747

CM 1

CRN 194294-93-4

CMF (C2 H4 O)<sub>n</sub> C12 H11 F13 O6 S . K

CCI PMS



CM 2

CRN 107-13-1


CMF C3 H3 N



CM 3

CRN 106-99-0


CMF C4 H6



CM 4

CRN 100-42-5

CMF C8 H8



RN 194295-20-0 HCAPLUS

CN 2-Propenenitrile, polymer with 1,3-butadiene, ethenylbenzene and .alpha.-sulfo-.omega.-[1-[(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-

10/596,747


hexadecafluorononyl)oxy)methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI) (CA INDEX NAME)

CM 1

CRN 194295-11-9

CMF (C2 H4 O)n C15 H14 F16 O6 S . H3 N

CCI PMS



CM 2

CRN 107-13-1


CMF C3 H3 N



CM 3

CRN 106-99-0


CMF C4 H6



CM 4

CRN 100-42-5

CMF C8 H8







RN 194295-23-3 HCAPLUS  
 CN 2-Propenenitrile, polymer with 1,3-butadiene, ethenylbenzene and  
 .alpha.-phosphono-.omega.-[1-  
 [[ (2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15  
 ,16,16,17,17,18,18,19,19,19-heptatriacontafluoro-1-  
 oxononadecyl)oxy)methyl]-2-[(1-methyl-2-propenyl)oxy]ethoxy]poly(oxy-  
 1,2-ethanediyl) disodium salt (9CI) (CA INDEX NAME)

CM 1

CRN 194294-99-0

CMF (C2 H4 O)n C26 H14 F37 O7 P . 2 Na

CCI PMS



CM 2

CRN 107-13-1


CMF C3 H3 N



CM 3

CRN 106-99-0


CMF C4 H6




CM 4

CRN 100-42-5


CMF C8 H8



RN 194295-26-6 HCAPLUS  
 CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
 .alpha.-sulfo-.omega.-[1-[(2-propenyloxy)methyl]-2-  
 [(tridecafluorohexyl)oxy]ethoxy]poly(oxy-1,2-ethanediyl) potassium  
 salt (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 194294-93-4  
 CMF (C2 H4 O)<sub>n</sub> C12 H11 F13 O6 S . K  
 CCI PMS




CM 2  
 CRN 80-62-6  
 CMF C5 H8 O2




RN 194295-30-2 HCAPLUS  
 CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
 .alpha.-sulfo-.omega.-[1-[[ (2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-  
 hexadecafluorononyl)oxy]methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-  
 ethanediyl) ammonium salt (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 194295-11-9  
 CMF (C2 H4 O)<sub>n</sub> C15 H14 F16 O6 S . H3 N  
 CCI PMS

10/596,747



CM 2

CRN 80-62-6  
CMF C5 H8 O2




RN 194295-33-5 HCAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
.alpha.-phosphono-.omega.-[1-  
[[ (2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15,  
,16,16,17,17,18,18,19,19,19-heptatriacontafluoro-1-  
oxononadecyl)oxy]methyl]-2-[(2-methyl-2-propenyl)oxy]ethoxy]poly(oxy-  
1,2-ethanediyl) disodium salt (9CI) (CA INDEX NAME)


CM 1

CRN 194294-99-0  
CMF (C2 H4 O)n C26 H14 F37 O7 P . 2 Na  
CCI PMS



CM 2

CRN 80-62-6  
CMF C5 H8 O2




```

RN      194295-36-8  HCAPLUS
CN      Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(2-
propenyloxy)methyl]-2-[(tridecafluorohexyl)oxy]ethoxy]-, potassium
salt, polymer with chloroethene (9CI)  (CA INDEX NAME)


CM      1

CRN     194294-93-4
CMF     (C2 H4 O)n C12 H11 F13 O6 S . K
CCI     PMS

```



CM	2
CRN	75-01-4
CMF	C2 H3 C1



```


RN      194295-40-4   HCAPLUS
CN      Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-
      [[(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluorononyl)oxy]methyl]-2-
      (2-propenyloxy)ethoxy]-, ammonium salt, polymer with chloroethene
      (9CI)   (CA INDEX NAME)

CM      1

CRN     194295-11-9
CMF     (C2 H4 O)n C15 H14 F16 O6 S . H3 N
CCI     PMS


```

10/596,747



CM 2

CRN 75-01-4  
CMF C2 H3 Cl




RN 194295-43-7 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-  
[[ (2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15  
,16,16,17,17,18,18,19,19,19-heptatriacontafluoro-1-  
oxononadecyl)oxy]methyl]-2-[(2-methyl-2-propenyl)oxy]ethoxy]-,  
disodium salt, polymer with chloroethene (9CI) (CA INDEX NAME)


CM 1

CRN 194294-99-0  
CMF (C2 H4 O)n C26 H14 F37 O7 P . 2 Na  
CCI PMS




CM 2


CRN 75-01-4  
CMF C2 H3 Cl



IT 194295-46-0P 194295-50-6P 194295-53-9P  
 194295-56-2P 194295-64-2P 194295-70-0P  
 (manuf. of antifogging and antistatic polymers and reactive  
 surfactants as emulsifiers for)  
 RN 194295-46-0 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(2-  
 propenyloxy)methyl]-2-[(tridecafluorohexyl)oxy]ethoxy]-, potassium  
 salt, polymer with ethenylbenzene (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 194294-93-4  
 CMF (C2 H4 O)n C12 H11 F13 O6 S . K  
 CCI PMS




CM 2  
 CRN 100-42-5  
 CMF C8 H8



RN 194295-50-6 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-  
 [[(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluorononyl)oxy]methyl]-2-  
 (2-propenyloxy)ethoxy]-, ammonium salt, polymer with ethenylbenzene  
 (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 194295-11-9  
 CMF (C2 H4 O)n C15 H14 F16 O6 S . H3 N  
 CCI PMS


10/596,747



CM 2

CRN 100-42-5

CMF C8 H8



RN 194295-53-9 HCAPLUS


CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-  
[[ (2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15  
,16,16,17,17,18,18,19,19,19-heptatriacontafluoro-1-  
oxononadecyl)oxy]methyl]-2-[(2-methyl-2-propenyl)oxy]ethoxy]-,  
disodium salt, polymer with ethenylbenzene (9CI) (CA INDEX NAME)

CM 1

CRN 194294-99-0

CMF (C2 H4 O)n C26 H14 F37 O7 P . 2 Na


CCI PMS



CM 2

CRN 100-42-5

CMF C8 H8



RN 194295-56-2 HCAPLUS


CN 2-Propenoic acid, 2-methyl-, polymer with butyl 2-propenoate and  
 .alpha.-sulfo-.omega.-[1-[(2-propenyloxy)methyl]-2-  
 [(tridecafluorohexyl)oxy]ethoxy]poly(oxy-1,2-ethanediyl) potassium  
 salt (9CI) (CA INDEX NAME)

CM 1

CRN 194294-93-4

CMF (C2 H4 O)n C12 H11 F13 O6 S . K


CCI PMS



CM 2

CRN 141-32-2


CMF C7 H12 O2



CM 3

CRN 79-41-4

CMF C4 H6 O2



RN 194295-64-2 HCAPLUS




CN 2-Propenoic acid, 2-methyl-, polymer with butyl 2-propenoate and .alpha.-sulfo-.omega.-[1-[[ (2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluorononyl)oxy)methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI) (CA INDEX NAME)

CM 1

CRN 194295-11-9

CMF (C2 H4 O)<sub>n</sub> C15 H14 F16 O6 S . H3 N


CCI PMS



CM 2

CRN 141-32-2


CMF C7 H12 O2



CM 3

CRN 79-41-4

CMF C4 H6 O2



RN 194295-70-0 HCAPLUS


CN 2-Propenoic acid, 2-methyl-, polymer with butyl 2-propenoate and .alpha.-phosphono-.omega.-[1-[[ (2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,19-heptatriacontafluoro-1-oxononadecyl)oxy)methyl]-2-[(1-methyl-2-propenyl)oxy]ethoxy]poly(oxy-1,2-ethanediyl) disodium salt (9CI) (CA INDEX NAME)

CM 1

CRN 194294-99-0

CMF (C2 H4 O)<sub>n</sub> C26 H14 F37 O7 P . 2 Na


CCI PMS



CM 2

CRN 141-32-2


CMF C7 H12 O2



CM 3

CRN 79-41-4

CMF C4 H6 O2




IT	194294-90-1P	194294-91-2P	194294-92-3P
	194294-93-4P	194294-94-5P	194294-95-6P
	194294-96-7P	194294-97-8P	194294-98-9P
	194294-99-0P	194295-00-6P	194295-01-7P
	194295-11-9P		

(reactive surfactants for emulsifiers for polymn. and fiber finishing)


RN 194294-90-1 HCAPLUS

CN 2-Propanol, 1-(2-propen-1-yloxy)-3-[(1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexyl)oxy]-, 2-(hydrogen sulfate), sodium salt (1:1) (CA INDEX NAME)




RN 194294-91-2 HCAPLUS

CN Heptanoic acid, 2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoro-,  
3-(2-propen-1-yloxy)-2-(sulfooxy)propyl ester, sodium salt (1:1) (CA  
INDEX NAME)




RN 194294-92-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(2-  
propenyloxy)methyl]-2-[(tridecafluorohexyl)oxy]ethoxy]- (9CI) (CA  
INDEX NAME)




RN 194294-93-4 HCAPLUS


CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(2-  
propenyloxy)methyl]-2-[(tridecafluorohexyl)oxy]ethoxy]-, potassium  
salt (9CI) (CA INDEX NAME)




RN 194294-94-5 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(2-propenyloxy)methyl]-2-[(2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoro-1-oxoheptyl)oxy]ethoxy]- (9CI) (CA INDEX NAME)





RN 194294-95-6 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(2-propenyloxy)methyl]-2-[(2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoro-1-oxoheptyl)oxy]ethoxy]-, potassium salt (9CI) (CA INDEX NAME)



RN 194294-96-7 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-[[heptatriacontafluorooctadecyl)oxy]methyl]-2-[(2-methyl-2-propenyl)oxy]ethoxy]-, disodium salt (9CI) (CA INDEX NAME)




RN 194294-97-8 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-[[heptatriacontafluorooctadecyl)oxy]methyl]-2-[(2-methyl-2-propenyl)oxy]ethoxy]-, diammonium salt (9CI) (CA INDEX NAME)




RN 194294-98-9 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-  
[[ (heptatriacontafluorooctadecyl)oxy]methyl]-2-[(2-methyl-2-  
propenyl)oxy]ethoxy]-, magnesium salt (9CI) (CA INDEX NAME)





RN 194294-99-0 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-  
[[ (2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15  
,16,16,17,17,18,18,19,19,19-heptatriacontafluoro-1-  
oxononadecyl)oxy]methyl]-2-[(2-methyl-2-propenyl)oxy]ethoxy]-,  
disodium salt (9CI) (CA INDEX NAME)




RN 194295-00-6 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-  
[[ (2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15  
,16,16,17,17,18,18,19,19,19-heptatriacontafluoro-1-  
oxononadecyl)oxy]methyl]-2-[(2-methyl-2-propenyl)oxy]ethoxy]-,  
diammonium salt (9CI) (CA INDEX NAME)




RN 194295-01-7 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-  
 [[(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15  
 ,16,16,17,17,18,18,19,19,19-heptatriacontafluoro-1-  
 oxononadecyl)oxy]methyl]-2-[(2-methyl-2-propenyl)oxy]ethoxy]-,  
 magnesium salt (9CI) (CA INDEX NAME)



RN 194295-11-9 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-  
 [[(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluorononyl)oxy]methyl]-2-  
 (2-propenyloxy)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)



IPCI C07C0043-178 [ICM,6]; C07C0069-34 [ICS,6]; C07C0069-66 [ICS,6];  
 C07C0305-10 [ICS,6]; C07F0009-09 [ICS,6]; C08G0065-28 [ICS,6];  
 C08G0065-32 [ICS,6]; C09K0003-00 [ICS,6]

IPCR C07C0043-178 [I,A]; C07C0069-63 [I,A]; C07C0305-10 [I,A]; C07F0009-09  
 [I,A]; C08G0065-00 [I,A]; C08G0065-14 [I,A]; C08G0065-26 [I,A];  
 C08G0065-28 [I,A]

CC 40-9 (Textiles and Fibers)

Section cross-reference(s): 37, 46

IT 194295-73-3P ~~194295-78-8P~~ 194295-80-2P 194295-83-5P

	194295-87-9P	194295-91-5P	194295-94-8P	194295-97-1P
	194296-01-0P	194296-05-4P		
	(antifogging and antistatic polymers)			
IT	194296-29-2P	194296-31-6P	194296-33-8P	194296-35-0P
	194296-37-2P	194296-39-4P	194296-41-8P	194296-43-0P
	194296-45-2P	194296-47-4P		
	(antistatic and antifogging polymers)			
IT	194296-07-6P	194296-09-8P	194296-11-2P	194296-13-4P
	194296-15-6P	194296-18-9P	194296-20-3P	194296-22-5P
	194296-25-8P	194296-27-0P		
	(fibers; antisoiling fabrics)			
IT	194295-15-3P	194295-16-4P	194295-17-5P	194295-18-6P
	194295-19-7P	194295-20-0P	194295-21-1P	194295-22-2P
	194295-23-3P	194295-24-4P	194295-25-5P	
	194295-26-6P	194295-27-7P	194295-28-8P	194295-29-9P
	194295-30-2P	194295-31-3P	194295-32-4P	
	194295-33-5P	194295-34-6P	194295-35-7P	
	194295-36-8P	194295-37-9P	194295-38-0P	194295-39-1P
	194295-40-4P	194295-41-5P	194295-42-6P	
	194295-43-7P	194295-44-8P		
	(manuf. and reactive surfactants as emulsifiers for)			
IT	194295-45-9P	194295-46-0P	194295-47-1P	194295-48-2P
	194295-49-3P	194295-50-6P	194295-51-7P	194295-52-8P
	194295-53-9P	194295-54-0P	194295-55-1P	
	194295-56-2P	194295-58-4P	194295-60-8P	194295-62-0P
	194295-64-2P	194295-66-4P	194295-68-6P	
	194295-70-0P	194295-72-2P		
	(manuf. of antifogging and antistatic polymers and reactive surfactants as emulsifiers for)			
IT	194294-82-1P	194294-83-2P	194294-84-3P	194294-85-4P
	194294-86-5P	194294-87-6P	194294-88-7P	194294-89-8P
	194294-90-1P	194294-91-2P	194294-92-3P	
	194294-93-4P	194294-94-5P	194294-95-6P	
	194294-96-7P	194294-97-8P	194294-98-9P	
	194294-99-0P	194295-00-6P	194295-01-7P	
	194295-02-8P	194295-03-9P	194295-04-0P	194295-05-1P
	194295-06-2P	194295-07-3P	194295-08-4P	194295-09-5P
	194295-10-8P	194295-11-9P	194295-12-0P	194295-13-1P
	194295-14-2P	194368-99-5P	194369-00-1P	194369-01-2P
	194369-02-3P			
	(reactive surfactants for emulsifiers for polymn. and fiber finishing)			
OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)		
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		
L39 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN				
ACCESSION NUMBER:	1996:248322 HCAPLUS <u>Full-text</u>			
DOCUMENT NUMBER:	124:345042			
ORIGINAL REFERENCE NO.:	124:64091a,64094a			
TITLE:	Storage-stable aqueous polymer compositions for coating films with good water and chemical resistances and strength			
INVENTOR(S):	Nakahata, Takashi; Nakada, Tadahihiro; Oka, Masashi			


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08034897	A	19960206	JP 1994-172225	19940725
			<--	
JP 3508030	B2	20040322		
PRIORITY APPLN. INFO.:			JP 1994-172225	19940725
			<--	

AB Title comps. (solids content 2-90%) contain (A) 1-85% polyurethanes and (B) 1-85% acrylic polymers obtained by polymg. acrylic unsatd. monomer mixts. in the presence of reactive emulsifiers having copolymerizable unsatd. bonds. The reactive emulsifiers may be  $\text{CH}_2:\text{CR}_1\text{XCH}_2\text{CH}(\text{OZ})\text{CH}_2\text{O}(\text{AO})\text{mR}_2$  [ $\text{R}_1 = \text{H, Me}$ ;  $\text{R}_2 = \text{C}_6\text{-30}$  hydrocarbyl, acyl;  $\text{A} = \text{C}_2\text{-4}$  alkylene;  $\text{X} = \text{CH}_2\text{O, C}(\text{O})\text{O, CH}_2\text{OC}(\text{O})$ ;  $\text{Z} = \text{H, nonionic or anionic hydrophilic group}$ ;  $\text{m} = 0\text{-100}$ ]. Thus, 200 parts aq. polyurethane (prepd. from polypropylene glycol 49, dicyclohexylmethane diisocyanate 176, dimethylolpropionic acid 70, N-methylpyrrolidone 196,  $\text{Et}_3\text{N}$  48, hexamethylenediamine 5, and  $\text{H}_2\text{O}$  456 parts) and 233 parts acrylic emulsion [prepd. from Me methacrylate 45, Bu acrylate 45, glycidyl methacrylate 10,  $\text{CH}_2:\text{CHCH}_2\text{OCH}_2\text{CH}[\text{O}(\text{C}_2\text{H}_4\text{O})_{10}\text{SO}_3\text{NH}_4]\text{CH}_2\text{OC}_6\text{H}_4\text{C}_9\text{H}_{19}\text{-p } 3, (\text{NH}_4)_2\text{S}_2\text{O}_8$  0.6, and  $\text{H}_2\text{O}$  130 parts] were mixed to give a 40% storage-stable aq. compn., which was applied on a glassplate to give a coating film with good water and chem. resistances.

(storage-stable aq. polyurethane-acrylic polymer compns. for coating films with good water and chem. resistances and strength)

CN	2-Propenoic acid, 2-methyl-, methyl ester, polymer with butyl 2-propenoate, oxiranylmethyl 2-methyl-2-propenoate and .alpha.-sulfo-.omega.-[1-[ (4-nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI)	(CA
	INDEX NAME)	


CCI	PMS
-----	-----






CM 2

CRN 141-32-2  
 CMF C7 H12 O2




CM 3

CRN 106-91-2  
 CMF C7 H10 O3



CM 4

CRN 80-62-6  
 CMF C5 H8 O2




RN 176744-69-7 HCAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with butyl  
 2-propenoate, ethenylbenzene, N-(hydroxymethyl)-2-propenamide,  
 oxiranylmethyl 2-methyl-2-propenoate and  
 .alpha.-sulfo-.omega.-[1-[(4-nonylphenoxy)methyl]-2-(2-  
 propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI) (CA  
 INDEX NAME)

CM 1


CRN 136931-77-6  
 CMF (C2 H4 O)<sub>n</sub> C21 H34 O6 S . H3 N  
 CCI PMS

10/596,747




CM 2

CRN 924-42-5  
CMF C4 H7 N O2




CM 3

CRN 141-32-2  
CMF C7 H12 O2




CM 4

CRN 106-91-2  
CMF C7 H10 O3



CM 5


CRN 100-42-5  
CMF C8 H8



CM 6

CRN 80-62-6

CMF C5 H8 O2



RN 176744-70-0 HCAPLUS


CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
ethenylbenzene, 2-ethylhexyl 2-propenoate,  
N-(hydroxymethyl)-2-propenamide, oxiranylmethyl 2-methyl-2-propenoate  
and .alpha.-sulfo-.omega.-[1-[(4-nonylphenoxy)methyl]-2-(2-  
propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI) (CA  
INDEX NAME)

CM 1

CRN 136931-77-6

CMF (C2 H4 O)<sub>n</sub> C21 H34 O6 S . H3 N


CCI PMS



CM 2


CRN 924-42-5

CMF C4 H7 N O2




CM 3

CRN 106-91-2  
 CMF C7 H10 O3




CM 4

CRN 103-11-7  
 CMF C11 H20 O2




CM 5

CRN 100-42-5  
 CMF C8 H8



CM 6


CRN 80-62-6  
 CMF C5 H8 O2



RN 176744-71-1 HCAPLUS  
 CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with butyl  
 2-propenoate and .alpha.-sulfo-.omega.-[1-[(4-nonylphenoxy)methyl]-2-  
 (2-propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI)  
 (CA INDEX NAME)


CM 1

CRN 136931-77-6  
 CMF (C2 H4 O)<sub>n</sub> C21 H34 O6 S . H3 N  
 CCI PMS




CM 2

CRN 141-32-2  
 CMF C7 H12 O2



CM 3

CRN 80-62-6  
 CMF C5 H8 O2





RN 176744-75-5 HCAPLUS  
 CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with butyl  
 2-propenoate, oxiranylmethyl 2-methyl-2-propenoate and  
 .alpha.-phosphono-.omega.-[1-[(dodecyloxy)methyl]-2-(2-  
 propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) diammonium salt (9CI) (CA  
 INDEX NAME)

CM 1

CRN 176744-74-4

CMF (C2 H4 O)<sub>n</sub> C18 H37 O6 P . 2 H3 N


CCI PMS



CM 2

CRN 141-32-2


CMF C7 H12 O2



CM 3

CRN 106-91-2


CMF C7 H10 O3



CM 4

CRN 80-62-6

CMF C5 H8 O2




RN 176744-77-7 HCAPLUS

CN Butanedioic acid, sulfo-, 1-dodecyl 4-(2-propenyl) ester, sodium salt, polymer with butyl 2-propenoate, methyl 2-methyl-2-propenoate and oxiranylmethyl 2-methyl-2-propenoate (9CI) (CA INDEX NAME)

CM 1

CRN 162880-23-1


CMF C19 H34 O7 S . Na



CM 2

CRN 141-32-2


CMF C7 H12 O2



CM 3

CRN 106-91-2


CMF C7 H10 O3



CM 4

CRN 80-62-6

CMF C5 H8 O2




IPCI C08L0033-14 [ICM,6]; C08F0002-24 [ICS,6]; C08L0075-04 [ICS,6]  
 IPCR C08L0033-14 [I,A]; C08F0002-24 [I,A]; C08L0033-04 [I,A]; C08L0075-00  
 [I,A]; C08L0075-04 [I,A]  
 CC 37-6 (Plastics Manufacture and Processing)  
 Section cross-reference(s): 38, 42  
 IT 103336-45-4 113988-50-4 143482-33-1 157609-04-6 176744-65-3  
 176744-66-4 176744-67-5 176744-68-6  
 176744-69-7 176744-70-0 176744-71-1  
 176744-73-3 176744-75-5 176744-76-6  
 176744-77-7  
 (storage-stable aq. polyurethane-acrylic polymer compns. for  
 coating films with good water and chem. resistances and strength)

L39 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 1995:654989 HCAPLUS Full-text  
 DOCUMENT NUMBER: 123:35414  
 ORIGINAL REFERENCE NO.: 123:6490h,6491a  
 TITLE: Heat blocking-resistant coatings  
 INVENTOR(S): Ikebayashi, Nobuhiko; Koshio, Takeaki  
 PATENT ASSIGNEE(S): Hoechst Gosei KK, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07026165	A	19950127	JP 1993-220382	19930706
			<--	
PRIORITY APPLN. INFO.:			JP 1993-220382	19930706
			<--	

ED Entered STN: 05 Jul 1995  
 GI



I

AB Title coatings contain .alpha., .beta.-ethylenic monomer-based polymers prep'd. in the presence of emulsifiers CH<sub>2</sub>:CR1CH<sub>2</sub>OCH<sub>2</sub>CH(OZ)CH<sub>2</sub>O(AO)mR<sub>2</sub> (A = C<sub>2</sub>-4 alkylene;



R1 = H, Me; R2 = C8-24 hydrocarbyl or acyl; Z = H, nonionic or anionic hydrophilic groups), pigments, and colloidal SiO<sub>2</sub> with  $Y \geq [25 - (1/4 \cdot X)]$  and  $X = 5-90$ , in which  $X \text{ wt.}\% = \text{pigments} / (\text{SiO}_2 \text{ composite polymers} + \text{pigments})$  and  $Y \text{ wt.}\% = \text{SiO}_2 / [\text{SiO}_2 \text{ composite polymers} - (\text{polymers} + \text{SiO}_2)]$ . A mixt. of 13-nm SiO<sub>2</sub> particles and an emulsion contg. 100-nm polymer particles prep'd. from Bu acrylate, Me methacrylate, and methacrylic acid in the presence of I was further mixed with TiO<sub>2</sub>, CaCO<sub>3</sub>, and other additives gave a compn. with  $X = 60\%$  and  $Y = 29.4\%$  and showing good heat blocking resistance and storage stability at 50.degree. for 1 wk.

IT	164463-57-4	164463-58-5	164463-59-6
	164463-60-9	164463-62-1	

(silica composite; coatings with heat blocking resistance and storage stability)

RN 164463-57-4 HCAPLUS


CN 2-Propenoic acid, 2-methyl-, polymer with butyl 2-propenoate, methyl 2-methyl-2-propenoate and .alpha.-sulfo-.omega.-[1-[4-(nonyloxy)phenoxy]methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI) (CA INDEX NAME)

CM 1

CRN 164463-56-3

CMF (C2 H4 O)<sub>n</sub> C21 H34 O7 S . H3 N


CCI      PMS



CM 2

CRN 141-32-2


CMF C7 H12 O2



CM 3

CRN 80-62-6


CMF C5 H8 O2



CM 4

CRN 79-41-4

CMF C4 H6 O2



RN 164463-58-5 HCAPLUS


CN	2-Propenoic acid, 2-methyl-, polymer with butyl 2-propenoate, ethenyltriethoxysilane, methyl 2-methyl-2-propenoate and .alpha.-sulfo-.omega.-[1-[4-(nonyloxy)phenoxy]methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI)	(CA INDEX NAME)
----	---	-----------------

CM 1

CRN 164463-56-3

$$\text{CMF} \quad (\text{C}_2 \text{ H}_4 \text{ O})_n \text{ C}_{21} \text{ H}_{34} \text{ O}_7 \text{ S} \cdot \text{H}_3 \text{ N}$$


CCI      PMS



CM 2


CRN 141-32-2

CMF C7 H12 O2




CM 3

CRN 80-62-6  
CMF C5 H8 O2




CM 4

CRN 79-41-4  
CMF C4 H6 O2



CM 5

CRN 78-08-0  
CMF C8 H18 O3 Si



RN 164463-59-6 HCAPLUS  
CN 2-Propenoic acid, 2-methyl-, polymer with butyl 2-propenoate, ethenylbenzene, methyl 2-methyl-2-propenoate and .alpha.-sulfo-.omega.-[1-[[4-(nonyloxy)phenoxy]methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI) (CA INDEX NAME)


CM 1

10/596,747

CRN 164463-56-3

CMF (C2 H4 O)<sub>n</sub> C21 H34 O7 S . H3 N


CCI PMS



CM 2

CRN 141-32-2


CMF C7 H12 O2



CM 3

CRN 100-42-5


CMF C8 H8



CM 4


CRN 80-62-6

CMF C5 H8 O2



CM 5

CRN 79-41-4  
 CMF C4 H6 O2




RN 164463-60-9 HCAPLUS

CN 2-Propenoic acid, 2-methyl-, polymer with butyl 2-propenoate, methyl 2-methyl-2-propenoate, 2-propenoic acid and .alpha.-sulfo-.omega.-[1-[[4-(nonyloxy)phenoxy]methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI) (CA INDEX NAME)


CM 1

CRN 164463-56-3  
 CMF (C2 H4 O)<sub>n</sub> C21 H34 O7 S . H3 N  
 CCI PMS



CM 2


CRN 141-32-2  
 CMF C7 H12 O2



CM 3

CRN 80-62-6


CMF C5 H8 O2



CM 4

CRN 79-41-4


CMF C4 H6 O2



CM 5

CRN 79-10-7

CMF C3 H4 O2



RN 164463-62-1 HCAPLUS

CN 2-Propenoic acid, 2-methyl-, polymer with butyl 2-propenoate, methyl 2-methyl-2-propenoate and .alpha.-phosphono-.omega.-[1-[[4-(nonyloxy)phenoxy]methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) disodium salt (9CI) (CA INDEX NAME)


CM 1

CRN 164463-61-0

CMF (C2 H4 O)<sub>n</sub> C21 H35 O7 P . 2 Na


CCI PMS

10/596,747




CM 2

CRN 141-32-2  
CMF C7 H12 O2




CM 3

CRN 80-62-6  
CMF C5 H8 O2



CM 4

CRN 79-41-4  
CMF C4 H6 O2



IPCI C09D0001-00 [ICM,6]; C08F0002-24 [ICS,6]; C09D0005-00 [ICS,6];  
C09D0005-02 [ICS,6]; C09D0007-12 [ICS,6]  
IPCR C08F0002-24 [I,A]; C09D0001-00 [I,A]; C09D0005-00 [I,A]; C09D0005-02  
[I,A]; C09D0007-12 [I,A]

CC 42-7 (Coatings, Inks, and Related Products)

IT 164463-57-4 164463-58-5 164463-59-6  
164463-60-9 164463-62-1

(silica composite; coatings with heat blocking resistance and storage stability)

L39 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1995:571394 HCAPLUS Full-text

DOCUMENT NUMBER: 123:229313

ORIGINAL REFERENCE NO.: 123:40977a,40980a

TITLE: Dispersing agents for suspension polymerization of vinyl chloride monomers

INVENTOR(S): Mizutari, Takeaki; Tsuzuki, Masahide; Komya, Kaoru

PATENT ASSIGNEE(S): Asahi Denka Kogyo KK, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 07062005	A	19950307	JP 1993-211809	19930826

<--

PRIORITY APPLN. INFO.: JP 1993-211809 19930826

<--

ED Entered STN: 25 May 1995

AB Title agents which do not remain in the product polymers in a free state comprise C2:CR1CH2OCH2CH(OX)CH2O(AO)nR2 [sic; A = C2-4 alkylene; R1 = H, Me; R2 = C1-24 hydrocarbyl, acyl; n = 0-50; X = hydrophilic group of (AO)mH, (AO)rSO3M, or (AO)kP(O)(OM1)(OM2); M1, M2 = H, alkali metal, alk. earth metal, (org.) ammonium; m = 1-100; r, k = 1-50]. Thus, equimolar nonylphenol and allyl glycidyl ether were reacted at 90 .+-. 5.degree. for 5 h and then 1 mol the resulting product was further reacted with 10 mol ethylene oxide to obtain a dispersing agent (I). Then 100 parts vinyl chloride was polymd. in H2O in the presence of 1 part I and di-2-ethylhexyl peroxydicarbonate at 57.degree. for 7 h showing no scale deposition on the reactor wall. The resulting polymer showed good water resistance and thermal stability.


IT 111144-58-2P 168009-71-0P

(reactive dispersants for manuf. of thermally stable water-resistant vinyl chloride polymers)

RN 111144-58-2 HCAPLUS



CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(nonylphenoxy)methyl]-2-(2-propen-1-yloxy)ethoxy]-, sodium salt (1:1)  
(CA INDEX NAME)



D1-(CH<sub>2</sub>)<sub>8</sub>-Me

Na

RN 168009-71-0 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-  
 [(nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]-, sodium salt (9CI)  
 (CA INDEX NAME)



D1-(CH<sub>2</sub>)<sub>8</sub>-Me

x Na

IT 168009-72-1P 168009-73-2P 168009-74-3P  
 168009-75-4P 168009-76-5P 168109-70-4P  
 168109-71-5P 169970-88-1P  
 (reactive dispersants for manuf. of thermally stable  
 water-resistant vinyl chloride polymers)  
 RN 168009-72-1 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-  
 [(nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]-, sodium salt, polymer  
 with chloroethene (9CI) (CA INDEX NAME)

CM 1


CRN 168009-71-0  
 CMF (C2 H4 O)<sub>n</sub> C21 H35 O6 P . x Na  
 CCI IDS, PMS

D1-(CH<sub>2</sub>)<sub>8</sub>-Me

CM 2

CRN 75-01-4

CMF C2 H3 Cl



RN 168009-73-2 HCAPLUS



CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-  
[(nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]-, polymer with  
chloroethene and ethene (9CI) (CA INDEX NAME)

CM 1

CRN 168009-71-0


CMF (C2 H4 O)<sub>n</sub> C21 H35 O6 P . x Na

CCI IDS, PMS

D1-(CH<sub>2</sub>)<sub>8</sub>-Me

CM 2

CRN 75-01-4  
CMF C2 H3 C1



CM 3


CRN 74-85-1  
CMF C2 H4



RN 168009-74-3 HCAPLUS  
CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-(nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]-, sodium salt, polymer with chloroethene and ethene (9CI) (CA INDEX NAME)


CM 1

CRN 111144-58-2  
CMF (C2 H4 O)<sub>n</sub> C21 H34 O6 S . Na  
CCI IDS, PMS

D1-(CH<sub>2</sub>)<sub>8</sub>-Me

CM 2

CRN 75-01-4  
CMF C2 H3 C1



CM 3

CRN 74-85-1  
CMF C2 H4



RN 168009-75-4 HCAPLUS



CN Acetic acid ethenyl ester, polymer with chloroethene and  
.alpha.-phosphono-.omega.-[1-[(nonylphenoxy)methyl]-2-(2-  
propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) sodium salt (9CI) (CA  
INDEX NAME)

CM 1

CRN 168009-71-0  
CMF (C2 H4 O)<sub>n</sub> C21 H35 O6 P . x Na  
CCI IDS, PMS




D1-(CH<sub>2</sub>)<sub>8</sub>-Me



CM 2

CRN 108-05-4


CMF C4 H6 O2



CM 3

CRN 75-01-4

CMF C2 H3 Cl



RN 168009-76-5 HCAPLUS


CN Acetic acid ethenyl ester, polymer with chloroethene and  
 .alpha.-sulfo-.omega.-[1-[(nonylphenoxy)methyl]-2-(2-  
 propenyloxy)ethoxy][poly(oxy-1,2-ethanediyl)] sodium salt (9CI) (CA  
 INDEX NAME)

CM 1

CRN 111144-58-2

CMF (C2 H4 O)<sub>n</sub> C21 H34 O6 S . Na


CCI IDS, PMS

D1-(CH<sub>2</sub>)<sub>8</sub>-Me

CM 2

CRN 108-05-4


CMF C4 H6 O2



CM 3

CRN 75-01-4

CMF C2 H3 Cl



RN 168109-70-4 HCAPLUS



CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-(nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]-, sodium salt, polymer with chloroethene and ethoxyethene (9CI) (CA INDEX NAME)

CM 1

CRN 168009-71-0

CMF (C2 H4 O)<sub>n</sub> C21 H35 O6 P . x Na


CCI IDS, PMS

D1-(CH<sub>2</sub>)<sub>8</sub>-Me

CM 2

CRN 109-92-2


CMF C4 H8 O



CM 3

CRN 75-01-4

CMF C2 H3 Cl



RN 168109-71-5 HCAPLUS


CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-(nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]-, sodium salt, polymer with chloroethene and ethoxyethene (9CI) (CA INDEX NAME)

CM 1

CRN 111144-58-2

CMF (C2 H4 O)<sub>n</sub> C21 H34 O6 S . Na


CCI IDS, PMS

D1-(CH<sub>2</sub>)<sub>8</sub>-Me

CM 2

CRN 109-92-2


CMF C4 H8 O



CM 3

CRN 75-01-4

CMF C2 H3 Cl



RN 169970-88-1 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-(nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]-, sodium salt, polymer with chloroethene (9CI) (CA INDEX NAME)


CM 1

CRN 111144-58-2

CMF (C2 H4 O)<sub>n</sub> C21 H34 O6 S . Na

CCI IDS, PMS




D1-(CH<sub>2</sub>)<sub>8</sub>-Me

CM 2

CRN 75-01-4

CMF C2 H3 C1



IPCI C08F0002-18 [ICM,6]; B01F0017-42 [ICS,6]; C08F0014-06 [ICS,6]  
 IPCR B01F0017-42 [I,A]; C08F0002-18 [I,A]; C08F0014-00 [I,A]; C08F0014-06 [I,A]  
 CC 35-4 (Chemistry of Synthetic High Polymers)  
 Section cross-reference(s): 46  
 IT 75-21-8DP, Oxirane, reaction products with glycerol (meth)allyl ethers  
 75-56-9DP, reaction products with glycerol (meth)allyl ethers  
 26249-20-7DP, Butylene oxide, reaction products with glycerol (meth)allyl ethers 111144-58-2P 111144-60-6P  
 168009-71-0P 168111-42-0P 168399-97-1P  
 (reactive dispersants for manuf. of thermally stable water-resistant vinyl chloride polymers)  
 IT 75-01-4DP, polymers with alkoxyated glycerol (meth)allyl ethers  
 79-10-7DP, 2-Propenoic acid, esters, polymers with vinyl chloride and alkoxyated glycerol (meth)allyl ethers 168009-69-6P 168009-70-9P  
 168009-72-1P 168009-73-2P 168009-74-3P  
 168009-75-4P 168009-76-5P 168036-63-3P  
 168109-69-1P 168109-70-4P 168109-71-5P  
 168111-44-2P 168112-60-5P 168253-58-5P 168397-31-7P  
 168397-32-8P 168397-33-9P 168609-02-7P 169970-88-1P  
 199542-29-5P  
 (reactive dispersants for manuf. of thermally stable water-resistant vinyl chloride polymers)

L39 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 1993:192325 HCAPLUS Full-text

DOCUMENT NUMBER: 118:192325  
ORIGINAL REFERENCE NO.: 118:33065a,33068a  
TITLE: Synthesis of polymerizable surfactant and its application to emulsion polymerization  
AUTHOR(S): Yokota, Kinya; Ichihara, Akinobu; Shinike, Hitoshi  
CORPORATE SOURCE: Appl. Lab., Dai-Ichi Kogyo Seiyaku Co. Ltd., Kyoto, 600, Japan  
SOURCE: Special Publication - Royal Society of Chemistry (1992), 107(Ind. Appl. Surfactants III), 29-48  
CODEN: SROCDO; ISSN: 0260-6291  
DOCUMENT TYPE: Journal  
LANGUAGE: English


ED Entered STN: 14 May 1993

AB As polymerizable surfactants, ethoxylated 1-nonylphenoxy-2-hydroxy-3-(allyloxy)propane, its sulfate, and its phosphate were synthesized. Ethoxylated 2-allyl-4-nonylphenol, its sulfate, and its phosphate were also synthesized. The yields of these polymerizable surfactants were >95%. These polymerizable surfactants were applied as emulsifiers for emulsion polymn. of Et acrylate and Bu acrylate/styrene. Their polymn. stabilities were the same as those of surfactants commonly used and great improvements were seen in low foaming of the emulsion and water resistance of the polymer film.

IT 136931-77-6P 146847-16-7P 146847-17-8P  
(prepn. and surfactant properties of polymerizable)


RN 136931-77-6 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(4-nonylphenoxy)methyl]-2-(2-propen-1-yloxy)ethoxy]-, ammonium salt (1:1)  
(CA INDEX NAME)





RN 146847-16-7 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-(4-nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]- (9CI) (CA INDEX NAME)



RN 146847-17-8 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.,.alpha.'-phosphinicobis[.omega.-[1-  
[(4-nonylphenoxy)methyl]-2-(2-propen-1-yloxy)ethoxy]- (CA INDEX NAME)



IT 146847-26-9P 146847-31-6P  
(prepn. of)

RN 146847-26-9 HCAPLUS


CN 2-Propenoic acid, ethyl ester, polymer with  
.alpha.-sulfo-.omega.-[1-[(4-nonylphenoxy)methyl]-2-(2-propen-1-  
yloxy)ethoxy][poly(oxy-1,2-ethanediyl)] ammonium salt (1:1) (CA INDEX  
NAME)

CM 1

CRN 136931-77-6

CMF (C2 H4 O)n C21 H34 O6 S . H3 N


CCI PMS



CM 2

CRN 140-88-5


CMF C5 H8 O2



RN 146847-31-6 HCAPLUS  
 CN 2-Propenoic acid, butyl ester, polymer with  
 .alpha.-sulfo-.omega.-[1-[(4-nonylphenoxy)methyl]-2-(2-propen-1-  
 yloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (1:1) (CA INDEX  
 NAME)


CM 1

CRN 136931-77-6  
 CMF (C2 H4 O)n C21 H34 O6 S . H3 N  
 CCI PMS



CM 2

CRN 141-32-2  
 CMF C7 H12 O2



CC 35-2 (Chemistry of Synthetic High Polymers)  
 Section cross-reference(s): 46  
 IT 136931-77-6P 140651-97-4P 146847-16-7P  
 146847-17-8P 146847-18-9P 146847-19-0P  
 (prepn. and surfactant properties of polymerizable)  
 IT 140651-98-5P 146847-26-9P 146847-28-1P 146847-29-2P  
 146847-30-5P 146847-31-6P 146847-32-7P  
 (prepn. of)  
 OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS  
 RECORD (5 CITINGS)

L39 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 1992:450024 HCAPLUS Full-text  
 DOCUMENT NUMBER: 117:50024

ORIGINAL REFERENCE NO.: 117:8937a,8940a  
 TITLE: Oriented polyester films containing acrylic resin-treated inorganic particles  
 INVENTOR(S): Kuze, Katsuro; Matsumoto, Haruo; Murashige, Ryuichi  
 PATENT ASSIGNEE(S): Toyobo Co., Ltd., Japan; Nippon Magphane Co., Ltd.  
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04039336	A	19920210	JP 1990-145041	19900601
			<--	
JP 2767485	B2	19980618		
PRIORITY APPLN. INFO.:			JP 1990-145041	19900601
			<--	

ED Entered STN: 08 Aug 1992

AB The title films contain 0.005-3.0% inert inorg. particles having improved compatibility as a result of treatment with copolymers of .gtoreq.1 monomer H<sub>2</sub>C:CR<sub>1</sub>CO<sub>2</sub>X (R<sub>1</sub> = H, Me, HOCH<sub>2</sub>CH<sub>2</sub>; X = H, monovalent or divalent metal, ammonium, amine) and .gtoreq.1 allyl ether H<sub>2</sub>C:CHCH<sub>2</sub>OCH<sub>2</sub>[CH[CH<sub>2</sub>(OR<sub>3</sub>)rZ]]p(OR<sub>2</sub>)qY [R<sub>2</sub>-3 = C<sub>2</sub>-4 alkylene; Y, Z = OH, C<sub>1</sub>-4 alkoxy, [monovalent or divalent metal-, ammonium salt-, org. amine (salt)-, or C<sub>1</sub>-4 alkyl ester-substituted] monovalent phosphate group or sulfate group; Y and Z may form divalent phosphate, sulfonate, or sulfate group]. A mixt. of CaCO<sub>3</sub> and 98:2 acrylic acid-H<sub>2</sub>C:CHCH<sub>2</sub>OCH<sub>2</sub>CH[(OCH<sub>2</sub>CH<sub>2</sub>)nOPO<sub>3</sub>H<sub>2</sub>]CH<sub>2</sub>(OCH<sub>2</sub>CH<sub>2</sub>)nOPO<sub>3</sub>H<sub>2</sub> copolymer was spray dried to prep. a filler, and a polyester was prepd. from terephthalic acid and ethylene glycol in the presence of the filler, giving a product which formed a film having dynamic friction coeff. 0.38, haze 5.7%, and void ratio 0.25%.

IT 142551-11-9 142551-13-1 142551-82-4  
 142571-36-6

(fillers modified by, for compatibility in oriented polyester films)


RN 142551-11-9 HCAPLUS

CN 2-Propenoic acid, 2-methyl-, sodium salt, polymer with  
 1-[(2-propenyloxy)methyl]-1,2-ethanediyl bis(hydrogen sulfate) (9CI)  
 (CA INDEX NAME)

CM 1


CRN 142551-10-8

CMF C6 H12 O9 S2



CM 2

CRN 5536-61-8  
CMF C4 H6 O2 . Na




● Na

RN 142551-13-1 HCAPLUS  
CN 2-Propenoic acid, ammonium salt, polymer with  
.alpha.,.alpha.'-[1-[(2-propenyloxy)methyl]-1,2-ethanediyl]bis[.omega.-  
(sulfooxy)poly(oxy-1,2-ethanediyl)] sodium salt (9CI) (CA INDEX NAME)

CM 1


CRN 142551-12-0  
CMF (C2 H4 O)n (C2 H4 O)n C6 H12 O9 S2 . x Na  
CCI PMS



●<sub>x</sub> Na

CM 2

CRN 10604-69-0  
CMF C3 H4 O2 . H3 N



● NH<sub>3</sub>

RN 142551-82-4 HCAPLUS  
CN 2-Propenoic acid, polymer with  
.alpha.,.alpha.'-[1-[(2-propenyloxy)methyl]-1,2-ethanediyl]bis[.omega.-

10/596,747


(phosphonooxy)poly(oxy-1,2-ethanediyl)] (9CI) (CA INDEX NAME)

CM 1

CRN 90717-19-4

CMF (C2 H4 O)n (C2 H4 O)n C6 H14 O9 P2


CCI PMS



CM 2

CRN 79-10-7

CMF C3 H4 O2




RN 142571-36-6 HCAPLUS

CN 2-Propenoic acid, sodium salt, polymer with  
2-hydroxy-3-(2-propenyloxy)-1-propanesulfonic acid monopotassium salt  
(9CI) (CA INDEX NAME)

CM 1

CRN 84019-66-9


CMF C6 H12 O5 S . K



CM 2

CRN 7446-81-3

CMF C3 H4 O2 . Na



● Na

IPCI C08J0005-18 [ICM,5]; C08K0009-04 [ICS,5]; C08F0216-14 [ICA,5];  
 C08F0216-16 [ICA,5]; C08L0067-02 [ICA,5]; C08L0067-02 [ICI,5]  
 IPCR C08J0005-18 [I,A]; B29C0055-02 [I,A]; B29K0067-00 [N,A]; B29L0007-00  
 [N,A]; C08F0016-14 [I,A]; C08F0016-16 [I,A]; C08F0216-14 [I,A];  
 C08F0216-16 [I,A]; C08K0009-04 [I,A]; C08L0067-00 [I,A]; C08L0067-02  
 [I,A]  
 CC 37-6 (Plastics Manufacture and Processing)  
 Section cross-reference(s): 38  
 IT 142551-11-9 142551-13-1 142551-82-4  
 142551-83-5 142571-36-6  
 (fillers modified by, for compatibility in oriented polyester  
 films)

L39 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 1992:428378 HCAPLUS Full-text  
 DOCUMENT NUMBER: 117:28378  
 ORIGINAL REFERENCE NO.: 117:5123a,5126a  
 TITLE: Allyl ether copolymers as coupling agents for  
 inert fillers in oriented polyester films for  
 improving sliding properties  
 INVENTOR(S): Kuze, Katsuro; Matsumoto, Haruo; Murashige,  
 Ryuichi  
 PATENT ASSIGNEE(S): Toyobo Co., Ltd., Japan; Nippon Magphane Co., Ltd.  
 SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 04033933	A	19920205	JP 1990-140667	19900529
			<--	
PRIORITY APPLN. INFO.:			JP 1990-140667	19900529
			<--	

ED Entered STN: 26 Jul 1992

AB The title couplers are obtained from copolymers of allyl ethers  
 $\text{CH}_2:\text{CHCH}_2\text{OCH}_2(\text{ZH})\text{p}(\text{OZ}_1)\text{qR}_1$  [I; Z = C[CH<sub>2</sub>(OZ<sub>2</sub>)rR<sub>2</sub>]; p = 1-4; q, r = 0-100; Z<sub>1</sub>-2 =  
 C<sub>2</sub>-4 alkylene; R<sub>1</sub>-2 = OH, alkoxy, monophosphoric acid, salts or esters, and  
 monosulfonic acid, salts or esters, or R<sub>1</sub>-2 together can form a divalent similar  
 phosphate and sulfonate group in the above], (meth)acrylic acids, their salts or  
 esters, and unsatd. dicarboxylic acids selected from maleic, fumaric or itaconic  
 acids, their salts or diesters. Thus, mixing an aq. soln. of a 80:18:2 acrylic  
 acid-diammonium maleate-3-allyloxy-1,2- di(polyoxyethylene)propanephosphate  
 (i.e. I, with q, r = .apprx.4) copolymer with CaCO<sub>3</sub> in solids wt. ratio 0.005:1,  
 and spray drying gave treated particles. Biaxially oriented PET film contg. 0.25%



of the particles had surface roughness 0.025 .mu.m, dynamic friction coeff. 0.37 .mu.d, haze 5.0%, void ratio 0.17%, and no. of broken void 0.05/mm2, compared to 0.020, 0.43, 13.2, 1.35, and 1.2, resp. for similar film contg. fillers without the I treatment.

IT 142357-64-0 142357-65-1 142357-67-3

(couplers, for inert fillers in polyester films for tapes, for improved sliding properties)

RN 142357-64-0 HCAPLUS


CN 2-Butenedioic acid (2Z)-, diammonium salt, polymer with 2-propenoic acid and .alpha.,.alpha.'-[1-[(2-propenyloxy)methyl]-1,2-ethanediyl]bis[.omega.-(phosphonooxy)poly(oxy-1,2-ethanediyl)] (9CI)  
(CA INDEX NAME)

CM 1

CRN 90717-19-4

CMF (C2 H4 O)n (C2 H4 O)n C6 H14 O9 P2

CCI PMS




CM 2

CRN 23705-99-9

CMF C4 H4 O4 . 2 H3 N

Double bond geometry as shown.




● 2 NH<sub>3</sub>

CM 3

CRN 79-10-7


CMF C3 H4 O2



RN 142357-65-1 HCAPLUS  
 CN 2-Butenedioic acid (2E)-, disodium salt, polymer with  
 2-hydroxy-3-(2-propenyloxy)-1-propanesulfonic acid monosodium salt and  
 sodium 2-propenoate (9CI) (CA INDEX NAME)

CM 1


CRN 52556-42-0  
 CMF C6 H12 O5 S . Na



CM 2


CRN 17013-01-3  
 CMF C4 H4 O4 . 2 Na

Double bond geometry as shown.



CM 3

CRN 7446-81-3  
 CMF C3 H4 O2 . Na




RN 142357-67-3 HCAPLUS  
 CN 2-Butenedioic acid (2Z)-, disodium salt, polymer with 2-propenoic acid  
 and .alpha.,.alpha.'-[1-[(2-propenyloxy)methyl]-1,2-  
 ethanediyl]bis[.omega.-(sulfooxy)poly(oxy-1,2-ethanediyl)] disodium  
 salt (9CI) (CA INDEX NAME)

CM 1

CRN 142357-66-2

CMF (C2 H4 O)n (C2 H4 O)n C6 H12 O9 S2 . 2 Na

CCI PMS




CM 2

CRN 371-47-1

CMF C4 H4 O4 . 2 Na


Double bond geometry as shown.



CM 3

CRN 79-10-7

CMF C3 H4 O2



IPCI C08J0005-18 [ICM,5]; C08K0009-04 [ICS,5]; C08L0067-02 [ICS,5];  
 C08L0067-00 [ICI,5]  
 IPCR C08J0005-18 [I,A]; C08K0009-04 [I,A]; C08L0067-00 [I,A]; C08L0067-02  
 [I,A]  
 CC 38-3 (Plastics Fabrication and Uses)  
 IT 142357-64-0 142357-65-1 142357-67-3  
 (couplers, for inert fillers in polyester films for tapes, for  
 improved sliding properties)

L39 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1988:133883 HCAPLUS Full-text

DOCUMENT NUMBER: 108:133883

ORIGINAL REFERENCE NO.: 108:21953a,21956a

TITLE: Surface-active compounds having a polymerizable  
 moiety from allyl glycidyl ether

INVENTOR(S): Yokota, Kinya; Ichihara, Akinobu

PATENT ASSIGNEE(S): Daiichi Kogyo Seiyaku Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 19 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 244841	A2	19871111	EP 1987-106533	19870506
			<--	
EP 244841	A3	19890607		
EP 244841	B1	19920318		
R: DE, FR, GB				
JP 63054927	A	19880309	JP 1986-105119	19860507
			<--	
JP 63054928	A	19880309	JP 1986-118956	19860522
			<--	
JP 63054929	A	19880309	JP 1986-121954	19860526
			<--	
JP 62279833	A	19871204	JP 1986-124305	19860528
			<--	
JP 63080837	A	19880411	JP 1986-127006	19860530
			<--	
JP 02022695	B	19900521		
US 4814514	A	19890321	US 1987-46353	19870506
			<--	
JP 63126535	A	19880530	JP 1987-198778	19870807
			<--	
JP 05076335	B	19931022		
JP 63214336	A	19880907	JP 1987-198779	19870807
			<--	
JP 04068013	B	19921030		
JP 63199271	A	19880817	JP 1987-208689	19870821
			<--	
JP 2589502	B2	19970312		
JP 63203872	A	19880823	JP 1987-208690	19870821
			<--	
JP 04002714	B	19920120		

JP 63205384	A	19880824	JP 1987-208691	19870821
			<--	
JP 05015753	B	19930302		
US 4939283	A	19900703	US 1988-284588	19881215
			<--	
PRIORITY APPLN. INFO.:			JP 1986-105119	A 19860507
			<--	
			JP 1986-118956	A 19860522
			<--	
			JP 1986-121954	A 19860526
			<--	
			JP 1986-124305	A 19860528
			<--	
			JP 1986-127006	A 19860530
			<--	
			US 1987-46353	A3 19870506
			<--	

## ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

ED Entered STN: 15 Apr 1988

AB Surfactants R1O(AO)xCH2CH[O(AO)yH]CH2OCH2CR2:CH2 (R1 = alkyl, alkenyl, alkyl aryl, or arylakylaryl contg. 8-30 C; R2 = H or Me; A = C2-4 alkylene; x = 0-100; y = 1-200) and their sulfate, phosphate, and sulfosuccinate esters are prepd. The surfactants are useful as emulsifiers in the emulsion or suspension polymn. of ethylenically unsatd. monomers, as finishing agents for hydrophobic textiles, as antistatic agents for plastics, as pigment dispersants, etc. A reaction product of 1.0 mol nonylphenol and 1.0 mol allyl glycidyl ether was ethoxylated with 10 mol oxirane and used as a copolymerizable emulsifier in the polymn. of a Bu acrylate-styrene mixt., giving a stable emulsion which was dried and cured at 110.degree. to give a water-resistant coating.

IT 113356-42-6P 113356-44-8P 113356-45-9P  
 113377-36-9P 113377-37-0P  
 113377-38-1P 113377-63-2P 113405-84-8P  
 113405-85-9P 113405-86-0P 113405-87-1P  
 113441-08-0P

(prepn. and surface activity of)

RN 113356-42-6 HCAPLUS


CN Oxirane, methyl-, polymer with oxirane, bis(1-phenylethyl)phenyl 2-hydroxy-3-(2-propenyloxy)propyl ether, diether with .alpha.,.alpha.'-(1,4-dioxo-2-sulfo-1,4-butanediyl)bis[.omega.-hydroxypoly(oxy-1,2-ethanediyl)], sodium salt, block (9CI) (CA INDEX NAME)


CM 1

CRN 177072-56-9

CMF (C2 H4 O)n (C2 H4 O)n C16 H26 O11 S

CCI PMS






CM 2


CRN 25640-70-4

CMF C22 H22 O

CCI IDS



1/2 ( D1—OH )



CM 3

CRN 106392-12-5


CMF (C3 H6 O . C2 H4 O) x

CCI PMS

CM 4

CRN 75-56-9

CMF C3 H6 O



CM 5


CRN 75-21-8  
CMF C2 H4 O




RN 113356-44-8 HCAPLUS  
CN Oxirane, methyl-, polymer with oxirane, bis(1-phenylethyl)phenyl  
2-hydroxy-3-(2-propenyloxy)propyl ether, diether with  
.alpha.,.alpha.'-phosphinicobis[.omega.-hydroxypoly(oxy-1,2-  
ethanediyl)], block (9CI) (CA INDEX NAME)

CM 1

CRN 177072-59-2  
CMF (C2 H4 O)<sub>n</sub> (C2 H4 O)<sub>n</sub> C12 H23 O8 P  
CCI PMS





PAGE 1-B



CM 2

CRN 25640-70-4  
CMF C22 H22 O  
CCI IDS



CM 3

CRN 106392-12-5


CMF (C3 H6 O . C2 H4 O) x

CCI PMS

CM 4

CRN 75-56-9

CMF C3 H6 O



CM 5

CRN 75-21-8

CMF C2 H4 O




RN 113356-45-9 HCAPLUS

CN Oxirane, methyl-, polymer with oxirane, bis(1-phenylethyl)phenyl  
2-hydroxy-3-(2-propenyloxy)propyl ether, ether with  
.alpha.-sulfo-.omega.-hydroxypoly(oxy-1,2-ethanediyl), ammonium salt,  
block (9CI) (CA INDEX NAME)

CM 1




CRN 177072-60-5  
 CMF (C2 H4 O)<sub>n</sub> C6 H12 O6 S  
 CCI PMS




CM 2

CRN 25640-70-4  
 CMF C22 H22 O  
 CCI IDS



$\frac{1}{2}$  ( D1-OH )




CM 3

CRN 106392-12-5  
 CMF (C3 H6 O . C2 H4 O)<sub>x</sub>  
 CCI PMS

CM 4

CRN 75-56-9  
 CMF C3 H6 O



CM 5


CRN 75-21-8

CMF C2 H4 O




RN 113377-36-9 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-  
[(dodecyloxy)methyl]-2-(2-propenyloxy)ethoxy]- (9CI) (CA INDEX NAME)



RN 113377-37-0 HCAPLUS


CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-  
[(dodecyloxy)methyl]-2-(2-propenyloxy)ethoxy]-, ammonium salt (9CI)  
(CA INDEX NAME)




RN 113377-38-1 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.,.alpha.'-phosphinicobis[.omega.-[1-  
[(dodecyloxy)methyl]-2-(2-propenyloxy)ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 113377-63-2 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.,.alpha.'-(1,4-dioxo-2-sulfo-1,4-butanediyl)bis[.omega.-[1-[(dodecyloxy)methyl]-2-(2-propenyloxy)ethoxy]-, sodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 113405-84-8 HCAPLUS


CN Poly(oxy-1,2-ethanediyl), .alpha.-phosphono-.omega.-[1-[(nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]- (9CI) (CA INDEX NAME)

D1-(CH<sub>2</sub>)<sub>8</sub>-Me

RN 113405-85-9 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-  
 [(nonylphenoxy)methyl]-2-(2-propen-1-yloxy)ethoxy]-, ammonium salt  
 (1:1) (CA INDEX NAME)




D1-(CH<sub>2</sub>)<sub>8</sub>-Me





RN 113405-86-0 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.,.alpha.'-phosphinicobis[.omega.-[1-  
 [(nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]- (9CI) (CA INDEX  
 NAME)

PAGE 1-A







2  $\left[ \text{D1-(CH}_2\text{)}_8\text{-Me} \right]$





RN 113405-87-1 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.,.alpha.'-(1,4-dioxo-2-sulfo-1,4-butanediyl)bis[.omega.-[1-[(nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]-, sodium salt (9CI) (CA INDEX NAME)





RN 113441-08-0 HCAPLUS


CN Oxirane, methyl-, polymer with oxirane, bis(1-phenylethyl)phenyl  
2-hydroxy-3-(2-propenyloxy)propyl ether, ether with  
.alpha.-phosphono-.omega.-hydroxypoly(oxy-1,2-ethanediyl) (9CI) (CA  
INDEX NAME)

CM 1

CRN 177072-61-6

CMF (C2 H4 O)<sub>n</sub> C6 H13 O6 P

CCI PMS




CM 2


CRN 25640-70-4

CMF C22 H22 O

CCI IDS



1/2 ( D1-OH )



CM 3

CRN 9003-11-6


CMF (C3 H6 O . C2 H4 O) x

CCI PMS

CM 4

CRN 75-56-9

CMF C3 H6 O



CM 5

CRN 75-21-8

CMF C2 H4 O




IT 113377-23-4P 113377-49-4P 113377-64-3P  
 (prepn. of self-emulsifiable, as adhesives)  
 RN 113377-23-4 HCAPLUS  
 CN Acetic acid ethenyl ester, polymer with  
 .alpha.-sulfo-.omega.-[1-[(dodecyloxy)methyl]-2-(2-  
 propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI) (CA  
 INDEX NAME)

CM 1

CRN 113377-37-0

CMF (C2 H4 O)<sub>n</sub> C18 H36 O6 S . H3 N


CCI PMS



CM 2

CRN 108-05-4

CMF C4 H6 O2



RN 113377-49-4 HCAPLUS


CN Acetic acid ethenyl ester, polymer with  
 .alpha.,.alpha.'-phosphinicobis[.omega.-[1-[(dodecyloxy)methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl)] and  
 .alpha.-phosphono-.omega.-[1-[(dodecyloxy)methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) (9CI) (CA INDEX NAME)

CM 1

CRN 113377-38-1


CMF (C2 H4 O)<sub>n</sub> (C2 H4 O)<sub>n</sub> C36 H71 O8 P

CCI PMS



PAGE 1-A






CM 2

CRN 113377-36-9

CMF (C2 H4 O)<sub>n</sub> C18 H37 O6 P


CCI PMS



CM 3

CRN 108-05-4

CMF C4 H6 O2



RN 113377-64-3 HCAPLUS


CN Acetic acid ethenyl ester, polymer with  
 .alpha.,.alpha.'-(1,4-dioxo-2-sulfo-1,4-butanediyl)bis[.omega.-[1-  
 [(dodecyloxy)methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl)]  
 sodium salt (9CI) (CA INDEX NAME)

CM 1


CRN 113377-63-2

CMF (C2 H4 O)<sub>n</sub> (C2 H4 O)<sub>n</sub> C40 H74 O11 S . Na

CCI PMS




● Na



CM 2

CRN 108-05-4

CMF C4 H6 O2



IT 113405-89-3P 113405-90-6P 113405-92-8P  
 113405-93-9P 113405-95-1P 113405-96-2P  
 113405-97-3P 113405-98-4P 113405-99-5P  
 113431-93-9P 113431-94-0P

(prepn. of self-emulsifiable, as coating materials)

RN 113405-89-3 HCAPLUS





CN 2-Propenoic acid, ethyl ester, polymer with  
 .alpha.,.alpha.'-phosphinicobis[.omega.-[1-[(nonylphenoxy)methyl]-2-(2-  
 propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl)] and  
 .alpha.-phosphono-.omega.-[1-[(nonylphenoxy)methyl]-2-(2-  
 propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) (9CI) (CA INDEX NAME)

CM 1

CRN 113405-86-0

CMF (C2 H4 O)n (C2 H4 O)n C42 H67 O8 P

CCI IDS, PMS




CM 2

CRN 113405-84-8

CMF (C2 H4 O)<sub>n</sub> C21 H35 O6 P


CCI IDS, PMS

D1-(CH<sub>2</sub>)<sub>8</sub>-Me

CM 3

CRN 140-88-5

CMF C5 H8 O2



RN 113405-90-6 HCAPLUS


CN 2-Propenoic acid, ethyl ester, polymer with  
 .alpha.-sulfo-.omega.-[1-[(nonylphenoxy)methyl]-2-(2-  
 propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI) (CA  
 INDEX NAME)

CM 1

CRN 113405-85-9

CMF (C2 H4 O)<sub>n</sub> C21 H34 O6 S . H3 N


CCI IDS, PMS

D1-(CH<sub>2</sub>)<sub>8</sub>-Me● NH<sub>3</sub>

CM 2

CRN 140-88-5

CMF C5 H8 O2



RN 113405-92-8 HCAPLUS


CN 2-Propenoic acid, butyl ester, polymer with ethenylbenzene and  
 .alpha.-sulfo-.omega.-[1-[(nonylphenoxy)methyl]-2-(2-  
 propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI) (CA  
 INDEX NAME)

CM 1

CRN 113405-85-9

CMF (C2 H4 O)<sub>n</sub> C21 H34 O6 S . H3 N


CCI IDS, PMS

D1-(CH<sub>2</sub>)<sub>8</sub>-Me

CM 2

CRN 141-32-2


CMF C7 H12 O2



CM 3

CRN 100-42-5

CMF C8 H8



RN 113405-93-9 HCAPLUS


CN 2-Propenoic acid, butyl ester, polymer with ethenylbenzene,  
 .alpha.-[1-[(nonylphenoxy)ethyl]-2-(2-propenyloxy)ethyl]-.omega.-  
 hydroxypoly(oxy-1,2-ethanediyl) and  
 .alpha.-sulfo-.omega.-[1-[(nonylphenoxy)methyl]-2-(2-  
 propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI) (CA  
 INDEX NAME)

CM 1

CRN 113405-85-9

CMF (C2 H4 O)<sub>n</sub> C21 H34 O6 S . H3 N

CCI IDS, PMS



D1-(CH<sub>2</sub>)<sub>8</sub>-Me

CM 2

CRN 111144-60-6


CMF (C2 H4 O)<sub>n</sub> C21 H34 O3

CCI IDS, PMS




CM 3

CRN 141-32-2  
CMF C7 H12 O2



CM 4

CRN 100-42-5  
CMF C8 H8




RN 113405-95-1 HCAPLUS  
CN 2-Propenoic acid, methyl ester, polymer with  
.alpha.-sulfo-.omega.-[1-[(nonylphenoxy)methyl]-2-(2-  
propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) ammonium salt (9CI) (CA  
INDEX NAME)

CM 1

CRN 113405-85-9  
CMF (C2 H4 O)n C21 H34 O6 S . H3 N  
CCI IDS, PMS




D1 - (CH<sub>2</sub>)<sub>8</sub> - Me



CM 2

CRN 96-33-3

CMF C4 H6 O2



RN 113405-96-2 HCAPLUS

CN 2-Propenoic acid, methyl ester, polymer with  
 .alpha.,.alpha.'-phosphinobis[.omega.-[1-[(nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl)] and  
 .alpha.-phosphono-.omega.-[1-[(nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) (9CI) (CA INDEX NAME)





CM 1

CRN 113405-86-0

CMF (C2 H4 O)<sub>n</sub> (C2 H4 O)<sub>n</sub> C42 H67 O8 P

CCI IDS, PMS





CM 2


CRN 113405-84-8

CMF (C2 H4 O)<sub>n</sub> C21 H35 O6 P

CCI IDS, PMS




D1-(CH<sub>2</sub>)<sub>8</sub>-Me



CM 3

CRN 96-33-3

CMF C4 H6 O2



RN 113405-97-3 HCAPLUS





CN 2-Propenoic acid, ethyl ester, polymer with  
 .alpha.,.alpha.'-(1,4-dioxo-2-sulfo-1,4-butanediyl)bis[.omega.-[1-  
 [(nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-  
 ethanediyl)] sodium salt (9CI) (CA INDEX NAME)

CM 1

CRN 113405-87-1

CMF (C2 H4 O)<sub>n</sub> (C2 H4 O)<sub>n</sub> C46 H70 O11 S . Na


CCI IDS, PMS



CM 2

CRN 140-88-5

CMF C5 H8 O2



RN 113405-98-4 HCAPLUS  
 CN 2-Propenoic acid, butyl ester, polymer with

.alpha.,.alpha.'-(1,4-dioxo-2-sulfo-1,4-butanediyl)bis[.omega.-[1-  
[(nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-  
ethanediyl)] sodium salt and ethenylbenzene (9CI) (CA INDEX NAME)




CM 1

CRN 113405-87-1


CMF (C2 H4 O)<sub>n</sub> (C2 H4 O)<sub>n</sub> C46 H70 O11 S . Na

CCI IDS, PMS

PAGE 1-A




PAGE 1-B



CM 2

CRN 141-32-2


CMF C7 H12 O2



CM 3

CRN 100-42-5

CMF C8 H8



RN 113405-99-5 HCAPLUS

CN 2-Propenoic acid, methyl ester, polymer with  
 .alpha.,.alpha.'-(1,4-dioxo-2-sulfo-1,4-butanediyl)bis[.omega.-[1-  
 [(nonylphenoxy)methyl]-2-(2-propenyloxy)ethoxy]poly(oxy-1,2-  
 ethanediyl)] sodium salt (9CI) (CA INDEX NAME)




CM 1


CRN 113405-87-1

CMF (C2 H4 O)<sub>n</sub> (C2 H4 O)<sub>n</sub> C46 H70 O11 S . Na

CCI IDS, PMS


PAGE 1-A





CM 2

CRN 96-33-3  
CMF C4 H6 O2







RN 113431-93-9 HCAPLUS

CN 2-Propenoic acid, butyl ester, polymer with ethenylbenzene,  
.alpha.,.alpha.'-phosphinicobis[.omega.-[1-[(nonylphenoxy)methyl]-2-(2-  
propenyloxy)ethyl]poly(oxy-1,2-ethanediyl)] and  
.alpha.-phosphono-.omega.-[1-[(nonylphenoxy)methyl]-2-(2-  
propenyloxy)ethyl]poly(oxy-1,2-ethanediyl) (9CI) (CA INDEX NAME)

CM 1

CRN 113405-86-0  
CMF (C2 H4 O)n (C2 H4 O)n C42 H67 O8 P  
CCI IDS, PMS




CM 2

CRN 113405-84-8


CMF (C2 H4 O)<sub>n</sub> C21 H35 O6 P

CCI IDS, PMS

D1-(CH<sub>2</sub>)<sub>8</sub>-Me


CM 3

CRN 141-32-2  
CMF C7 H12 O2



CM 4

CRN 100-42-5  
CMF C8 H8







RN 113431-94-0 HCAPLUS  
CN 2-Propenoic acid, butyl ester, polymer with ethenylbenzene,  
.alpha.-[1-[(nonylphenoxy)methyl]-2-(2-propenyloxy)ethyl]-.omega.-  
hydroxypoly(oxy-1,2-ethanediyl) and  
.alpha.,.alpha.'-phosphinicobis[.omega.-[1-[(nonylphenoxy)methyl]-2-(2-  
propenyloxy)ethyl]poly(oxy-1,2-ethanediyl)] (9CI) (CA INDEX NAME)

CM 1

CRN 113405-86-0  
CMF (C2 H4 O)n (C2 H4 O)n C42 H67 O8 P  
CCI IDS, PMS







CM 2

CRN 111144-60-6


CMF (C2 H4 O)<sub>n</sub> C21 H34 O3

CCI IDS, PMS




CM 3

CRN 141-32-2  
CMF C7 H12 O2



CM 4

CRN 100-42-5  
CMF C8 H8



IPCI C07C0043-23 [ICM,4]; C07C0043-178 [ICS,4]; C07C0141-08 [ICS,4];  
C07C0143-12 [ICS,4]; C07F0009-09 [ICS,4]; C08G0065-28 [ICS,4];  
C08F0002-24 [ICS,4]  
IPCR B01F0017-00 [I,A]; C07C0043-11 [I,A]; C07C0043-178 [I,A]; C07C0043-23  
[I,A]; C07C0305-06 [I,A]; C07C0305-10 [I,A]; C07C0309-17 [I,A];  
C07F0009-09 [I,A]; C08F0002-26 [I,A]; C08G0065-26 [I,A]; C08G0065-327  
[I,A]; C08G0065-334 [I,A]  
CC 46-4 (Surface Active Agents and Detergents)  
Section cross-reference(s): 35, 37, 38, 40, 42  
IT 111100-57-3P 111144-60-6P 113356-42-6P 113356-43-7P  
113356-44-8P 113356-45-9P 113356-46-0P  
113356-47-1P 113356-48-2P 113356-49-3P 113356-50-6P  
113356-51-7P 113356-52-8P 113377-36-9P  
113377-37-0P 113377-38-1P 113377-63-2P  
113405-81-5P 113405-83-7P 113405-84-8P  
113405-85-9P 113405-86-0P 113405-87-1P

113405-88-2P 113431-90-6P 113441-08-0P 113441-10-4P  
 (prepn. and surface activity of)  
 IT 113377-23-4P 113377-48-3P 113377-49-4P  
 113377-64-3P 113472-80-3P  
 (prepn. of self-emulsifiable, as adhesives)  
 IT 111144-66-2P 111144-70-8P 113405-89-3P  
 113405-90-6P 113405-91-7P 113405-92-8P  
 113405-93-9P 113405-94-0P 113405-95-1P  
 113405-96-2P 113405-97-3P 113405-98-4P  
 113405-99-5P 113431-93-9P 113431-94-0P  
 113473-94-2P 113473-95-3P 113473-96-4P  
 (prepn. of self-emulsifiable, as coating materials)  
 OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS  
 RECORD (20 CITINGS)

L39 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 1987:599133 HCAPLUS Full-text  
 DOCUMENT NUMBER: 107:199133  
 ORIGINAL REFERENCE NO.: 107:31967a,31970a  
 TITLE: Emulsifiers for emulsion polymerization  
 INVENTOR(S): Oka, Masashi; Komiya, Kaoru  
 PATENT ASSIGNEE(S): Asahi Denka Kogyo K. K., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
JP 62104802	A	19870515	JP 1986-171816	19860723
			<--	
JP 05075001	B	19931019		
JP 07165806	A	19950627	JP 1994-210055	19940902
			<--	
JP 07165807	A	19950627	JP 1994-210056	19940902
			<--	
PRIORITY APPLN. INFO.:			JP 1985-162055	A1 19850724
			<--	

ED Entered STN: 27 Nov 1987


AB The reactive title emulsifiers CH<sub>2</sub>:CRCH<sub>2</sub>OCH<sub>2</sub>CH(OX)CH<sub>2</sub>O(AO)<sub>n</sub>R<sub>1</sub> (A = C<sub>2</sub>-4 alkylene; R = H, Me; R<sub>1</sub> = C<sub>8</sub>-24 hydrocarbyl, acyl; n = 0-50; X = H, nonionic or nonionic hydrophilic group). Thus, nonylphenol was treated with allyl glycidyl ether in the presence of NaOH at 90.degree. for 5 h and ethoxylated to give an emulsifier (I). A soln. was prepd. from 80 g Et acrylate and 4 g I, and 8.4 g of this soln. was heated to 50.degree. with 0.08 g K<sub>2</sub>S<sub>2</sub>O<sub>8</sub> and 0.04 g NaHSO<sub>4</sub> in 120 g water to initiate the polymn., treated over 2 h with the remaining monomer soln. and further polymd. for 2 h to give a stable emulsion forming water-, weather- and heat-resistant films.

IT 111115-38-9 111115-40-3 111123-58-1  
 111123-59-2 111123-61-6 111123-62-7  
 111123-64-9 111123-65-0 111144-58-2  
 111144-59-3  
 (emulsifiers, reactive, for acrylic emulsion polymn.)  
 RN 111115-38-9 HCAPLUS

CN 2-Propanol, 1-(nonylphenoxy)-3-(2-propenyloxy)-, hydrogen sulfate,  
ammonium salt (9CI) (CA INDEX NAME)



D1-(CH<sub>2</sub>)<sub>8</sub>-Me




RN 111115-40-3 HCAPLUS

CN 2-Propanol, 1-(nonylphenoxy)-3-(2-propenyloxy)-, hydrogen sulfate,  
sodium salt (9CI) (CA INDEX NAME)




D1-(CH<sub>2</sub>)<sub>8</sub>-Me




RN 111123-58-1 HCAPLUS

CN 2-Propanol, 1-(dodecyloxy)-3-(2-propenyloxy)-, dihydrogen phosphate,  
dipotassium salt (9CI) (CA INDEX NAME)




RN 111123-59-2 HCAPLUS  
 CN 2-Propanol, 1-(2-propenyloxy)-3-(tridecyloxy)-, dihydrogen phosphate, dipotassium salt (9CI) (CA INDEX NAME)




● 2 K

RN 111123-61-6 HCAPLUS  
 CN 2-Propanol, 1-(dodecyloxy)-3-(2-propenyloxy)-, dihydrogen phosphate, disodium salt (9CI) (CA INDEX NAME)




● 2 Na

RN 111123-62-7 HCAPLUS  
 CN 2-Propanol, 1-(2-propenyloxy)-3-(tridecyloxy)-, dihydrogen phosphate, disodium salt (9CI) (CA INDEX NAME)




● 2 Na

RN 111123-64-9 HCAPLUS  
 CN 2-Propanol, 1-(dodecyloxy)-3-(2-propen-1-yloxy)-, 2-(hydrogen sulfate), sodium salt (1:1) (CA INDEX NAME)





● Na


RN 111123-65-0 HCAPLUS  
 CN 2-Propanol, 1-(2-propen-1-yloxy)-3-(tridecyloxy)-, 2-(hydrogen sulfate), sodium salt (1:1) (CA INDEX NAME)



RN 111144-58-2 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-[1-[(nonylphenoxy)methyl]-2-(2-propen-1-yloxy)ethoxy]-, sodium salt (1:1) (CA INDEX NAME)



RN 111144-59-3 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl), .alpha.-[3-(2-propenyloxy)-2-(sulfoxy)propyl]-.omega.-(nonylphenoxy)-, sodium salt (9CI) (CA INDEX NAME)

D1-(CH<sub>2</sub>)<sub>8</sub>-Me

● Na

IT    111123-60-5    111123-63-8    111123-66-1  
       111123-67-2    111123-68-3    111123-69-4  
       111144-68-4    111144-69-5    111144-72-0  
       111144-73-1    111165-72-1    111165-73-2  
       111165-74-3    111165-75-4

(emulsions, self-emulsifying, for water-, weather- and  
 heat-resistant films)


RN    111123-60-5    HCAPLUS

CN    2-Propenoic acid, butyl ester, polymer with  
 1-[(dodecyloxy)methyl]-2-(2-propenyloxy)ethyl dipotassium phosphate,  
 ethenylbenzene and 1-[(2-propenyloxy)methyl]-2-(tridecyloxy)ethyl  
 dipotassium phosphate (9CI)    (CA INDEX NAME)

CM    1

CRN    111123-59-2

CMF    C19 H39 O6 P . 2 K




● 2 K

CM    2

CRN    111123-58-1


CMF    C18 H37 O6 P . 2 K



● 2 K


CM 3

CRN 141-32-2  
CMF C7 H12 O2



CM 4


CRN 100-42-5  
CMF C8 H8



RN 111123-63-8 HCAPLUS  
CN 2-Propenoic acid, butyl ester, polymer with disodium  
1-[(dodecyloxy)methyl]-2-(2-propenyloxy)ethyl phosphate, disodium  
1-[(2-propenyloxy)methyl]-2-(tridecyloxy)ethyl phosphate and  
ethenylbenzene (9CI) (CA INDEX NAME)

CM 1

CRN 111123-62-7  
CMF C19 H39 O6 P . 2 Na




● 2 Na



CM 2

CRN 111123-61-6


CMF C18 H37 O6 P . 2 Na



CM 3

CRN 141-32-2


CMF C7 H12 O2



CM 4

CRN 100-42-5

CMF C8 H8




RN 111123-66-1 HCAPLUS

CN 2-Propenoic acid, butyl ester, polymer with ethenylbenzene, sodium  
 1-[(dodecyloxy)methyl]-2-(2-propenyloxy)ethyl sulfate and sodium  
 1-[(2-propenyloxy)methyl]-2-(tridecyloxy)ethyl sulfate (9CI) (CA  
 INDEX NAME)

CM 1

CRN 111123-65-0


CMF C19 H38 O6 S . Na



CM 2

CRN 111123-64-9


CMF C18 H36 O6 S . Na



CM 3

CRN 141-32-2


CMF C7 H12 O2



CM 4

CRN 100-42-5

CMF C8 H8




RN 111123-67-2 HCAPLUS

CN 2-Propenoic acid, ethyl ester, polymer with dipotassium  
 1-[(dodecyloxy)methyl]-2-(2-propenyloxy)ethyl phosphate and  
 dipotassium 1-[(2-propenyloxy)methyl]-2-(tridecyloxy)ethyl phosphate  
 (9CI) (CA INDEX NAME)

CM 1

CRN 111123-59-2

CMF C19 H39 O6 P . 2 K




● 2 K

CM 2

CRN 111123-58-1

CMF C18 H37 O6 P . 2 K




● 2 K

CM 3

CRN 140-88-5

CMF C5 H8 O2




RN 111123-68-3 HCAPLUS

CN 2-Propenoic acid, ethyl ester, polymer with disodium  
 1-[(dodecyloxy)methyl]-2-(2-propenyloxy)ethyl phosphate and disodium  
 1-[(2-propenyloxy)methyl]-2-(tridecyloxy)ethyl phosphate (9CI) (CA  
 INDEX NAME)

CM 1

CRN 111123-62-7


CMF C19 H39 O6 P . 2 Na



CM 2

CRN 111123-61-6


CMF C18 H37 O6 P . 2 Na



CM 3

CRN 140-88-5

CMF C5 H8 O2



RN 111123-69-4 HCAPLUS

CN 2-Propenoic acid, ethyl ester, polymer with sodium

1-[(dodecyloxy)methyl]-2-(2-propenyloxy)ethyl sulfate and sodium


1-[(2-propenyloxy)methyl]-2-(tridecyloxy)ethyl sulfate (9CI) (CA

INDEX NAME)

CM 1

CRN 111123-65-0


CMF C19 H38 O6 S . Na



CM 2

CRN 111123-64-9


CMF C18 H36 O6 S . Na



CM 3

CRN 140-88-5

CMF C5 H8 O2



RN 111144-68-4 HCAPLUS


CN 2-Propenoic acid, ethyl ester, polymer with  
 .alpha.-[3-(2-propenyloxy)-2-(sulfooxy)propyl]-.omega.-  
 (nonylphenoxy)poly(oxy-1,2-ethanediyl) sodium salt (9CI) (CA INDEX  
 NAME)

CM 1

CRN 111144-59-3

CMF (C2 H4 O)n C21 H34 O6 S . Na


CCI IDS, PMS

D1-(CH<sub>2</sub>)<sub>8</sub>-Me

CM 2

CRN 140-88-5

CMF C5 H8 O2



RN 111144-69-5 HCAPLUS


CN 2-Propenoic acid, ethyl ester, polymer with  
 .alpha.-sulfo-.omega.-[1-[(nonylphenoxy)methyl]-2-(2-  
 propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) sodium salt (9CI) (CA  
 INDEX NAME)

CM 1

CRN 111144-58-2

CMF (C2 H4 O)<sub>n</sub> C21 H34 O6 S . Na


CCI IDS, PMS

D1-(CH<sub>2</sub>)<sub>8</sub>-Me

CM 2

CRN 140-88-5

CMF C5 H8 O2



RN 111144-72-0 HCAPLUS


CN 2-Propenoic acid, butyl ester, polymer with ethenylbenzene and  
 .alpha.-[3-(2-propenyloxy)-2-(sulfooxy)propyl]-.omega.-  
 (nonylphenoxy)poly(oxy-1,2-ethanediyl) sodium salt (9CI) (CA INDEX  
 NAME)

CM 1

CRN 111144-59-3


CMF (C2 H4 O)<sub>n</sub> C21 H34 O6 S . Na

CCI IDS, PMS

D1-(CH<sub>2</sub>)<sub>8</sub>-Me


CM 2

CRN 141-32-2  
CMF C7 H12 O2



CM 3

CRN 100-42-5  
CMF C8 H8





RN 111144-73-1 HCAPLUS

CN 2-Propenoic acid, butyl ester, polymer with ethenylbenzene and  
.alpha.-sulfo-.omega.-[1-[(nonylphenoxy)methyl]-2-(2-  
propenyloxy)ethoxy]poly(oxy-1,2-ethanediyl) sodium salt (9CI) (CA  
INDEX NAME)

CM 1


CRN 111144-58-2  
CMF (C2 H4 O)<sub>n</sub> C21 H34 O6 S . Na  
CCI IDS, PMS






CM 2

CRN 141-32-2  
CMF C7 H12 O2



CM 3



CRN 100-42-5  
CMF C8 H8



RN 111165-72-1 HCAPLUS  
CN 2-Propenoic acid, butyl ester, polymer with ammonium  
1-[(nonylphenoxy)methyl]-2-(2-propenyloxy)ethyl sulfate and  
ethenylbenzene (9CI) (CA INDEX NAME)


CM 1

CRN 111115-38-9  
CMF C21 H34 O6 S . H3 N  
CCI IDS




CM 2

CRN 141-32-2  
CMF C7 H12 O2



CM 3

CRN 100-42-5  
CMF C8 H8




RN 111165-73-2 HCAPLUS  
CN 2-Propenoic acid, butyl ester, polymer with ethenylbenzene and sodium  
1-[(nonylphenoxy)methyl]-2-(2-propenyloxy)ethyl sulfate (9CI) (CA  
INDEX NAME)

CM 1

CRN 111115-40-3  
CMF C21 H34 O6 S . Na  
CCI IDS




D1-(CH<sub>2</sub>)<sub>8</sub>-Me




CM 2

CRN 141-32-2  
CMF C7 H12 O2



CM 3

CRN 100-42-5  
CMF C8 H8




RN 111165-74-3 HCAPLUS  
CN 2-Propenoic acid, ethyl ester, polymer with ammonium  
1-[(nonylphenoxy)methyl]-2-(2-propenyloxy)ethyl sulfate (9CI) (CA  
INDEX NAME)

CM 1

CRN 111115-38-9  
CMF C21 H34 O6 S . H3 N  
CCI IDS




D1-(CH<sub>2</sub>)<sub>8</sub>-Me



CM 2

CRN 140-88-5

CMF C5 H8 O2



RN 111165-75-4 HCAPLUS

CN 2-Propenoic acid, ethyl ester, polymer with sodium  
1-[(nonylphenoxy)methyl]-2-(2-propenyloxy)ethyl sulfate (9CI) (CA  
INDEX NAME)

CM 1


CRN 111115-40-3

CMF C21 H34 O6 S . Na

CCI IDS



D1-(CH<sub>2</sub>)<sub>8</sub>-Me



CM 2

CRN 140-88-5

CMF C5 H8 O2



IPCI C08F0002-24 [ICM,4]; B01F0017-42 [ICS,4]

IPCR B01F0017-42 [I,A]; B01F0017-00 [I,A]; C08F0002-24 [I,A]; C08F0216-14 [N,A]; C08F0230-02 [N,A]

CC 35-4 (Chemistry of Synthetic High Polymers)

Section cross-reference(s): 46

IT 25322-68-3D, ethers with secondary alcs., allyl derivs. 111100-57-3

111100-58-4 111115-38-9 111115-40-3

111123-58-1 111123-59-2 111123-61-6

111123-62-7 111123-64-9 111123-65-0

111144-58-2 111144-59-3 111144-60-6

111144-61-7

(emulsifiers, reactive, for acrylic emulsion polymn.)

IT 111100-59-5 111100-60-8 111123-60-5

111123-63-8 111123-66-1 111123-67-2

111123-68-3 111123-69-4 111144-66-2

111144-67-3 111144-68-4 111144-69-5

111144-70-8 111144-71-9 111144-72-0

111144-73-1 111165-72-1 111165-73-2

111165-74-3 111165-75-4




(emulsions, self-emulsifying, for water-, weather- and heat-resistant films)

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

=&gt; d que 148

L5 STR

SO3H @6 G1 7



G3 17

VAR G1=1/6

VAR G2=O/N/S

VAR G3=8/12

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

L7 28963 SEA FILE=REGISTRY SSS FUL L5

L10 STR



REP G1=(1-20) 13

NODE ATTRIBUTES:

NSPEC IS RC AT 13

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:



RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

L12 797 SEA FILE=REGISTRY SUB=L7 SSS FUL L10

L16 STR



A @19

REP G1=(1-20) 19

VAR G2=6/16

NODE ATTRIBUTES:

NSPEC IS RC AT 19

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED




NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L18 13442 SEA FILE=REGISTRY SUB=L7 SSS FUL L16  
 L20 14 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L12 AND L18  
 L21 8 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L20  
 L22 400 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L12  
 L23 13991 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L18  
 L25 58 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L22 AND PHARM?/SC,  
 SX  
 L26 44 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L25 AND (1802-2003  
 )/PRY,AY,PY  
 L27 37 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L22 AND L23  
 L28 20 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L27 AND (1802-2003  
 )/PRY,AY,PY  
 L29 2 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L21 AND (1802-2003  
 )/PRY,AY,PY  
 L30 20 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L28 OR L29  
 L33 STR



A @13



REP G1=(1-20) 13

VAR G2=15/18/21/COOH/SO3H

NODE ATTRIBUTES:


NSPEC IS RC AT 13

DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

L35 24 SEA FILE=REGISTRY SUB=L12 SSS FUL L33  
 L37 8 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L35  
 L38 3 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L37 AND (1802-2003  
 ) /PRY,AY,PY  
 L39 19 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L30 NOT L38  
 L40 STR



REP G1=(1-20) 13  
 NODE ATTRIBUTES:  
 NSPEC IS RC AT 13  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L42 112 SEA FILE=REGISTRY SUB=L12 SSS FUL L40  
 L43 30 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L42  
 L45 15 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L43 AND (1802-2003  
 ) /PRY,AY,PY  
 L46 54 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L45 OR L26  
 L47 48 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L46 NOT (38 OR  
 L39)  
 L48 39 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L47 AND PHARM?/SC,  
 SX

=> d l48 1-39 ibib ed abs fhitstr hitind

L48 ANSWER 1 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 2010:1405036 HCAPLUS Full-text  
 DOCUMENT NUMBER: 153:618952  
 TITLE: Novel hexahydropyrazinotriazinedione compounds of  
 reverse turn mimetics and their preparation and  
 use thereof  
 INVENTOR(S): Chung, Jae Uk; Jung, Kyung-Yun; Jeong, Min-Wook;  
 Jung, Hee-Kyung; La, Hyun-Ju



PATENT ASSIGNEE(S): Choongwae Pharma Corporation, S. Korea  
 SOURCE: U.S. Pat. Appl. Publ., 320 pp., Cont.-in-part of  
 U. S. Ser. No. 974,941.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 11  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20100286094	A1	20101111	US 2010-738066	20100723
			<--	
US 8080657	B2	20111220		
WO 2003031448	A1	20030417	WO 2002-KR1901	20021011
			<--	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,				
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,				
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,				
NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR,				
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1872856	A	20061206	CN 2006-10093786	20021011
			<--	
CN 1872857	A	20061206	CN 2006-10093787	20021011
			<--	
US 20040072831	A1	20040415	US 2003-411877	20030409
			<--	
US 20070021431	A1	20070125	US 2004-803179	20040317
			<--	
US 7232822	B2	20070619		
US 20070021425	A1	20070125	US 2004-826972	20040416
			<--	
US 7576084	B2	20090818		
US 20070043052	A1	20070222	US 2005-108164	20050415
			<--	
US 7566711	B2	20090728		
US 7671054	B1	20100302	US 2007-974941	20071015
			<--	
WO 2009051397	A2	20090423	WO 2008-KR6070	20081015
WO 2009051397	A3	20090604		
WO 2009051397	A9	20100527		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY,				
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE,				
EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN,				
IS, JP, KE, KG, KM, KN, KP, KR, LA, LC, LK, LR, LS, LT,				
LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,				
NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK,				
SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,				
VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,				
HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE,				

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ,  
 TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA,  
 EP, OA


PRIORITY APPLN. INFO.:	US 2001-976470	B2 20011012
	<--	
	US 2002-87443	B2 20020301
	<--	
	WO 2002-KR1901	A 20021011
	<--	
	US 2003-411877	A2 20030409
	<--	
	US 2004-803179	A2 20040317
	US 2004-826972	A2 20040416
	US 2005-108164	A2 20050415
	US 2007-974941	A2 20071015
	WO 2008-KR6070	W 20081015
	CN 2002-822567	A3 20021011
	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 153:618952

ED Entered STN: 12 Nov 2010

GI



AB Conformationally constrained compds. of formula I that mimic the secondary structure of reverse-turn regions of biol. active peptides and proteins and having bicyclic framework are disclosed, as well as their prodrugs. Compds. of formula I wherein E is CO, CHR3 and NR3; W is CO, CONH, CO2, COS, SO2 and a bond; R1 is (un)substituted (hetero)aryl; R2, R3, R4 and R5 are independently an amino acid side chain moiety or an amino acid side chain deriv. and stereoisomers, mixt. of stereoisomers and pharmaceutically acceptable salts thereof, are claimed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. The invention also relates to a use of such compds. for the prepn. of a medicament for treating or

preventing cancer including an acute myeloid leukemia. Example compd. II was prepd. by a general procedure (general procedure given). All the invention compds. were evaluated for their CYP3A4 inhibitory activity (some data given).


IT 1145676-59-0P

(drug candidate; prepn. of hexahydropyrazinotriazinedione compds. as CYP3A4 inhibitors useful as reverse turn mimetics and in the treatment of cancer)

RN 1145676-59-0 HCAPLUS

CN 2H-Pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide, hexahydro-4,7-dioxo-N-(phenylmethyl)-6-[[4-(phosphonooxy)phenyl]methyl]-2-(2-propen-1-yl)-8-[[4-(2-propen-1-yloxy)phenyl]methyl]-, sodium salt (1:2), (6S,9aS)- (CA INDEX NAME)

Absolute stereochemistry.



INCL 514081000; 544184000; 544112000; 514243000; 514233200

IPCI A61K0031-53 [I,A]; C07D0487-04 [I,A]; A61K0031-5377 [I,A]; A61K0031-675 [I,A]; A61P0035-02 [I,A]; C07D0487-04 [I,A]; A61K0031-53 [I,A]; A61P0035-00 [I,A]

NCL 514/081.000; 514/233.200; 514/243.000; 544/112.000; 544/184.000

CC 28-19 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): i, 34, 63

IT	1145674-73-2P	1145674-74-3P	1145674-75-4P	1145674-76-5P
	1145674-77-6P	1145674-78-7P	1145674-79-8P	1145674-80-1P
	1145674-81-2P	1145674-82-3P	1145674-83-4P	1145674-84-5P
	1145674-85-6P	1145674-86-7P	1145674-87-8P	1145674-88-9P
	1145674-89-0P	1145674-90-3P	1145674-91-4P	1145674-92-5P
	1145674-93-6P	1145674-94-7P	1145674-95-8P	1145674-96-9P
	1145674-97-0P	1145674-98-1P	1145674-99-2P	1145675-00-8P
	1145675-01-9P	1145675-02-0P	1145675-03-1P	1145675-04-2P
	1145675-05-3P	1145675-06-4P	1145675-07-5P	1145675-08-6P
	1145675-09-7P	1145675-10-0P	1145675-11-1P	1145675-12-2P
	1145675-13-3P	1145675-14-4P	1145675-15-5P	1145675-16-6P
	1145675-17-7P	1145675-18-8P	1145675-19-9P	1145675-21-3P
	1145675-22-4P	1145675-23-5P	1145675-24-6P	1145675-25-7P
	1145675-26-8P	1145675-27-9P	1145675-28-0P	1145675-29-1P
	1145675-30-4P	1145675-31-5P	1145675-32-6P	1145675-33-7P
	1145675-34-8P	1145675-35-9P	1145675-36-0P	1145675-37-1P

1145675-38-2P	1145675-39-3P	1145675-40-6P	1145675-41-7P
1145675-42-8P	1145675-43-9P	1145675-44-0P	1145675-45-1P
1145675-46-2P	1145675-47-3P	1145675-48-4P	1145675-49-5P
1145675-50-8P	1145675-51-9P	1145675-53-1P	1145675-55-3P
1145675-56-4P	1145675-57-5P	1145675-58-6P	1145675-59-7P
1145675-60-0P	1145675-61-1P	1145675-62-2P	1145675-63-3P
1145675-64-4P	1145675-65-5P	1145675-66-6P	1145675-67-7P
1145675-68-8P	1145675-72-4P	1145675-74-6P	1145675-78-0P
1145675-83-7P	1145675-87-1P	1145675-91-7P	1145675-95-1P
1145675-98-4P	1145676-01-2P	1145676-03-4P	1145676-06-7P
1145676-08-9P	1145676-09-0P	1145676-10-3P	1145676-11-4P
1145676-12-5P	1145676-13-6P	1145676-14-7P	1145676-15-8P
1145676-16-9P	1145676-17-0P	1145676-18-1P	1145676-19-2P
1145676-20-5P	1145676-21-6P	1145676-22-7P	1145676-23-8P
1145676-24-9P	1145676-25-0P	1145676-26-1P	1145676-27-2P
1145676-28-3P	1145676-29-4P	1145676-30-7P	1145676-31-8P
1145676-32-9P	1145676-33-0P	1145676-35-2P	1145676-36-3P
1145676-37-4P	1145676-38-5P	1145676-39-6P	1145676-40-9P
1145676-41-0P	1145676-42-1P	1145676-43-2P	1145676-44-3P
1145676-45-4P	1145676-46-5P	1145676-47-6P	1145676-48-7P
1145676-49-8P	1145676-50-1P	1145676-51-2P	1145676-52-3P
1145676-53-4P	1145676-54-5P	1145676-55-6P	1145676-56-7P
1145676-57-8P	1145676-58-9P	<del>1145676-59-0P</del>	
1145676-60-3P	1145676-61-4P	1145676-62-5P	1145676-63-6P
1145676-64-7P	1145676-65-8P	1145676-66-9P	1145676-67-0P
1145676-68-1P	1145676-69-2P	1145676-70-5P	1145676-71-6P
1145676-72-7P	1145676-73-8P	1145676-74-9P	1145676-75-0P
1145676-76-1P	1145676-77-2P	1145676-78-3P	1145676-79-4P
1145676-80-7P	1145676-81-8P	1145676-82-9P	1145676-83-0P
1145676-84-1P	1145676-85-2P	1145676-86-3P	1145676-87-4P
1145676-88-5P	1145676-89-6P	1145676-90-9P	1145676-91-0P
1145676-93-2P	1145676-95-4P	1145676-97-6P	1145676-98-7P
1145677-00-4P	1145677-02-6P	1145677-03-7P	1145677-04-8P
1145677-05-9P	1145677-06-0P	1145677-07-1P	1145677-08-2P
1145677-09-3P	1145677-10-6P	1145677-11-7P	1145677-13-9P
1145677-15-1P	1145677-16-2P	1145677-18-4P	1145677-20-8P
1145677-22-0P	1145677-24-2P	1145677-26-4P	1145677-27-5P
1145677-28-6P	1145677-29-7P	1145677-31-1P	1145677-32-2P
1145677-33-3P	1145677-34-4P	1145677-35-5P	1145677-36-6P
1145677-37-7P	1145677-38-8P	1145677-39-9P	1145677-40-2P
1145677-41-3P	1145677-42-4P	1145677-43-5P	1145677-44-6P
1145677-45-7P	1145677-46-8P	1145677-47-9P	1145677-48-0P
1145677-49-1P	1145677-50-4P	1145677-51-5P	1145677-52-6P
1145677-53-7P	1145677-54-8P	1145677-55-9P	1145677-56-0P

(drug candidate; prepn. of hexahydropyrazinotriazinedione compds.  
as CYP3A4 inhibitors useful as reverse turn mimetics and in the  
treatment of cancer)

L48 ANSWER 2 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 2010:261208 HCAPLUS Full-text  
 DOCUMENT NUMBER: 152:335464  
 TITLE: Reverse-turn mimetics for treatment of cancer and  
 rheumatoid arthritis  
 INVENTOR(S): Moon, Sung Hwan; Chung, Jae Uk; Lee, Sung Chan;  
 Eguchi, Masakatsu; Kahn, Michael; Jeong, Kwang  
 Won; Nguyen, Cu; Lee, Soo Jin

PATENT ASSIGNEE(S): Choongwae Pharma Corp., S. Korea  
 SOURCE: U.S., 1320 pp., Cont.-in-part of U.S. Ser. No. 108,164.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 11  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7671054	B1	20100302	US 2007-974941	20071015
			<--	
CN 1872856	A	20061206	CN 2006-10093786	20021011
			<--	
CN 1872857	A	20061206	CN 2006-10093787	20021011
			<--	
US 20040072831	A1	20040415	US 2003-411877	20030409
			<--	
US 20070021431	A1	20070125	US 2004-803179	20040317
			<--	
US 7232822	B2	20070619		
US 20070021425	A1	20070125	US 2004-826972	20040416
			<--	
US 7576084	B2	20090818		
US 20070043052	A1	20070222	US 2005-108164	20050415
			<--	
US 7566711	B2	20090728		
AU 2008312191	A1	20090423	AU 2008-312191	20081015
AU 2008312193	A1	20090423	AU 2008-312193	20081015
CA 2701735	A1	20090423	CA 2008-2701735	20081015
CA 2702461	A1	20090423	CA 2008-2702461	20081015
WO 2009051397	A2	20090423	WO 2008-KR6070	20081015
WO 2009051397	A3	20090604		
WO 2009051397	A9	20100527		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
WO 2009051398	A2	20090423	WO 2008-KR6071	20081015
WO 2009051398	A3	20090604		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,			

NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK,  
 SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
 VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,  
 HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ,  
 TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA,  
 EP, OA

WO 2009051399 A2 20090423 WO 2008-KR6072 20081015  
 WO 2009051399 A3 20090604

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY,  
 BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE,  
 EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN,  
 IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT,  
 LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK,  
 SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
 VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,  
 HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ,  
 TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA,  
 EP, OA

KR 2010085102 A 20100728 KR 2010-7010575 20081015  
 KR 2010085107 A 20100728 KR 2010-7010682 20081015  
 EP 2212328 A2 20100804 EP 2008-839260 20081015  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,  
 HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO,  
 SE, SI, SK, TR, AL, BA, MK, RS

EP 2212329 A2 20100804 EP 2008-839568 20081015  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,  
 HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO,  
 SE, SI, SK, TR, AL, BA, MK, RS

EP 2212330 A2 20100804 EP 2008-840475 20081015  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,  
 HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO,  
 SE, SI, SK, TR, AL, BA, MK, RS

KR 2010099116 A 20100910 KR 2010-7010576 20081015  
 JP 2011500666 T 20110106 JP 2010-529857 20081015  
 JP 2011500667 T 20110106 JP 2010-529858 20081015  
 JP 2011500668 T 20110106 JP 2010-529859 20081015  
 US 20100222303 A1 20100902 US 2009-649161 20091229  
 <--

US 8138337 B2 20120320  
 US 20100240662 A1 20100923 US 2010-756095 20100407  
 <--

US 8049008 B2 20111101  
 US 20100228027 A1 20100909 US 2010-682881 20100413  
 US 8071764 B2 20111206  
 MX 2010004046 A 20100625 MX 2010-4046 20100414  
 MX 2010004045 A 20100706 MX 2010-4045 20100414  
 CN 101827849 A 20100908 CN 2008-80111662 20100415  
 CN 101827850 A 20100908 CN 2008-80111810 20100415  
 IN 2010KN01611 A 20100917 IN 2010-KN1611 20100506


IN 2010KN01633	A	20111125	IN 2010-KN1633	20100507
CN 101896485	A	20101124	CN 2008-80120785	20100613
US 20100286094	A1	20101111	US 2010-738066	20100723
			<--	
US 8080657	B2	20111220		
PRIORITY APPLN. INFO.:			US 2001-976470	B2 20011012
			<--	
			US 2002-87443	B2 20020301
			<--	
			US 2003-411877	B2 20030409
			<--	
			US 2004-803179	A2 20040317
			US 2004-826972	A2 20040416
			US 2005-108164	A2 20050415
			CN 2002-822567	A3 20021011
			<--	
			WO 2002-KR1901	A 20021011
			<--	
			US 2007-974941	A 20071015
			WO 2008-KR6070	W 20081015
			WO 2008-KR6071	W 20081015
			WO 2008-KR6072	W 20081015
			US 2009-649161	A1 20091229

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 152:335464; MARPAT 152:335464

ED Entered STN: 03 Mar 2010

GI



AB The invention discloses conformationally-constrained compds. I [A is CO; B is CHR<sup>4</sup>; D is CO; E is Z-R<sup>6</sup>; G is X-R<sup>7</sup>; W is CONH, COO, COS, SO<sub>2</sub> or null; Z = CH; X = N; R<sup>1</sup>-2, R<sup>4</sup>, R<sup>6</sup>-7 are the same or different and independently selected from an amino acid side chain or deriv.], their stereoisomers and pharmaceutically acceptable

salts that mimic the secondary structure of reverse-turn regions of biol. active peptides and proteins and have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries contg. the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening them to identify biol. active members. The invention also relates to the use of such compds. for inhibiting or treating disorders modulated by the Wnt-signaling pathway, such as cancer, restenosis assocd. with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis. Thus, triazolopyrazinone deriv. II was prepd. using a bromoacetal resin and showed IC50 = 2.349 .mu.M against SW480 cells.


IT 1145676-59-0P

(prepn. of reverse-turn mimetics for treatment of cancer and rheumatoid arthritis)

RN 1145676-59-0 HCAPLUS

CN 2H-Pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide, hexahydro-4,7-dioxo-N-(phenylmethyl)-6-[[4-(phosphonooxy)phenyl]methyl]-2-(2-propen-1-yl)-8-[[4-(2-propen-1-yloxy)phenyl]methyl]-, sodium salt (1:2), (6S,9aS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 Na

INCL 514243000; 544184000

IPCI C07D0487-04 [I,A]; A61K0031-53 [I,A]; A61P0019-02 [I,A]; A61P0035-00 [N,A]

IPCR C07D0487-04 [I,A]; A61K0031-53 [I,A]; A61P0019-02 [I,A]; A61P0035-00 [N,A]

NCL 514/243.000; 544/184.000

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1, 3

IT	512854-88-5P	512856-49-4P	512856-50-7P	512856-51-8P
	870887-94-8P	959657-54-6P	1144043-48-0P	1144043-50-4P
	1144043-54-8P	1144043-73-1P	1144043-78-6P	1144043-79-7P
	1144043-80-0P	1144043-82-2P	1144043-83-3P	1144043-84-4P
	1144043-85-5P	1144043-87-7P	1144043-88-8P	1144043-89-9P
	1144043-90-2P	1144043-91-3P	1144045-60-2P	1145673-99-9P
	1145674-00-5P	1145674-01-6P	1145674-02-7P	1145674-03-8P
	1145674-04-9P	1145674-05-0P	1145674-06-1P	1145674-07-2P



1145674-08-3P	1145674-09-4P	1145674-10-7P	1145674-11-8P
1145674-12-9P	1145674-14-1P	1145674-15-2P	1145674-16-3P
1145674-17-4P	1145674-18-5P	1145674-21-0P	1145674-27-6P
1145674-32-3P	1145674-35-6P	1145674-37-8P	1145674-38-9P
1145674-42-5P	1145674-44-7P	1145674-45-8P	1145674-46-9P
1145674-47-0P	1145674-48-1P	1145674-50-5P	1145674-51-6P
1145674-52-7P	1145674-66-3P	1145674-67-4P	1145674-68-5P
1145674-69-6P	1145674-71-0P	1145674-72-1P	1145674-73-2P
1145675-10-0P	1145675-14-4P	1145675-18-8P	1145675-28-0P
1145675-29-1P	1145675-32-6P	1145675-40-6P	1145675-58-6P
1145675-61-1P	1145675-64-4P	1145675-65-5P	1145675-72-4P
1145676-12-5P	1145676-18-1P	1145676-23-8P	1145676-41-0P
1145676-42-1P	1145676-46-5P	1145676-47-6P	1145676-48-7P
1145676-49-8P	1145676-50-1P	1145676-51-2P	1145676-52-3P
1145676-53-4P	1145676-54-5P	1145676-55-6P	1145676-56-7P
1145676-57-8P	1145676-58-9P	<del>1145676-59-0P</del>	
1145676-60-3P	1145676-62-5P	1145676-63-6P	1145676-64-7P
1145676-65-8P	1145676-66-9P	1145676-67-0P	1145676-68-1P
1145676-69-2P	1145676-70-5P	1145676-71-6P	1145676-72-7P
1145676-73-8P	1213831-01-6P	1213831-05-0P	1213831-07-2P
1213831-10-7P	1213831-12-9P	1213831-15-2P	1213831-18-5P
1213831-20-9P	1213831-23-2P	1213831-26-5P	1213831-44-7P
1213832-15-5P	1213832-28-0P	1213832-68-8P	1213833-40-9P
1213833-48-7P	1213833-64-7P	1213833-83-0P	1213833-97-6P
1213834-02-6P			

(prepn. of reverse-turn mimetics for treatment of cancer and  
rheumatoid arthritis)

REFERENCE COUNT: 149 THERE ARE 149 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
RE FORMAT

L48 ANSWER 3 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2009:490612 HCAPLUS Full-text

DOCUMENT NUMBER: 150:447990

TITLE: Novel hexahydropyrazinotriazinedione compounds of  
reverse turn mimetics and their preparation and  
use thereof

INVENTOR(S): Chung, Jae Uk; Jung, Kyung-Yun; Jeong, Min-Wook;  
Jung, Hee-Kyung; La, Hyun-Ju

PATENT ASSIGNEE(S): Choongwae Pharma Corporation, S. Korea

SOURCE: PCT Int. Appl., 192 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 11

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2009051397	A2	20090423	WO 2008-KR6070	20081015
WO 2009051397	A3	20090604		
WO 2009051397	A9	20100527		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY,			
	BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE,			
	EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN,			
	IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT,			

LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK,  
 SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
 VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,  
 HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ,  
 TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA,  
 EP, OA

US 7671054	B1	20100302	US 2007-974941	20071015
			<--	
AU 2008312191	A1	20090423	AU 2008-312191	20081015
CA 2701735	A1	20090423	CA 2008-2701735	20081015
KR 2010085107	A	20100728	KR 2010-7010682	20081015
EP 2212330	A2	20100804	EP 2008-840475	20081015
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,			
	HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO,			
	SE, SI, SK, TR, AL, BA, MK, RS			
JP 2011500666	T	20110106	JP 2010-529857	20081015
MX 2010004046	A	20100625	MX 2010-4046	20100414
IN 2010KN01633	A	20111125	IN 2010-KN1633	20100507
CN 101896485	A	20101124	CN 2008-80120785	20100613
US 20100286094	A1	20101111	US 2010-738066	20100723
			<--	



US 8080657	B2	20111220		
PRIORITY APPLN. INFO.:			US 2007-974941	A 20071015
			US 2001-976470	B2 20011012
			<--	
			US 2002-87443	B2 20020301
			<--	
			WO 2002-KR1901	A 20021011
			<--	
			US 2003-411877	B2 20030409
			<--	
			US 2004-803179	A2 20040317
			US 2004-826972	A2 20040416
			US 2005-108164	A2 20050415
			WO 2008-KR6070	W 20081015

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 150:447990; MARPAT 150:447990

ED Entered STN: 24 Apr 2009

GI



AB Conformationally constrained compds. of formula I that are novel and mimic the secondary structure of reverse-turn regions of biol. active peptides and proteins and having bicyclic framework are disclosed, as well as their prodrugs.1 Compds. of formula I wherein E is CO, CHR3 and NR3; W is CO, CONH, CO2, COS, SO2 and a bond; R1 is (un)substituted (hetero)aryl; R2, R3, R4 and R5 are independently an amino acid side chain moiety or an amino acid side chain deriv. and stereoisomers, mixt. of stereoisomers and pharmaceutically acceptable salts thereof, are claimed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. The invention also relates to a use of such compds. for the prepn. of a medicament for treating or preventing cancer including an acute myeloid leukemia. Example compd. II was prepd. by a general procedure (general procedure given). All the invention compds. were evaluated for their CYP3A4 inhibitory activity (some data given).


IT 1145676-59-0P

(drug candidate; prepn. of hexahydropyrazinotriazinedione compds. as CYP3A4 inhibitors useful as reverse turn mimetics and in the treatment of cancer)

RN 1145676-59-0 HCAPLUS

CN 2H-Pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide, hexahydro-4,7-dioxo-N-(phenylmethyl)-6-[[4-(phosphonooxy)phenyl]methyl]-2-(2-propen-1-yl)-8-[[4-(2-propen-1-yloxy)phenyl]methyl]-, sodium salt (1:2), (6S,9aS)- (CA INDEX NAME)

Absolute stereochemistry.



IPCI C07D0487-04 [I,A]; C07D0487-00 [I,C]; C07D0487-04 [I,A]; C07D0487-00 [I,C]; C07D0487-04 [I,A]

IPCR C07D0487-04 [I,A]

CC 28-19 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 34, 63

IT	1145674-70-9P	1145674-71-0P	1145674-72-1P	1145674-73-2P
	1145674-74-3P	1145674-75-4P	1145674-76-5P	1145674-77-6P
	1145674-78-7P	1145674-79-8P	1145674-80-1P	1145674-81-2P
	1145674-82-3P	1145674-83-4P	1145674-84-5P	1145674-85-6P
	1145674-86-7P	1145674-87-8P	1145674-88-9P	1145674-89-0P
	1145674-90-3P	1145674-91-4P	1145674-92-5P	1145674-93-6P
	1145674-94-7P	1145674-95-8P	1145674-96-9P	1145674-97-0P
	1145674-98-1P	1145674-99-2P	1145675-00-8P	1145675-01-9P
	1145675-02-0P	1145675-03-1P	1145675-04-2P	1145675-05-3P
	1145675-06-4P	1145675-07-5P	1145675-08-6P	1145675-09-7P
	1145675-10-0P	1145675-11-1P	1145675-12-2P	1145675-13-3P
	1145675-14-4P	1145675-15-5P	1145675-16-6P	1145675-17-7P
	1145675-18-8P	1145675-19-9P	1145675-20-2P	1145675-21-3P
	1145675-22-4P	1145675-23-5P	1145675-24-6P	1145675-25-7P
	1145675-26-8P	1145675-27-9P	1145675-28-0P	1145675-29-1P
	1145675-30-4P	1145675-31-5P	1145675-32-6P	1145675-33-7P
	1145675-34-8P	1145675-35-9P	1145675-36-0P	1145675-37-1P
	1145675-38-2P	1145675-39-3P	1145675-40-6P	1145675-41-7P
	1145675-42-8P	1145675-43-9P	1145675-44-0P	1145675-45-1P
	1145675-46-2P	1145675-47-3P	1145675-48-4P	1145675-49-5P
	1145675-50-8P	1145675-51-9P	1145675-52-0P	1145675-53-1P
	1145675-54-2P	1145675-55-3P	1145675-56-4P	1145675-57-5P
	1145675-58-6P	1145675-59-7P	1145675-60-0P	1145675-61-1P
	1145675-62-2P	1145675-63-3P	1145675-64-4P	1145675-65-5P
	1145675-66-6P	1145675-67-7P	1145675-68-8P	1145675-72-4P
	1145675-74-6P	1145675-78-0P	1145675-83-7P	1145675-87-1P
	1145675-91-7P	1145675-95-1P	1145675-98-4P	1145676-01-2P
	1145676-03-4P	1145676-06-7P	1145676-08-9P	1145676-09-0P
	1145676-10-3P	1145676-11-4P	1145676-12-5P	1145676-13-6P
	1145676-14-7P	1145676-15-8P	1145676-16-9P	1145676-17-0P
	1145676-18-1P	1145676-19-2P	1145676-20-5P	1145676-21-6P
	1145676-22-7P	1145676-23-8P	1145676-24-9P	1145676-25-0P
	1145676-26-1P	1145676-27-2P	1145676-28-3P	1145676-29-4P

1145676-30-7P	1145676-31-8P	1145676-32-9P	1145676-33-0P
1145676-35-2P	1145676-36-3P	1145676-37-4P	1145676-38-5P
1145676-39-6P	1145676-40-9P	1145676-41-0P	1145676-42-1P
1145676-43-2P	1145676-44-3P	1145676-45-4P	1145676-46-5P
1145676-47-6P	1145676-48-7P	1145676-49-8P	1145676-50-1P
1145676-51-2P	1145676-52-3P	1145676-53-4P	1145676-54-5P
1145676-55-6P	1145676-56-7P	1145676-57-8P	1145676-58-9P
<del>1145676-59-0P</del>	1145676-60-3P	1145676-61-4P	1145676-62-5P
1145676-63-6P	1145676-64-7P	1145676-65-8P	1145676-66-9P
1145676-67-0P	1145676-68-1P	1145676-69-2P	1145676-70-5P
1145676-71-6P	1145676-72-7P	1145676-73-8P	1145676-74-9P
1145676-75-0P	1145676-76-1P	1145676-77-2P	1145676-78-3P
1145676-79-4P	1145676-80-7P	1145676-81-8P	1145676-82-9P
1145676-83-0P	1145676-84-1P	1145676-85-2P	1145676-86-3P
1145676-87-4P	1145676-88-5P	1145676-89-6P	1145676-90-9P
1145676-91-0P	1145676-93-2P	1145676-95-4P	1145676-97-6P
1145676-98-7P	1145677-00-4P	1145677-02-6P	1145677-03-7P
1145677-04-8P	1145677-05-9P	1145677-06-0P	1145677-07-1P
1145677-08-2P	1145677-09-3P	1145677-10-6P	1145677-11-7P
1145677-13-9P	1145677-15-1P	1145677-16-2P	1145677-18-4P
1145677-20-8P	1145677-22-0P	1145677-24-2P	1145677-26-4P
1145677-27-5P	1145677-28-6P	1145677-29-7P	1145677-31-1P
1145677-32-2P	1145677-33-3P	1145677-34-4P	1145677-35-5P
1145677-36-6P	1145677-37-7P	1145677-38-8P	1145677-39-9P
1145677-40-2P	1145677-41-3P	1145677-42-4P	1145677-43-5P
1145677-44-6P	1145677-45-7P	1145677-46-8P	1145677-47-9P
1145677-48-0P	1145677-49-1P	1145677-50-4P	

(drug candidate; prepn. of hexahydropyrazinotriazinedione compds.  
as CYP3A4 inhibitors useful as reverse turn mimetics and in the  
treatment of cancer)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS  
RECORD (1 CITINGS)

L48 ANSWER 4 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN  
ACCESSION NUMBER: 2005:568976 HCAPLUS Full-text  
DOCUMENT NUMBER: 143:83603  
TITLE: One-part self-etching, self-priming dental  
adhesive composition  
INVENTOR(S): Klee, Joachim E.; Lehmann, Uwe; Walz, Uwe  
PATENT ASSIGNEE(S): Dentsply Detrey GmbH, Germany  
SOURCE: Eur. Pat. Appl., 30 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 1548021	A1	20050629	EP 2003-29824	20031223
			<--	
EP 1548021	B1	20070321		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,				
PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 357450	T	20070415	AT 2003-29824	20031223
			<--	

CA 2551228	A1	20050714	CA 2004-2551228	20041215
			<--	
WO 2005063778	A1	20050714	WO 2004-EP14307	20041215
			<--	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
JP 2007520465	T	20070726	JP 2006-545998	20041215
			<--	
US 20070293642	A1	20071220	US 2007-596747	20070508
			<--	
PRIORITY APPLN. INFO.:			EP 2003-29824	A 20031223
			<--	
			WO 2004-EP14307	W 20041215

## ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

ED Entered STN: 01 Jul 2005


AB One-part self-etching, self-priming dental adhesive compn. having a pH of at most 2 comprises (a) a polymerizable acidic phosphoric acid ester monomer; (b) one or more polymerizable acidic monomers; (c) a polymerizable N-substituted alkylacrylic or acrylic acid amide monomer; (d) an org. and/or inorg. acid; (e) an org. water sol. solvent and/or water; and (f) polymn. initiator, inhibitor and stabilizer. An adhesive polymer was prepd. from 2-acrylamido-2-methyl-propane-sulfonic acid, 3,(4),8,(9)-bis(acrylamido methyl) tricyclo-5.2.1.02,6 decane, Et 2-[13-dihydrogen phosphoryl-13,2-dioxatridecyl]acrylate, and N,N'-bisacrylamido-N,N'-diethyl-1,3-propane.

IT 752234-98-3P

(one-part self-etching, self-priming dental adhesive compn.)

RN 752234-98-3 HCAPLUS

CN 2-Propenoic acid, 2-[[[10-(phosphonooxy)decyl]oxy]methyl]-, 1-ethyl ester (CA INDEX NAME)



IPCI C07F0009-00 [I,C]; A61K0006-00 [I,C]; A61K0006-02 [I,C]; C08F0030-00 [I,C]; C07F0009-09 [I,A]; A61K0006-00 [I,A]; A61K0006-083 [I,A]; C08F0030-02 [I,A]

IPCR A61K0006-00 [I,A]; A61K0006-083 [I,A]; C07F0009-09 [I,A]; C08F0030-02 [I,A]

CC 63-8 (Pharmaceuticals)

IT 752234-97-2P 752234-98-3P 752234-99-4P

752235-00-0P 855894-56-3P

(one-part self-etching, self-priming dental adhesive compn.)  
 IT 855894-57-4P, 2-Acrylamido-2-methyl-propane-sulfonic  
 acid-3, (4), 8, (9)-bis(acrylamido methyl) tricyclo-5.2.1.02,6  
 decane-Ethyl 2-[13-dihydrogen phosphoryl-13,2-dioxatridecyl]acrylate-  
 N,N'-Bisacrylamido-N,N'-diethyl-1,3-propane copolymer  
 855894-58-5P

(one-part self-etching, self-priming dental adhesive compn.)  
 OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS  
 RECORD (7 CITINGS)  
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
 RE FORMAT

L48 ANSWER 5 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2005:216597 HCAPLUS Full-text

DOCUMENT NUMBER: 142:291323

TITLE: Compositions and methods for the treatment of  
 severe acute respiratory syndrome (SARS)

INVENTOR(S): Hardee, Greg; Dellamary, Luis

PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 217 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020885	A2	20050310	WO 2004-US16196	20040521

<--

WO 2005020885 A3 20050804

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,  
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
 GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,  
 KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
 MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,  
 SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
 VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,  
 DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL,  
 PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
 GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-472774P P 20030521

<--

ED Entered STN: 11 Mar 2005

AB The invention provides compns. and methods for treating a coronavirus infection,  
 esp. a SARS CoV infection. The compns. comprise an antiviral nucleoside or mimetic  
 thereof, or an antiviral antisense agent, in a form suitable for pulmonary or nasal  
 delivery. The methods comprise administration to a patient in need thereof the  
 effective amt. of an antiviral compn. by pulmonary or nasal instillation.


IT 847648-34-4

(compns. and methods for treatment of severe acute respiratory  
 syndrome)

RN 847648-34-4 HCAPLUS

CN Guanosine 5'-(tetrahydrogen triphosphate), 2'-O-2-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IPCI A61K [ICM,7]

IPCR A61K [I,S]; A61K0031-7052 [I,A]; C07H0019-22 [I,A]

CC 1-5 (Pharmacology)

Section cross-reference(s): 63

IT	686301-76-8	690269-86-4	690269-87-5	714249-82-8	760965-53-5
	764644-12-4	781672-21-7	784151-35-5	784151-48-0	790240-68-5
	793655-42-2	809277-13-2	809277-14-3	809277-17-6	809277-18-7
	809277-20-1	809277-21-2	809277-23-4	809277-27-8	847647-09-0
	847647-10-3	847647-11-4	847647-12-5	847647-13-6	847647-14-7
	847647-15-8	847647-16-9	847647-17-0	847647-18-1	847647-19-2
	847647-20-5	847647-21-6	847647-22-7	847647-23-8	847647-24-9
	847647-25-0	847647-26-1	847647-27-2	847647-28-3	847647-29-4
	847647-30-7	847647-31-8	847647-32-9	847647-33-0	847647-34-1
	847647-35-2	847647-36-3	847647-37-4	847647-38-5	847647-39-6
	847647-40-9	847647-43-2	847647-45-4	847647-48-7	847647-54-5
	847647-55-6	847647-56-7	847647-57-8	847647-58-9	847647-59-0
	847647-60-3	847647-61-4	847647-62-5	847647-63-6	847647-64-7
	847647-65-8	847647-67-0	847647-68-1	847647-69-2	847647-70-5
	847647-71-6	847647-72-7	847647-73-8	847647-74-9	847647-75-0
	847647-76-1	847647-77-2	847647-78-3	847647-79-4	847647-80-7
	847647-81-8	847647-82-9	847647-83-0	847647-84-1	847647-85-2
	847647-86-3	847647-87-4	847647-88-5	847647-89-6	847647-90-9
	847647-91-0	847647-92-1	847647-93-2	847647-94-3	847647-95-4
	847647-96-5	847647-97-6	847647-98-7	847647-99-8	847648-00-4
	847648-01-5	847648-02-6	847648-03-7	847648-04-8	847648-05-9
	847648-06-0	847648-07-1	847648-08-2	847648-09-3	847648-10-6
	847648-11-7	847648-12-8	847648-13-9	847648-14-0	847648-15-1
	847648-16-2	847648-17-3	847648-18-4	847648-19-5	847648-20-8
	847648-21-9	847648-22-0	847648-23-1	847648-24-2	847648-25-3
	847648-26-4	847648-27-5	847648-28-6	847648-29-7	847648-30-0
	847648-31-1	847648-32-2	847648-33-3	<del>847648-34-4</del>	
	847648-35-5	847648-36-6	847648-37-7	847648-38-8	847648-39-9
	847648-40-2	847648-41-3	847648-42-4	847648-43-5	847648-44-6
	847648-45-7	847648-46-8	847648-47-9	847648-48-0	847648-49-1
	847648-50-4	847648-51-5	847648-52-6	847648-53-7	847648-54-8
	847648-55-9	847648-56-0	847648-57-1	847648-58-2	847648-59-3
	847648-60-6	847648-61-7	847648-62-8	847648-63-9	847648-64-0
	847648-65-1	847648-66-2	847648-67-3	847648-68-4	847648-69-5
	847648-70-8	847648-71-9	847648-72-0	847648-73-1	847648-74-2
	847648-75-3	847648-76-4	847648-77-5	847648-78-6,	biological



studies 847648-79-7, biological studies 847648-80-0 847648-81-1  
 847648-82-2 847648-83-3 847648-84-4 847648-85-5 847648-86-6  
 847648-87-7 847648-88-8 847648-89-9 847648-90-2 847648-91-3  
 847648-92-4 847648-93-5 847648-94-6 847648-95-7 847648-96-8  
 847648-97-9 847648-98-0 847648-99-1 847649-00-7 847649-01-8  
 847649-02-9 847649-03-0 847649-04-1 847649-05-2 847649-06-3  
 847649-07-4 847649-08-5 847649-09-6 847649-10-9 847649-11-0  
 847649-12-1 847649-13-2 847649-14-3 847649-15-4 847649-16-5  
 847649-17-6 847649-18-7 847649-19-8 847649-20-1 847649-21-2  
 847649-22-3 847649-23-4 847649-24-5 847649-25-6 847649-26-7  
 847649-27-8 847649-28-9 847649-29-0 847649-30-3 847649-31-4  
 847649-32-5 847649-33-6 847649-34-7 847649-35-8 847649-36-9  
 847649-37-0 847649-38-1 847649-39-2

(compsns. and methods for treatment of severe acute respiratory  
 syndrome)

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS  
 RECORD (7 CITINGS)  
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
 RE FORMAT

L48 ANSWER 6 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 2005:120948 HCAPLUS Full-text  
 DOCUMENT NUMBER: 142:197761  
 TITLE: Preparation of nucleobase phosphonate analogs for  
 antiviral treatment and as retroviral reverse  
 transcriptase inhibitors  
 INVENTOR(S): Krawczyk, Steven H.  
 PATENT ASSIGNEE(S): Gilead Sciences, Inc., USA  
 SOURCE: PCT Int. Appl., 140 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012324	A2	20050210	WO 2004-US24922	20040730
<--				
WO 2005012324	A3	20050506		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004260789	A1	20050210	AU 2004-260789	20040730
<--				
AU 2004260789	B2	20110630		



CA 2533966	A1	20050210	CA 2004-2533966	20040730
			<--	
US 20050059637	A1	20050317	US 2004-903288	20040730
			<--	
US 7579332	B2	20090825		
EP 1656387	A2	20060517	EP 2004-779855	20040730
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007500727	T	20070118	JP 2006-522128	20040730
			<--	
NZ 544988	A	20091127	NZ 2004-544988	20040730
			<--	
US 20060252729	A1	20061109	US 2006-566819	20060127
			<--	
PRIORITY APPLN. INFO.:			US 2003-491123P	P 20030730
			<--	
			WO 2004-US24922	W 20040730

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 142:197761; MARPAT 142:197761

ED Entered STN: 11 Feb 2005

GI



AB The present invention provides the prepn. of nucleobase phosphonate analogs I, wherein X1 is C:CR1R2, C:N-OR, C:O, CR1R2, C:N-NR2, S:O; X2 is O, NR, S; Y1 is O, S, NR, N-Nr2, +N(O)(R), +N(OR), +N(O)(OR), sulfonyl; Y3 and Z are independently H, OH, OR, NR2, CN, NO2, F, Cl, Br, iodo; Rx is H, protecting group; R1-R8 are independently H, F, Cl, Br, iodo, OH, C(:Y1)R, C(:Y1)OR, C(:Y1)NR2+NR3, SR, S(O)R, S(O2)R, S(O)2(ORx), OC(:Y)Rx, -OC(=Y1)OR, -OC(=Y1)(N(Rx)2), -SC(=Y1)Rx, -SC(=Y1)OR, -SC(=Y1)(N(Rx)2), -N(Rx)C(=Y1)R, -N(Rx)C(=Y1)OR, or -N(Rx)C(=Y1)N(Rx)2, amino, ammonium, alkylamino, dialkylamino, trialkyl-ammonium, alkyl, alkyl-halide, carboxylate sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, alkyl sulfonate, alkylamino, 4-dialkylamino-pyridinium, alkyl-hydroxy, alkyl-thiol, alkyl sulfone, aryl sulfone, aryl sulfoxide, arylthio, sulfonamide, alkyl sulfoxide, ester, amido, 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile, azido, nitro, alkoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl, polyethylene-oxy; two of R1-R8 form a carbocyclic ring of 3 to 7 carbon atoms; R is alkyl, alkenyl, alkynyl, aryl, with activity against infectious viruses. The


comps. of the invention may inhibit retroviral reverse transcriptases and thus inhibit the replication of the virus. They are useful for treating human patients infected with a human retrovirus, such as human immunodeficiency virus (strains of HIV-1 or HIV-2) or human T-cell leukemia viruses (HTLV-I or HTLV-II) which results in acquired immunodeficiency syndrome (AIDS) and/or related diseases. The present invention also relates generally to the accumulation or retention of therapeutic comps. inside cells. The invention is more particularly related to attaining high concns. of active metabolite mols. in HIV infected cells. Intracellular targeting may be achieved by methods and compns. which allow accumulation or retention of biol. active agents inside cells. Such effective targeting may be applicable to a variety of therapeutic formulations and procedures. Thus, nucleobase phosphonate II was prepd. and tested as antiviral agent and retroviral reverse transcriptase inhibitor. Within the context of the invention, typically compns. are first screened for inhibition of HIV reverse transcriptase in vitro and compns. showing inhibitory activity are then screened for activity in vivo. Compns. having in vitro  $K_i$  (inhibitory consts.) of less than about  $5 \times 10^{-6}$  M, typically less than about  $1 \times 10^{-7}$  M and preferably less than about  $5 \times 10^{-8}$  M are preferred for in vivo use.

IT 839711-04-5P

(prepn. of nucleobase phosphonate analogs for antiviral treatment  
and as retroviral reverse transcriptase inhibitors)

RN 839711-04-5 HCAPLUS

CN Diphosphoric acid, monoanhydride with  
[[3-(3-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-4-hydroxy-2-methylenebutoxy)methyl]phosphonic acid (9CI) (CA INDEX NAME)



IPCI C07H0019-00 [ICM,7]

IPCR C07F0009-6561 [I,A]

CC 26-9 (Biomolecules and Their Synthetic Analogs)

Section cross-reference(s): 1, 7, 33, 63

IT 839710-27-9P 839710-29-1P 839710-43-9P 839710-45-1P  
839710-56-4P 839710-59-7P 839710-73-5P 839710-77-9P  
839710-78-0P 839710-83-7P 839710-85-9P 839710-86-0P  
839710-90-6P 839710-93-9P 839711-02-3P 839711-04-5P  
839711-08-9P 839711-13-6P 839711-18-1P  
839711-19-2P

(prepn. of nucleobase phosphonate analogs for antiviral treatment  
and as retroviral reverse transcriptase inhibitors)

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS  
RECORD (2 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
RE FORMAT

L48 ANSWER 7 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2004:732258 HCAPLUS Full-text  
 DOCUMENT NUMBER: 141:243056  
 TITLE: Polymerizable phosphoric acid ester derivatives  
 for dental compositions  
 INVENTOR(S): Klee, Joachim E.; Lehmann, Uwe; Walz, Uwe; Liu,  
 Huaibing  
 PATENT ASSIGNEE(S): Dentsply Detrey GmbH, Germany  
 SOURCE: Eur. Pat. Appl., 20 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 1454911	A1	20040908	EP 2003-5174	20030307
			<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CA 2518202	A1	20040916	CA 2004-2518202	20040305
			<--	
WO 2004078100	A2	20040916	WO 2004-EP2289	20040305
			<--	
WO 2004078100	A3	20041028		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1601679	A2	20051207	EP 2004-717576	20040305
			<--	
EP 1601679	B1	20110511		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2006520344	T	20060907	JP 2006-504563	20040305
			<--	
JP 4594297	B2	20101208		
US 20060246017	A1	20061102	US 2006-548362	20060626
			<--	
PRIORITY APPLN. INFO.:			EP 2003-5174	A 20030307
			<--	
			WO 2004-EP2289	W 20040305

ED Entered STN: 09 Sep 2004


AB The present invention provides a polymerizable phosphoric acid ester deriv. for  
 use in dental compns. E.g.,  
 2,2,2-tris(2,6-dioxa-4-methylene-5-oxo-octyl)ethanol phosphoric acid ester was  
 prepd. from pentaerythritol, Et chloromethacrylate, and then treatment with the  
 product with POCl<sub>3</sub> and hydrolyzed.

IT 752234-96-1P

(polymerizable phosphoric acid ester derivs. for dental compns.)

RN 752234-96-1 HCAPLUS

CN 2-Propenoic acid, 2,2'-[[2-[[[2-(ethoxycarbonyl)-2-propenyl]oxy]methyl]-2-[(phosphonooxy)methyl]-1,3-propanediyl]bis(oxyethylene)]bis-, 1,1'-diethyl ester (9CI) (CA INDEX NAME)



IPCI C07F0009-09 [ICM,7]; A61K0006-08 [ICS,7]; C08F0030-02 [ICS,7]

IPCR A61K0006-00 [I,A]; A61K0006-08 [I,A]; A61K0006-083 [I,A]; C07F0009-09 [I,A]; C08F0030-02 [I,A]

CC 23-17 (Aliphatic Compounds)

Section cross-reference(s): 63

IT 752234-96-1P 752234-98-3P 752235-00-0P

(polymerizable phosphoric acid ester derivs. for dental compns.)

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 8 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2004:252299 HCAPLUS Full-text

DOCUMENT NUMBER: 140:283384

TITLE: Modulators of GTPases and modulator-resistant enzymes and their uses in drug design and target validation

INVENTOR(S): Shah, Kavita; Vincent, Fabien; Cuento, Maria A.

PATENT ASSIGNEE(S): Irm, Llc, UK; Novartis Pharmaceuticals Corporation

SOURCE: PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024082	A2	20040325	WO 2003-US28594	20030910

&lt;--

WO 2004024082 A3 20090618

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,

ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG, AP, EA, EP, OA

AU 2003267145 A1 20040430 AU 2003-267145 20030910

<--

US 20040241706 A1 20041202 US 2003-660113 20030910

<--

PRIORITY APPLN. INFO.:

US 2002-410536P P 20020913

<--

US 2003-461755P P 20030409

<--


WO 2003-US28594 W 20030910

<--

OTHER SOURCE(S): CASREACT 140:283384; MARPAT 140:283384

ED Entered STN: 26 Mar 2004

GI



AB Guanine derivs. that act as modulators of GTPases and GTPase variants that do not interact with these modulators are described for use in the design of improved modulators of GTPase activity. The method involves generating variants of the enzyme that do not interact with a known modulator and then developing effectors that interact with the resistant variant. The prepn. of guanosine derivs. and of a series of p21c-Ha-ras protein substitution variants is described,.


IT 674796-08-8P

(prepn. and use of; modulators of GTPases and modulator-resistant enzymes and their uses in drug design and target validation)

RN 674796-08-8 HCAPLUS

CN Guanosine 5'-(tetrahydrogen triphosphate), 6-O-2-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IPCI A01N0043-02 [I,C]; A01N0043-04 [I,A]; A61K0031-70 [I,C]; A61K0031-70 [I,A]

IPCR A01N0043-04 [I,A]; A61K0031-70 [I,A]; A61K0048-00 [I,A]; C07H0021-04 [I,A]; C12Q0001-68 [I,A]

CC 7-5 (Enzymes)

Section cross-reference(s): 1, 3

IT 1074-41-5DP, derivs. 15867-02-4P 17670-19-8P 26775-35-9P  
 26783-32-4P 26783-36-8P 67831-83-8DP, derivs. 99404-63-4P  
 282531-50-4P 674795-54-1P 674795-55-2P 674795-56-3P  
 674795-57-4P 674795-58-5P 674795-59-6P 674795-60-9P  
 674795-61-0P 674795-62-1P 674795-63-2P 674795-64-3P  
 674795-65-4P 674795-66-5P 674795-67-6P 674795-68-7P  
 674795-69-8P 674795-70-1P 674795-71-2P 674795-72-3P  
 674795-73-4P 674795-74-5P 674795-75-6P 674795-77-8P  
 674795-78-9P 674795-85-8P 674795-86-9P 674795-87-0P  
 674795-88-1P 674795-89-2P 674795-90-5P 674795-91-6P  
 674795-92-7P 674795-93-8P 674795-95-0P 674795-96-1P  
 674795-97-2P 674795-98-3P 674795-99-4P 674796-00-0P  
 674796-01-1P 674796-02-2P 674796-03-3P 674796-04-4P  
 674796-05-5P 674796-06-6P 674796-07-7P ~~674796-08-8P~~  
 674796-09-9P 674796-10-2P 674796-11-3P 674796-12-4P  
 674796-13-5P 674796-14-6P 674796-16-8P

(prepn. and use of; modulators of GTPases and modulator-resistant enzymes and their uses in drug design and target validation)

L48 ANSWER 9 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2003:972032 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:16928

TITLE: Synthetic methods for the large scale production from glucose of analogs of sphingosine, azidosphingosine, ceramides, lactosyl ceramides, and glycosyl phytosphingosine

INVENTOR(S): Bundle, David R.; Ling, Chang Chun; Zhang, Ping

PATENT ASSIGNEE(S): Can.

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2003101937	A1	20031211	WO 2003-CA832	20030602


AU 2003233725      A1      20031219      AU 2003-233725      20030602

US 2002-384435P P 20020531

WO 2003-CA832                      W 20030602

ED Entered STN: 14 Dec 2003

GI




IT 631090-29-4P

RN 631090-29-4 HCAPLUS

208



Absolute stereochemistry.



IPCI C07C0247-08 [ICM,7]; C07C0215-24 [ICS,7]; C07C0233-18 [ICS,7];  
 C07C0323-25 [ICS,7]  
 IPCR C07C0215-24 [I,A]; C07C0233-18 [I,A]; C07C0247-04 [I,A]; C07C0247-08  
 [I,A]; C07C0323-25 [I,A]; C07H0015-10 [I,A]  
 CC 33-7 (Carbohydrates)  
 Section cross-reference(s): 1, 15, 34, 63  
 IT 631090-29-4P 631090-30-7P 631090-31-8P 631090-32-9P  
 631090-33-0P  
 (claimed compd.; synthetic methods for the large scale prodn. from  
 glucose of analogs of sphingosine, azidosphingosine, ceramides,  
 lactosyl ceramides, and glycosyl phytosphingosines)  
 OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS  
 RECORD (12 CITINGS)  
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
 RE FORMAT

L48 ANSWER 10 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 2003:656778 HCAPLUS Full-text  
 DOCUMENT NUMBER: 139:180298  
 TITLE: Preparation of substituted inositols and their use  
 as phosphatidylinositol hexamannoside mimics and  
 potential drug delivery agents  
 INVENTOR(S): Rademacher, Thomas William; Schmidt, Richard;  
 Stadelmaier, Andreas  
 PATENT ASSIGNEE(S): Lascaux Pharmaceuticals Limited, UK  
 SOURCE: PCT Int. Appl., 87 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068789	A1	20030821	WO 2003-GB604	20030213

<--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
 NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ,  
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,  
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

AU 2003245767 A1 20030904 AU 2003-245767 20030213

<--

EP 1480991 A1 20041201 EP 2003-739562 20030213

<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,  
 PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

US 20050143290 A1 20050630 US 2005-504605 20050218

<--

PRIORITY APPLN. INFO.:

GB 2002-3535 A 20020214

<--



WO 2003-GB604 W 20030213

<--

OTHER SOURCE(S): MARPAT 139:180298

ED Entered STN: 22 Aug 2003

GI



AB Inositol phosphate esters and conjugates I and II, wherein R1 is hydroxyl, phosphate, phosphatidic acid or a phosphate ester; R2 is a sugar moiety; R3 is are selected from hydroxyl or phosphate; R4 and/or R6 is or are independently selected from: an amino acid; or a peptide or polypeptide; or a group having the general formula: O-(CH<sub>2</sub>)<sub>n</sub>-CH(NR<sub>7</sub>R<sub>8</sub>)-CO<sub>2</sub>X, wherein: n is an integer between 1 and 10, R<sub>7</sub> and R<sub>8</sub> are independently selected from hydrogen, nitrogen, acyl or alkyl; and X is hydrogen, alkyl or a cation where the terminal group is CO<sub>2</sub>-; or a substituted or unsubstituted arom. group, formed between the compds. and a coupling partner are disclosed, in particular compds. based on a myo-inositol which is substituted at position 1 with a phosphate ester group, at position 2 with a sugar group and at position 4 and/or position 6 with an amino acid group. The compds. are based on the structure of phosphatidylinositol hexamannosides (PIM6) of Mycobacteria and may be used as mimics of the naturally occurring PIMs in order to induce biol. responses normally attributed to the natural compd. or may be used as biol. inert carriers in order to deliver specific pharmaceutically active compds. to lipid rafts/caveolae (no data). Thus, triethylammonium-[2-O-(.alpha.-D-mannopyranosyl)-L-myo-inosit-1-yl]-[(2R)-2,3-bis(myristoyloxy)propyl]-phosphate was prepd. as phosphatidylinositol hexamannoside mimic and potential drug delivery agent.

IT 579493-79-1P


(prepn. of substituted inositols and their use as phosphatidylinositol hexamannoside mimics and potential drug delivery agents)

RN 579493-79-1 HCAPLUS

CN D-myo-Inositol, 3,4,5-tris-O-(phenylmethyl)-6-O-2-propenyl-2-O-

[2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-mannopyranosyl]-,  
(2R)-2,3-bis[(1-oxotetradecyl)oxy]propyl hydrogen phosphate (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



IPCI C07H0015-207 [ICM,7]; A61K0031-70 [ICS,7]

IPCR C07H0015-207 [I,A]

CC 33-6 (Carbohydrates)

Section cross-reference(s): 63

IT	22006-88-8P, Liriodendritol	55123-24-5P	111901-82-7P
	120202-94-0P	126722-28-9P	131233-71-1P
	154372-20-0P	154459-79-7P	154459-80-0P
	154459-83-3P	154459-84-4P	154459-93-5P
	170900-79-5P	380366-30-3P	164904-89-6P
	579493-72-4P	579493-70-2P	579493-71-3P
	579493-76-8P	579493-73-5P	579493-74-6P
	579493-83-7P	579493-77-9P	579493-75-7P
	579493-87-1P	579493-84-8P	579493-80-4P
	579493-91-7P	579493-85-9P	579493-86-0P
	579493-95-1P	579493-87-1P	579493-89-3P
	579493-99-5P	579493-88-2P	579493-90-6P
	579494-05-6P	579493-91-7P	579493-92-8P
	579494-10-3P	579493-95-1P	579493-93-9P
	579494-15-8P	579493-99-5P	579493-94-0P
		579494-00-1P	579493-95-1P
		579494-03-4P	579493-96-2P
		579494-06-7P	579493-97-3P
		579494-07-8P	579493-98-4P
		579494-12-5P	579494-04-5P
		579494-14-7P	579494-05-6P
		581078-76-4P	579494-06-7P
			579494-07-8P
			579494-09-0P
			579494-10-3P
			579494-11-4P
			579494-12-5P
			579494-13-6P
			579494-14-7P
			579494-15-8P
			579494-16-9P
			579494-17-0P

(prepn. of substituted inositols and their use as  
phosphatidylinositol hexamannoside mimics and potential drug  
delivery agents)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
RE FORMAT

L48 ANSWER 11 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2003:456232 HCAPLUS Full-text


DOCUMENT NUMBER: 139:22337

TITLE: New phosphonate derivatives, their preparation  
method, and their use as modulators of the

activity of t.gamma.9.delta.2 lymphocytes  
 INVENTOR(S): Montero, Jean Louis; Zgani, Ibrahim; Menut,  
 Chantal; Gallois, Valerie  
 PATENT ASSIGNEE(S): Laboratoires Mayoly Spindler, Fr.; Centre National  
 de la Recherche Scientifique CNRS; Universite  
 Montpellier II  
 SOURCE: Fr. Demande, 118 pp.  
 CODEN: FRXXBL  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2833266	A1	20030613	FR 2001-15971	20011211
			<--	
FR 2833266	B1	20041022		
WO 2003050128	A1	20030619	WO 2002-FR4190	20021205
			<--	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,			
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,			
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,			
	LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,			
	NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ,			
	TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,			
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,			
	EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,			
	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,			
	TD, TG			
AU 2002366577	A1	20030623	AU 2002-366577	20021205
			<--	
EP 1453840	A1	20040908	EP 2002-804596	20021205
			<--	
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,			
	PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005511748	T	20050428	JP 2003-551152	20021205
			<--	
US 20060241087	A1	20061026	US 2005-498313	20051104
			<--	
US 20100204184	A1	20100812	US 2010-656049	20100114
			<--	
US 8017596	B2	20110913		
PRIORITY APPLN. INFO.:			FR 2001-15971	A 20011211
			<--	
			WO 2002-FR4190	W 20021205
			<--	
			US 2005-498313	A1 20051104

OTHER SOURCE(S): MARPAT 139:22337  
 ED Entered STN: 15 Jun 2003  
 GI




AB The invention refers to new phosphonates A-[P(:O)(O-)-O]n-B X+ [I, A = C1-C50 alkyl which may be linear, branched, cyclic, satd. or unsatd. (alkenyl or alkynyl), (un)substituted by arom. groups, functionalized by bridging ethers, carboxylic acids, esters, amides, nitriles, hydroxyls, aldehydes, ketones, halogens, amines, thiols, thioketones, episulfides, selenols, selenoketones, sulfides, sulfones, sulfoxides, or may contain one or more heterocycles; n = 1-4; X = H or a pharmaceutically acceptable cationic org. group or mineral; B = X and -P(:O)(A)O-X+ (same X and A as above)]. Compds. I, e.g., pyrophosphonate [(E)-Me2C:CHCH:CHP(O)(O-)OP(O)(O-)2](NH4+)3, and their pharmaceutical compns. modulate the proliferation of T .gamma.9.delta.2 lymphocytes, and are useful for the treatment or prevention of infectious diseases, tumors, and chronic inflammatory diseases. A claimed method for conversion of di-Et alkylphosphonates of the invention to the corresponding phosphonic diacid is by treatment with a trimethylsilyl halide to give a bis(trimethylsilyl) phosphonate which is then hydrolyzed. A method is also claimed for prepg. compds. I which has a step comprising reaction of a phosphonic diacid with di-Ph phosphate tributylammonium chloride salt to give a phosphonic anhydride which is then treated with tributylammonium orthophosphate in pyridine. Diagnostic kits contg. compds. I for modulating activity of T .gamma.9.delta.2 lymphocytes are claimed.

IT 537696-98-3F

(prepn. of phosphonate derivs. as modulators of T .gamma.9.delta.2 lymphocyte activity and for treatment/prevention of infectious diseases, tumors, and chronic inflammatory diseases)

RN 537696-98-3 HCAPLUS

CN Isohypophosphoric acid, [[(2-methyl-2-propenyl)oxy]methyl]-, triammonium salt (9CI) (CA INDEX NAME)



● 3 NH3

IPCI C07F0009-40 [ICM,7]; C07F0009-38 [ICS,7]; A61K0031-662 [ICS,7]; A61K0031-663 [ICS,7]; A61P0031-00 [ICS,7]

IPCR G01N0033-15 [I,A]; A61K0031-662 [I,A]; A61K0031-663 [I,A]; A61K0035-14 [I,A]; A61K0035-26 [I,A]; A61P0001-00 [I,A]; A61P0001-16 [I,A]; A61P0019-02 [I,A]; A61P0021-00 [I,A]; A61P0029-00 [I,A]; A61P0031-00 [I,A]; A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0031-22 [I,A];

A61P0035-00 [I,A]; A61P0037-00 [I,A]; A61P0037-02 [I,A]; A61P0037-04 [I,A]; A61P0043-00 [I,A]; C07F0009-38 [I,A]; C07F0009-655 [I,A]; C12N0005-0783 [I,A]

CC 29-7 (Organometallic and Organometalloidal Compounds)

Section cross-reference(s): 1

IT 496042-87-6P 496042-88-7P 496042-89-8P 496042-90-1P  
 496042-91-2P 496042-92-3P 537696-50-7P 537696-53-0P  
 537696-54-1P 537696-55-2P 537696-56-3P 537696-57-4P  
 537696-58-5P 537696-59-6P 537696-68-7P 537696-72-3P  
 537696-74-5P 537696-75-6P 537696-77-8P 537696-78-9P  
 537696-81-4P 537696-82-5P 537696-83-6P 537696-84-7P  
 537696-85-8P 537696-86-9P 537696-87-0P 537696-89-2P  
 537696-90-5P 537696-92-7P 537696-96-1P ~~537696-98-3P~~  
~~537696-99-4P~~ 537697-00-0P 537697-01-1P

(prepn. of phosphonate derivs. as modulators of T .gamma.9.delta.2 lymphocyte activity and for treatment/prevention of infectious diseases, tumors, and chronic inflammatory diseases)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 12 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2003:282375 HCAPLUS Full-text

DOCUMENT NUMBER: 138:309276

TITLE: Liposomes containing (ether)-lysolecithins for treating Leishmanioses and other protozoan diseases

INVENTOR(S): Eibl, Joerg

PATENT ASSIGNEE(S): Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., Germany

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003028701	A2	20030410	WO 2002-EP10650	20020927
<--				
WO 2003028701	A3	20031224		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10148066	A1	20030424	DE 2001-10148066	20010928
<--				

AU 2002362507      A1      20030414      AU 2002-362507      20020927  
 <--  
 PRIORITY APPLN. INFO.:      DE 2001-10148066      A      20010928  
 <--  
                                  WO 2002-EP10650      W      20020927  
 <--

OTHER SOURCE(S):      MARPAT 138:309276

ED    Entered STN:    11 Apr 2003


AB    The invention relates to a novel pharmaceutical formulation contg.  
 (ether)lysolecithin compds. in a liposomal form; further cholesterol and a neg.  
 charged component are included in the liposomes. The pharmaceutical formulation  
 is esp. suitable for stimulating leucopoiesis, and for treating tumor diseases and  
 protozoan diseases, esp. Leishmanioses and amoebic diseases, acariasis and  
 diseases caused by arthropods. Other drugs can be added. Thus  
 1-O-octadecyl-2-O-methyl-glycero-3-phosphocholine (ET18OCH3) liposomes were  
 prepd. from 47.5 .mu.M cholesterol, 7.5 .mu.M  
 1,2-dioleoyl-sn-glycero-3-phosphoglycerin monosodium salt and 45.0 .mu.M ET18OCH3  
 in 200 mL chloroform by mixing, heating and evapg. the solvent. To the residue  
 450 g 0.25 M 1,2-propanediol were added, heated and filtered.

IT    149143-20-4

(liposomes contg. (ether)-lysolecithins for treating Leishmanioses  
 and other protozoan diseases)

RN    149143-20-4    HCAPLUS

CN    Ethanaminium, 2-[[hydroxy[3-(octadecyloxy)-2-(2-propen-1-  
 yloxy)propoxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt    (CA INDEX  
 NAME)



IPCI A61K0009-10 [ICM,7]; A61P0043-00 [ICS,7]

IPCR A61K0009-127 [I,A]; A61K0031-575 [I,A]; A61K0031-685 [I,A];  
 A61P0027-02 [I,A]; A61P0031-04 [I,A]; A61P0033-00 [I,A]; A61P0035-00  
 [I,A]; A61P0043-00 [I,A]

CC    63-6 (Pharmaceuticals)

Section cross-reference(s): 14

IT    57-55-6, 1,2-Propane diol, biological studies    57-88-5, Cholesterol,  
 biological studies    64-17-5, Ethanol, biological studies    67-63-0,  
 2-Propanol, biological studies    78-92-2, 2-Butanol    79-57-2,  
 Oxytetracycline    126-07-8, Griseofulvin    564-25-0, Doxycycline  
 1397-89-3, Amphotericin B    4358-16-1D, esters with poly glycerols  
 10118-90-8, Minocycline    70641-51-9    77249-78-6    77286-66-9  
 78858-43-2    79217-60-0, Cyclosporin    87746-72-3    91605-33-3  
 102340-77-2    105405-91-2    149143-20-4    508174-70-7  
 508174-73-0    508182-36-3    508182-37-4    508190-02-1    508190-03-2  
 508190-04-3    508190-05-4    508190-06-5    508190-07-6    508190-08-7  
 508190-09-8    508190-10-1    508190-11-2    508190-12-3    508190-13-4  
 508190-14-5    508190-15-6    508190-16-7    508190-17-8  
 508190-18-9    508190-19-0    508190-20-3    508190-21-4    509076-44-2  
 509076-45-3

(liposomes contg. (ether)-lysolecithins for treating Leishmanioses and other protozoan diseases)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 13 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2002:794472 HCAPLUS Full-text

DOCUMENT NUMBER: 138:24910

TITLE: Syntheses and Calcium-Mobilizing Evaluations of N1-Glycosyl-Substituted Stable Mimics of Cyclic ADP-Ribose

AUTHOR(S): Huang, Li-Jun; Zhao, Yong-Yuan; Yuan, Lan; Min, Ji-Mei; Zhang, Li-He

CORPORATE SOURCE: National Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100083, Peop. Rep. China

SOURCE: Journal of Medicinal Chemistry (2002), 45(24), 5340-5352

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:24910

ED Entered STN: 20 Oct 2002

AB Cyclic ADP-ribose (cADPR) is not only a potent endogenous calcium modulator but also a second messenger. However, studies on the mechanism of cADPR action were limited due to its instability and lack of available structural modifications in the N1-glycosyl unit of cADPR. In the present work, a series of N1-glycosyl mimics with different configurational glycosyls or an ether strand were designed and synthesized mimicking the furanose ring. SN2 substitutions were carried out between the protected inosine and glycosyl triflates to form the N1-glycosylinosine derivs., accompanied with some O6-glycosyl-substituted derivs. as side products. The intramol. cyclization followed the strategy described by Matsuda et al. It was found that the 8-unsubstituted substrate could also be used to construct the intramol. cyclic pyrophosphate. The activities of N1-glycosyl-substituted cADPR mimics were evaluated by induced Ca<sup>2+</sup> release in rat brain microsomes and HeLa cells. It was found that the configuration of the N1-glycosyl moiety in cADPR is not a crit. structural factor for retaining the activity of mobilizing Ca<sup>2+</sup> release. More interestingly, the N1-acyclic analog exhibited strong activity by inducing Ca<sup>2+</sup> release in both rat brain microsomes and HeLa cells. It constitutes a useful tool for further studies.

IT 478044-49-4P

(syntheses and calcium-mobilizing evaluations of N1-glycosyl-substituted stable mimics of cyclic ADP-ribose)

RN 478044-49-4 HCAPLUS

CN D-Arabinitol, 2,5-anhydro-4-[8-bromo-9-(2,3-di-O-acetyl-5-O-phosphono-.beta.-D-ribofuranosyl)-6,9-dihydro-6-oxo-1H-purin-1-yl]-4-deoxy-3-O-2-propenyl-, 1-(S-phenyl hydrogen phosphorothioate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Section cross-reference(s): 1, 6

IT	444989-14-4P	444989-15-5P	444989-16-6P	444989-17-7P
	444989-18-8P	478044-19-8P	478044-20-1P	478044-21-2P
	478044-22-3P	478044-23-4P	478044-24-5P	478044-25-6P
	478044-27-8P	478044-28-9P	478044-29-0P	478044-30-3P
	478044-31-4P	478044-32-5P	478044-33-6P	478044-34-7P
	478044-35-8P	478044-36-9P	478044-37-0P	478044-38-1P
	478044-39-2P	478044-40-5P	478044-41-6P	478044-42-7P
	478044-44-9P	478044-46-1P	478044-47-2P	478044-48-3P
	<del>478044-49-4P</del>	478044-51-8P	<del>478044-53-0P</del>	
	478044-54-1P	478044-59-6P	<del>478044-63-2P</del>	

(syntheses and calcium-mobilizing evaluations of  
N1-glycosyl-substituted stable mimics of cyclic ADP-ribose)

OS.CITING REF COUNT: 30 THERE ARE 30 CAPLUS RECORDS THAT CITE THIS  
RECORD (30 CITINGS)

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
RE FORMAT

L48 ANSWER 14 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2002:516677 HCAPLUS Full-text

DOCUMENT NUMBER: 137:57599

TITLE: Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of anti-endotoxin drugs

INVENTOR(S) :                    Rossignol, Daniel P.; Vermeulen, Mary W.

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: U.S., 37 pp., Cont.-in-part of U.S. 293,856.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6417172	B1	20020709	US 1999-449601	19991123
			<--	
US 5750664	A	19980512	US 1995-461675	19950605
			<--	
US 5935938	A	19990810	US 1996-658656	19960605
			<--	
US 6184366	B1	20010206	US 1999-293856	19990416
			<--	

10/596,747


CA 2392356	A1	20010531	CA 2000-2392356	20001122
			<--	
WO 2001037843	A1	20010531	WO 2000-US32177	20001122
			<--	
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,	
			CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH,	
			GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,	
			LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,	
			PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ,	
			UA, UG, US, UZ, VN, YU, ZA, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,	
			CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,	
			TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
EP 1248629	A1	20021016	EP 2000-980723	20001122
			<--	
EP 1248629	B1	20050126		
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,	
			PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
JP 2003514862	T	20030422	JP 2001-539457	20001122
			<--	
AT 287719	T	20050215	AT 2000-980723	20001122
			<--	
ES 2237475	T3	20050801	ES 2000-980723	20001122
			<--	
US 20030134805	A1	20030717	US 2002-167222	20020611
			<--	
US 6683063	B2	20040127		
HK 1051490	A1	20050422	HK 2003-102773	20030416
			<--	
JP 2007269812	A	20071018	JP 2007-154127	20070611
			<--	
JP 4712001	B2	20110629		
JP 2011121970	A	20110623	JP 2011-18401	20110131
			<--	
PRIORITY APPLN. INFO.:			US 1995-461675	A2 19950605
			<--	
			US 1996-658656	A1 19960605
			<--	
			US 1999-293856	A2 19990416
			<--	
			JP 1997-501868	A3 19960605
			<--	
			US 1999-449601	A 19991123
			<--	
			WO 2000-US32177	W 20001122
			<--	
			JP 2007-154127	A3 20070611

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 137:57599

ED Entered STN: 11 Jul 2002

GI



I



II

AB Disaccharide compds. I, wherein R is H, CH<sub>2</sub>OH, alkoxide; R<sub>1</sub> is acyl; R<sub>2</sub> is C<sub>5</sub>-C<sub>15</sub> alkyl R<sub>3</sub> is C<sub>5</sub>-C<sub>18</sub> alkyl, acyl, R<sub>4</sub> is C<sub>4</sub>-C<sub>20</sub> alkyl, oxyalkyl; A<sub>1</sub> and A<sub>2</sub> are independently OH, phosphate, phosphonate, ester; were prepd. for and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin. The invention provides methods of preventing and treating pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin and related conditions in a patient by administering to the patient anti-endotoxin compds. by inhalation. The invention provides methods of preventing and treating pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin and related conditions in a patient by administering to the patient anti-endotoxin compds. by inhalation. Thus, disaccharide lipid II was prepd. and tested in mice and suppressed the prodn. of TNF following administration of LPS.

IT 234088-16-5F


(prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of anti-endotoxin drugs such as disaccharide lipid A analogs in relation to inhibition of cytokine prodn.)

RN 234088-16-5 HCAPLUS


CN .alpha.-D-Glucopyranose, 6-O-[4-O-[bis(2-propenyloxy)phosphinyl]-2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[ (11Z)-1-oxo-11-octadecenyl]amino]-.beta.-D-glucopyranosyl]-3-O-decyl-2-deoxy-2-[(1,3-dioxotetradecyl)amino]-, 4-(3-butenate) 1-(dihydrogen phosphate), disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



● 2 Na



INCL 514053000

IPCI A61K0031-70 [ICM,7]

IPCR C07H0003-04 [I,A]; C07H0011-00 [I,A]; C07H0015-04 [I,A]; C07H0015-12 [I,A]

NCL 514/053.000

CC 1-12 (Pharmacology)

Section cross-reference(s): 26, 33, 63

IT	5509-08-0P	19525-80-5P	36875-26-0P	128313-03-1P	128387-27-9P
	137766-83-7P	139629-59-7P	139686-99-0P	185954-74-9P	
	185954-75-0P	185954-76-1P	185954-77-2P	185954-78-3P	
	185954-79-4P	185954-80-7P	185954-81-8P	185954-82-9P	
	185954-83-0P	185954-84-1P	185954-85-2P	185954-86-3P	
	185954-87-4P	185954-88-5P	185954-89-6P	185954-90-9P	
	185955-12-8P	185955-13-9P	185955-14-0P	185955-15-1P	
	185955-16-2P	185955-17-3P	185955-18-4P	185955-19-5P	
	185955-20-8P	185955-21-9P	185955-22-0P	185955-23-1P	
	185955-24-2P	185955-25-3P	185955-26-4P	185955-28-6P	
	185955-29-7P	234088-12-1P	234088-13-2P	234088-14-3P	
	234088-15-4P	<del>234088-16-5P</del>	234088-19-8P	234088-20-1P	

234088-21-2P 234088-22-3P 234088-23-4P 234088-24-5P

(prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of anti-endotoxin drugs such as disaccharide lipid A analogs in relation to inhibition of cytokine prodn.)

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 15 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2002:107823 HCAPLUS Full-text

DOCUMENT NUMBER: 136:156515

TITLE: Adhesive compositions containing monophosphates for bonding to hard tissues

INVENTOR(S): Stangel, Ivan; Xu, Jingwei; Ellis, Thomas; Sacher, Edward

PATENT ASSIGNEE(S): Biomat Sciences, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 5 pp., Cont.-in-part of Appl. No. PCT/US99/18582.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20020015682	A1	20020207	US 2001-785555	20010220
			<--	
US 6645952	B2	20031111		
WO 2000010478	A1	20000302	WO 1999-US18582	19990817
			<--	
W: AU, CA, CN, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 20030118523	A1	20030626	US 2003-339621	20030110
			<--	
US 6664245	B2	20031216		
PRIORITY APPLN. INFO.:			US 1998-96838P	P 19980818
			<--	
			WO 1999-US18582	A2 19990817
			<--	
			US 2001-785555	A3 20010220
			<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

ED Entered STN: 10 Feb 2002

AB An adhesive compn. is provided which is suitable for the bonding of polymeric materials, in whole or in part, such as composite resins, or methacrylate-contg. glass-ionomer filling materials, to tooth enamel, or tooth dentin, or to other hard tissues of the human body, such as bone. The compn. comprises an unsatd. carboxylic acid ester, an unsatd. phosphate ester and other crosslinking agents. The esp. preferred ethylenically unsatd. monophosphates,  $(CH_2::C(R)CH_2OCH_2)nR_1OP(O)(OH)_2$  (R = H, C1-4 alkyl, CN; R1 = aliph., cycloaliph., aryl), are provided as new compds. For example, a mixt. of 2-hydroxyethyl methacrylate (HEMA) (35% by wt.) and


pentaerythritol triallyl ether monophosphate acid ester (PTEPAE) (10% by wt.), the balance being acetone, was prepd. and the bond strength of the soln. to dentin was tested. The mean peak stress at failure for seven dentin samples was 20.5 MPa. However, the mean peak stress at failure for six dentin samples etched by 35% phosphoric acid was 25.5 MPa.

IT 259250-33-4

(adhesive compns. for bonding of polymeric materials to hard tissues)

RN 259250-33-4 HCAPLUS

CN 1-Propanol, 3-(2-propen-1-yloxy)-2,2-bis[(2-propen-1-yloxy)methyl]-, 1-(dihydrogen phosphate) (CA INDEX NAME)



INCL 424049000

IPCI A61K0007-16 [ICM]; C07F0009-113 [ICS]

IPCR A61K0006-00 [I,A]; C07F0009-09 [I,A]

NCL 424/049.000; 558/208.000; 514/112.000; 514/129.000; 558/183.000

CC 63-7 (Pharmaceuticals)

Section cross-reference(s): 23

IT 259250-33-4 395068-31-2

(adhesive compns. for bonding of polymeric materials to hard tissues)

L48 ANSWER 16 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2001:693328 HCAPLUS Full-text

DOCUMENT NUMBER: 135:257469

TITLE: Preparation of caprolactam derivatives with Src-SH2 domain inhibitor activity and their intermediates, and their application as bone resorption inhibitors

INVENTOR(S): Deprez, Pierre; Lesuisse, Dominique; Benard, Didier

PATENT ASSIGNEE(S): Ariad Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2001068655	A2	20010920	WO 2001-US7935	20010312
			<--	
WO 2001068655	A3	20020801		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW,			


10/596,747

MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR,  
 TT, UA, UG, US, UZ, VN, YU, ZA  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 AU 2001043601 A 20010924 AU 2001-43601 20010312

PRIORITY APPLN. INFO.:

<--  
 US 2000-523243 A 20000310  
 <--  
 WO 2001-US7935 W 20010312  
 <--

OTHER SOURCE(S): MARPAT 135:257469  
 ED Entered STN: 21 Sep 2001  
 GI




AB Caprolactam derivs. [I; X = XH<sub>2</sub>, N; R<sub>1</sub> = alkyl, alkenyl, alkynyl, arylalkyl, aryl-alkenyl, aryl-alkynyl, (un)substituted cycloalkyl etc.; A<sub>1</sub> = CH(Z)-alkylaryl, CH(Z):CH-alkylaryl, CH(Z)-aryl, alkylaryl, aryl; Z = H, tetrazole, (un)substituted NH<sub>2</sub> and CONH<sub>2</sub>; A<sub>2</sub> = P(O)(OH)<sub>2</sub> or esters, B(OH)<sub>2</sub> or esters, various carboxylic or sulfonic acids or their derivs.], as well as isomers, physiol. acceptable salts, and/or prodrugs, were prepd. as inhibitors of the Src-SH<sub>2</sub> receptor. Thus, caprolactam deriv. (II) was prepd. via a multistep synthetic sequence starting from (2S)-N-Boc-Tyr-O-(PO<sub>3</sub>Bn<sub>2</sub>) and (S)-3-amino-hexahydro-2H-azepin-2-one. In a scintillation proximity assay for inhibition of the binding of the ligand [125I]-EPQpYEEIPIYL to biotinylated SH<sub>2</sub> protein, II had an IC<sub>50</sub> of 0.009 .mu.M, vs. 0.2-0.4 .mu.M for the ref. peptide PYEEI.

IT 361385-61-7DF, Wang resin-bound  
 (prepn. of caprolactam derivs. as Src-SH<sub>2</sub> domain antagonists)

RN 361385-61-7 HCAPLUS

CN D-Tyrosine, N-acetyl-, 2-propenyl ester, 1,1-dimethylethyl hydrogen phosphate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IPCI C07F0009-02 [ICM,7]  
 IPCR A61K0038-00 [N,A]; C07F0009-12 [I,A]; C07F0009-40 [I,A]; C07F0009-553  
 [I,A]; C07K0005-06 [I,A]; C07K0005-065 [I,A]  
 CC 34-2 (Amino Acids, Peptides, and Proteins)  
 Section cross-reference(s): 1, 27  
 IT 76944-95-1P 361385-59-3P 361385-60-6P 361385-61-7DP,  
 Wang resin-bound 361385-62-8DP, Wang resin-bound 361385-63-9P  
 361385-64-0P 361385-65-1P  
 (prepn. of caprolactam derivs. as Src-SH2 domain antagonists)  
 OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS  
 RECORD (6 CITINGS)  
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
 RE FORMAT

L48 ANSWER 17 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 2001:396678 HCAPLUS Full-text  
 DOCUMENT NUMBER: 135:528  
 TITLE: Prevention and treatment of pulmonary bacterial  
 infection or symptomatic pulmonary exposure to  
 endotoxin by inhalation of antiendotoxin drugs  
 INVENTOR(S): Rossignol, Daniel P.; Vermeulen, Mary W.  
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 87 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037843	A1	20010531	WO 2000-US32177	20001122
<--				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6417172	B1	20020709	US 1999-449601	19991123
<--				
CA 2392356	A1	20010531	CA 2000-2392356	20001122
<--				



EP 1248629	A1	20021016	EP 2000-980723	20001122
			<--	
EP 1248629	B1	20050126		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,				
PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003514862	T	20030422	JP 2001-539457	20001122
			<--	
AT 287719	T	20050215	AT 2000-980723	20001122
			<--	
HK 1051490	A1	20050422	HK 2003-102773	20030416
			<--	
PRIORITY APPLN. INFO.:			US 1999-449601	A2 19991123
			<--	
			US 1995-461675	A2 19950605
			<--	
			US 1996-658656	A1 19960605
			<--	
			US 1999-293856	A2 19990416
			<--	
			WO 2000-US32177	W 20001122
			<--	

## ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 135:528

ED Entered STN: 01 Jun 2001

AB The invention provides methods of preventing and treating pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin and related conditions in a patient by administering to the patient antiendotoxin compds. by inhalation.

IT 234088-16-5P


(prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs such as lipid A analogs in relation to inhibition of cytokine prodn.)

RN 234088-16-5 HCAPLUS


CN .alpha.-D-Glucopyranose, 6-O-[4-O-[bis(2-propenyloxy)phosphinyl]-2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[ (11Z)-1-oxo-11-octadecenyl]amino]-.beta.-D-glucopyranosyl]-3-O-decyl-2-deoxy-2-[(1,3-dioxotetradecyl)amino]-, 4-(3-butenate) 1-(dihydrogen phosphate), disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



● 2 Na



IPCI A61K0031-70 [ICM, 7]

IPCR A61K0009-12 [I,A]; A61K0009-00 [I,A]; A61K0031-6615 [I,A]; A61K0031-70 [I,A]; A61K0045-00 [I,A]; A61P0011-00 [I,A]; A61P0031-00 [I,A]

CC 1-12 (Pharmacology)

Section cross-reference(s): 26, 33, 63

IT 5509-08-0P	19525-80-5P	36875-26-0P	128313-03-1P	128387-27-9P
137766-83-7P	139629-59-7P	139686-99-0P	185954-74-9P	
185954-75-0P	185954-76-1P	185954-77-2P	185954-78-3P	
185954-79-4P	185954-80-7P	185954-81-8P	185954-82-9P	
185954-83-0P	185954-84-1P	185954-85-2P	185954-86-3P	
185954-87-4P	185954-88-5P	185954-89-6P	185954-90-9P	
185955-12-8P	185955-13-9P	185955-14-0P	185955-15-1P	
185955-16-2P	185955-17-3P	185955-18-4P	185955-19-5P	
185955-20-8P	185955-21-9P	185955-22-0P	185955-23-1P	
185955-24-2P	185955-25-3P	185955-26-4P	185955-28-6P	
185955-29-7P	234088-12-1P	234088-13-2P	234088-14-3P	
234088-15-4P	<del>234088-16-5P</del>	234088-19-8P	234088-20-1P	
234088-21-2P	234088-22-3P	234088-23-4P	234088-24-5P	

(prevention and treatment of pulmonary bacterial infection or

symptomatic pulmonary exposure to endotoxin by inhalation of  
antiendotoxin drugs such as lipid A analogs in relation to  
inhibition of cytokine prodn.)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
RE FORMAT

L48 ANSWER 18 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN  
ACCESSION NUMBER: 2000:144683 HCAPLUS Full-text  
DOCUMENT NUMBER: 132:185486  
TITLE: Adhesive compositions containing ethylenically  
unsaturated monophosphates for the hard tissues of  
the human body such as tooth enamel and tooth  
dentin  
INVENTOR(S): Xu, Jingwei; Stangel, Ivan; Ellis, Thomas; Sacher,  
Edward  
PATENT ASSIGNEE(S): Biomat Services, Inc., USA  
SOURCE: PCT Int. Appl., 14 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010478	A1	20000302	WO 1999-US18582	19990817
<--				
W: AU, CA, CN, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2340900	A1	20000302	CA 1999-2340900	19990817
<--				
AU 9954876	A	20000314	AU 1999-54876	19990817
<--				
EP 1105063	A1	20010613	EP 1999-941168	19990817
<--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002523525	T	20020730	JP 2000-565804	19990817
<--				
CN 100389731	C	20080528	CN 1999-809765	19990817
<--				
US 20020015682	A1	20020207	US 2001-785555	20010220
<--				
US 6645952	B2	20031111		
US 20030118523	A1	20030626	US 2003-339621	20030110
<--				
US 6664245	B2	20031216		
PRIORITY APPLN. INFO.:			US 1998-96838P	P 19980818
<--				
			WO 1999-US18582	W 19990817
<--				
			US 2001-785555	A3 20010220
<--				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 132:185486

ED Entered STN: 03 Mar 2000

AB Title compns. are suitable for the bonding of polymeric materials, in whole or in part, such as composite resins, or methacrylate-contg. glass-ionomer filling materials, to tooth enamel, or tooth dentin, or to other hard tissues of the human body, such as bone. The compns. comprise unsatd. carboxylic acid esters, unsatd. phosphate esters represented by the formula  $[\text{CH}_2:\text{C}(\text{R}_1)\text{CH}_2\text{OCH}_2]_n\text{ROPO}_3\text{H}_2$ , and other crosslinking agents, where  $\text{R}_1$  is a hydrogen atom,  $\text{C}_1\text{-C}_4$  alkyl, or  $\text{CN}$ ;  $\text{R}$  is an aliph., cycloaliph., or aryl radical contg. from 1 to 10 carbon atoms and having a valence of  $n + 1$ ; and  $n$  is an integer from 1 to 5.

IT 259250-34-5P

(prepn. of dental adhesive compns. contg. ethylenically unsatd. monophosphates)


RN 259250-34-5 HCAPLUS

CN 2-Propenoic acid, 2-methyl-, 2-hydroxyethyl ester, polymer with 3-(2-propenyloxy)-2,2-bis[(2-propenyloxy)methyl]propyl dihydrogen phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 259250-33-4


CMF C14 H25 O7 P



CM 2

CRN 868-77-9

CMF C6 H10 O3



IPCI A61C0005-00 [ICM,6]; C07F0009-09 [ICS,6]; C07F0009-113 [ICS,6]

IPCR A61C0005-04 [I,A]; A61K0006-00 [I,A]; A61K0006-08 [I,A]; A61K0006-083 [I,A]; C07F0009-09 [I,A]; C09J0004-02 [I,A]; C09J0143-02 [I,A]

CC 63-7 (Pharmaceuticals)

IT 259250-34-5P 259250-35-6P

(prepn. of dental adhesive compns. contg. ethylenically unsatd. monophosphates)

IT 259250-33-4P

(prepn. of ethylenically satd. monophosphates for dental adhesives)

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
RE FORMAT

L48 ANSWER 19 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 2000:117065 HCAPLUS Full-text

DOCUMENT NUMBER: 132:161274

TITLE: CMP derivative sialyltransferase inhibitors,  
preparation, pharmaceutical compositions, and  
therapeutic use

INVENTOR(S): Schmidt, Richard R.; Schaub, Christoph; Muller,  
Bernd; Amann, Franz

PATENT ASSIGNEE(S): Germany

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2000008040	A1	20000217	WO 1999-EP5697	19990806

<--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU,  
CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,  
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9960791	A	20000228	AU 1999-60791	19990806
------------	---	----------	---------------	----------

<--

PRIORITY APPLN. INFO.:	US 1998-95700P	P	19980807
------------------------	----------------	---	----------

<--


WO 1999-EP5697	W	19990806
----------------	---	----------

<--

OTHER SOURCE(S): MARPAT 132:161274

ED Entered STN: 18 Feb 2000

GI



AB The invention provides potent inhibitors of sialyltransferases. The  
sialyltransferase inhibitors are useful for inhibiting the synthesis of sialylated

glycosides. The sialyltransferase inhibitors find use in the modulation of biol. processes that involve sialyl glycoside-mediated cell adhesion. The compds. of the invention may be used e.g. to treat inflammation.

IT 218939-23-2

(reaction; CMP deriv. sialyltransferase inhibitors, prepn.,  
pharmaceutical compns., and therapeutic use)

RN 218939-23-2 HCAPLUS


CN 5'-Cytidylic acid, N-acetyl-, 2',3'-diacetate, monoester with  
5-(acetylamino)-2,6-anhydro-1-C-[bis(2-propenyloxy)phosphinyl]-3,5-  
dideoxy-D-glycero-D-galacto-non-2-enitol 4,7,8,9-tetraacetate, compd.  
with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 218939-22-1

CMF C40 H54 N4 O24 P2


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



IPCI C07H0019-10 [ICM,7]; A61K0031-70 [ICS,7]

IPCR C07H0019-10 [I,A]

CC 1-12 (Pharmacology)

Section cross-reference(s): 33, 63

IT 218939-23-2

(reaction; CMP deriv. sialyltransferase inhibitors, prepn.,  
pharmaceutical compns., and therapeutic use)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS  
RECORD (1 CITINGS)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
RE FORMAT

L48 ANSWER 20 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN  
ACCESSION NUMBER: 1999:505657 HCAPLUS Full-text  
DOCUMENT NUMBER: 131:130224  
TITLE: Substituted liposaccharides useful in the  
treatment and prevention of endotoxemia  
INVENTOR(S): Christ, William J.; Rossignol, Daniel P.;  
Kobayashi, Seiichi; Kawata, Tsutomu  
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan  
SOURCE: U.S., 40 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:

PATENT NO. -----	KIND ----	DATE -----	APPLICATION NO. -----	DATE -----
US 5935938	A	19990810	US 1996-658656	19960605
			<--	
US 5681824	A	19971028	US 1995-461677	19950605
			<--	
US 5750664	A	19980512	US 1995-461675	19950605
			<--	
ZA 9604666	A	19970311	ZA 1996-4666	19960605
			<--	
CN 1192216	A	19980902	CN 1996-195890	19960605
			<--	
CN 1067082	C	20010613		
PT 853627	E	20040531	PT 1996-923234	19960605
			<--	
ES 2214543	T3	20040916	ES 1996-923234	19960605
			<--	
US 6184366	B1	20010206	US 1999-293856	19990416
			<--	
US 6417172	B1	20020709	US 1999-449601	19991123
			<--	
US 20020028927	A1	20020307	US 2001-774541	20010130
			<--	
US 20030144503	A1	20030731	US 2002-144670	20020513
			<--	
US 20030134805	A1	20030717	US 2002-167222	20020611
			<--	
US 6683063	B2	20040127		
JP 2007269812	A	20071018	JP 2007-154127	20070611
			<--	
JP 4712001	B2	20110629		
US 20080214802	A1	20080904	US 2007-830412	20070730
			<--	
US 7737129	B2	20100615		
US 20100227835	A1	20100909	US 2010-781166	20100517
			<--	
US 7994154	B2	20110809		

JP 2011121970	A	20110623	JP 2011-18401	20110131
			<--	
PRIORITY APPLN. INFO.:			US 1995-461675	A2 19950605
			<--	
			JP 1997-501868	A3 19960605
			<--	
			US 1996-658656	A1 19960605
			<--	
			US 1999-293856	A2 19990416
			<--	
			US 1999-449601	A1 19991123
			<--	
			US 2001-774541	B1 20010130
			<--	
			US 2002-144670	B1 20020513
			<--	
			JP 2007-154127	A3 20070611
			US 2007-830412	A1 20070730

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 131:130224

ED Entered STN: 16 Aug 1999

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Novel substituted liposaccharides I ( R1 = acyl; R2 = C5 to C15 alkyl; R3 = C5 to C18 acyl-alkenyl or acyl-alkynyl; R4 = C4 to C20 alkoxy-substituted alkyl; RA = CH2O-X where X is H or alkyl group; A1,A2 = OH, PO4H2, O-alkyl-OP03H2, etc.) useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock are prepd. Also provided are processes for prepg. the compds., e.g. II, and intermediates useful therein. The aminodeoxy disaccharide analogs inhibit tumor necrosis factor prodn. in vivo, exhibiting IC50s between 1.5 nM and 159 nM.

IT 234088-16-5P

(prepn. of substituted lipodisaccharides useful in the treatment and prevention of endotoxemia)



RN 234088-16-5 HCAPLUS

CN .alpha.-D-Glucopyranose, 6-O-[4-O-[bis(2-propenyloxy)phosphinyl]-2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[ (11Z)-1-oxo-11-octadecenyl]amino]-.beta.-D-glucopyranosyl]-3-O-decyl-2-deoxy-2-[(1,3-dioxotetradecyl)amino]-, 4-(3-butenate) 1-(dihydrogen phosphate), disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.





INCL 514053000

IPCI A61K0031-70 [ICM,6]; C13K0005-00 [ICS,6]

IPCR C07H0015-12 [I,A]; A61K0031-70 [I,A]; A61K0031-7028 [I,A]; A61P0031-00 [I,A]; A61P0031-04 [I,A]; C07H0003-04 [I,A]; C07H0011-00 [I,A]; C07H0011-04 [I,A]; C07H0013-06 [I,A]; C07H0015-04 [I,A]

NCL 514/053.000; 536/017.200; 536/017.900; 536/123.130

CC 33-7 (Carbohydrates)

Section cross-reference(s): 1.

IT	19525-80-5P	36875-26-0P	41233-29-8P	99049-68-0P	128313-03-1P
	128387-27-9P	137766-83-7P	139629-59-7P	139686-99-0P	
	185954-74-9P	185954-75-0P	185954-76-1P	185954-77-2P	
	185954-78-3P	185954-79-4P	185954-80-7P	185954-81-8P	
	185954-82-9P	185954-83-0P	185954-84-1P	185954-85-2P	
	185954-86-3P	185954-87-4P	185954-88-5P	185955-12-8P	
	185955-13-9P	185955-14-0P	185955-15-1P	185955-16-2P	
	185955-17-3P	185955-18-4P	185955-19-5P	185955-20-8P	
	185955-21-9P	185955-22-0P	185955-23-1P	185955-24-2P	
	234088-08-5P	234088-09-6P	234088-10-9P	234088-11-0P	
	234088-12-1P	234088-13-2P	234088-14-3P	234088-15-4P	

234088-16-5P 234088-17-6P 234088-18-7P 234088-19-8P  
 234088-20-1P 234088-21-2P 234088-22-3P 234088-23-4P  
 234088-24-5P

(prepn. of substituted lipodisaccharides useful in the treatment  
 and prevention of endotoxemia)

OS.CITING REF COUNT: 28 THERE ARE 28 CAPLUS RECORDS THAT CITE THIS  
 RECORD (28 CITINGS)  
 REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
 RE FORMAT

L48 ANSWER 21 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1999:499942 HCAPLUS Full-text

DOCUMENT NUMBER: 131:257780

TITLE: 5'-Phosphoramidates and 5'-Diphosphates of  
 2'-O-Allyl-.beta.-D-arabinofuranosyl-uracil,  
 -cytosine, and -adenine: Inhibition of  
 Ribonucleotide Reductase

AUTHOR(S): Manfredini, Stefano; Baraldi, Pier Giovanni;  
 Durini, Elisa; Vertuani, Silvia; Balzarini, Jan;  
 De Clercq, Erik; Karlsson, Anna; Buzzoni,  
 Valentina; Thelander, Lars

CORPORATE SOURCE: Department of Pharmaceutical Sciences, Ferrara  
 University, Italy

SOURCE: Journal of Medicinal Chemistry (1999), 42(17),  
 3243-3250

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 12 Aug 1999

AB Continuing our studies on ribonucleotide reductase (RNR) mechanism-based  
 inhibitors, we have now prepd. the diphosphates (DP) of  
 2'-O-allyl-1-.beta.-D-arabinofuranosyl-uracil and -cytosine and  
 2'-O-allyl-9-.beta.-D-arabinofuranosyl-adenine and evaluated their inhibitory  
 activity against recombinant murine RNR. 2'-O-Allyl-araUDP proved to be  
 inhibitory to RNR at an IC50 of 100 .mu.M, whereas 2'-O-allyl-araCDP was only  
 marginally active (IC50 1 mM) and 2'-O-allyl-araADP was completely inactive. The  
 susceptibility of the parent nucleosides to phosphorylation by thymidine kinase  
 and 2'-deoxycytidine kinase was also investigated, and all nucleosides proved to  
 be poor substrates for the above-cited kinases. Moreover, prodrugs of  
 2'-O-allyl-araU and -araC monophosphates, namely  
 2'-O-allyl-5'-(phenylethoxy-L-alanyl phosphate)-araU and -araC, were prepd. and  
 tested against tumor cell proliferation but proved to be inactive. A mol. modeling  
 study has been conducted in order to explain our results. The data confirm that  
 for both the natural and analog nucleoside diphosphates, the principal determinant  
 interaction with the active site of RNR is with the diphosphate group, which forms  
 strong hydrogen bonds with Glu623, Thr624, Ser625, and Thr209. Our findings  
 indicate that the poor phosphorylation may represent an explanation for the lack  
 of marked in vitro cytostatic activity of the test compds.

IT 245078-03-9P


(prepn. and ribonucleotide reductase inhibition of phosphoramidates  
 and diphosphates of allyl-D-arabinofuranosyl-uracil, -cytosine and  
 -adenine)

RN 245078-03-9 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-

O-2-propenyl-.beta.-D-arabinofuranosyl]-, trisodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 3 Na

CC 33-9 (Carbohydrates)

Section cross-reference(s): 1

IT 245078-03-9P 245078-08-4P 245078-13-1P

(prepn. and ribonucleotide reductase inhibition of phosphoramidates and diphosphates of allyl-D-arabinofuranosyl-uracil, -cytosine and -adenine)

OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 22 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1999:448710 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 131:170568

TITLE: Synthesis, cytostatic activity and inhibition of ribonucleotide reductase by 5'-phosphoramidates and 5'-diphosphates, of 2'-O-allyl-arabinofuranosyl nucleosides

AUTHOR(S): Manfredini, S.; Baraldi, P. G.; Durini, E.; Balzarini, J.; De Clercq, E.; Karlsson, A.; Buzzoni, V.; Thelander, L.

CORPORATE SOURCE: Department of Pharmaceutical Sciences, Ferrara University, Italy

SOURCE: Nucleosides & Nucleotides (1999), 18(4 & 5), 1007-1008

CODEN: NUNUD5; ISSN: 0732-8311

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 22 Jul 1999

AB A symposium reporting that the diphosphates of a series of 2'-O-allyl-1-.beta.-D-arabinofuranosyl derivs., previously obtained by the authors, have been prepd. and tested for their inhibitory activity in an in vitro assay using R1 and R2 subunits of the purified recombinant mouse ribonucleotide reductase (RNR). 2'-O-Allyl-araU diphosphate proved to be inhibitory, with an

IC50 of 100 .mu.M. The 5'-phosphoramidate pronucleotide of 2'-O-allyl-araU was also prepd. and tested for inhibition of tumor cell proliferation.


IT 239117-77-2P

(prepn., cytostatic activity and inhibition of ribonucleotide reductase by phosphoramidates and diphosphates of allylarabinofuranosyl nucleosides)

RN 239117-77-2 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-O-2-propen-1-yl-.beta.-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.



CC 33-9 (Carbohydrates)

Section cross-reference(s): 1

IT 239117-77-2P 239117-78-3P 239117-79-4P  
239117-80-7P

(prepn., cytostatic activity and inhibition of ribonucleotide reductase by phosphoramidates and diphosphates of allylarabinofuranosyl nucleosides)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 23 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1999:166753 HCAPLUS Full-text

DOCUMENT NUMBER: 130:232458

TITLE: Drug discovery using multiple membrane mimetic affinities

INVENTOR(S): Pidgeon, Charles; Liu, Hanlan; Hauer, Kimberly; Yin, Jiaming; Cai, Song J.

PATENT ASSIGNEE(S): Purdue Research Foundation, USA

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9910522	A1	19990304	WO 1998-US17398	19980821

<--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,  
DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP,

KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,  
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
 TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2300863	A1	19990304	CA 1998-2300863	19980821
			<--	
AU 9892018	A	19990316	AU 1998-92018	19980821
			<--	
AU 736198	B2	20010726		
EP 1015623	A1	20000705	EP 1998-944484	19980821
			<--	
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		
JP 2001514375	T	20010911	JP 2000-507830	19980821
			<--	
NO 2000000838	A	20000330	NO 2000-838	20000221
			<--	
MX 2000001798	A	20001026	MX 2000-1798	20000221
			<--	
US 6829540	B1	20041207	US 2000-486168	20000222
			<--	
PRIORITY APPLN. INFO.:			US 1997-56833P	P 19970822
			<--	
			WO 1998-US17398	W 19980821
			<--	

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

ED Entered STN: 15 Mar 1999

AB The measurement of multiple membrane affinities of test compds., methods and compns. useful for acquiring data characteristic of such affinities, and a method and system for using such data alone or in combination with other mol. descriptors for the prediction of biol. activity are described. The numerical values characteristic of biol. relevant interaction of test compds. with membrane mimetic surfaces are compared with corresponding values of one or more control compds. having a known biol. activity. Probable biol. activity of a test compd. is identified with those control compds. whose multiple membrane interaction values most closely correlate to those of the test compd. In another embodiment, membrane binding data are obtained for test compds. and control compds. for use in accordance with this invention using immobilized artificial membrane chromatog. substrates in high pressure liq. chromatog. systems using aq. mobile phases. Data relevant to the thermodyn. and kinetics of compd./membrane interaction is reflected in retention time and peak width, resp. All data are preferably normalized relative to a std. compd. or a set of compds., for example, a set of compds. having a common biol. activity or function. This invention also provides novel carboxylfunctional, head group-protected phospholipids useful for prepg. immobilized artificial membrane structures useful for acquiring membrane interaction data. They are prepd. by novel high yielding transphosphatidylation of phosphatidylcholine derivs. using phospholipase D in the presence of protected alcs.

IT 221108-36-7P


(intermediate; drug discovery using multiple membrane mimetic affinities and use of HPLC and prepn. of protected phospholipids useful for prepn. of immobilized artificial membranes)

RN 221108-36-7 HCAPLUS

CN L-Serine, N-[(1,1-dimethylethoxy)carbonyl]-, 2-propenyl ester,

(2R)-2-[(13-carboxy-1-oxotridecyl)oxy]-3-[(1-oxotetradecyl)oxy]propyl  
hydrogen phosphate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IPCI C12Q0001-00 [ICM,6]; G01N0033-53 [ICS,6]; G01N0033-566 [ICS,6]  
IPCR G01N0033-50 [I,A]; B01J0020-281 [I,A]; C12Q0001-00 [I,A]; G01N0030-02  
[N,A]; G01N0030-88 [I,A]; G01N0030-89 [N,A]; G01N0033-15 [I,A];  
G01N0033-543 [I,A]

CC 1-1 (Pharmacology)

Section cross-reference(s): 26

IT 123-78-4P 20559-16-4P 85483-04-1P, Oxacyclotridecane-2,13-dione  
88224-08-2P 102308-32-7P 108149-60-6P 115464-01-2P  
116467-63-1P 117487-53-3P 119766-79-9P 143966-57-8P  
203439-80-9P 221108-33-4P 221108-34-5P 221108-35-6P  
221108-36-7P

(intermediate; drug discovery using multiple membrane mimetic  
affinities and use of HPLC and prepn. of protected phospholipids  
useful for prepn. of immobilized artificial membranes)

IT 221108-33-4DP, silica propylamine-immobilized 221108-34-5DP, silica  
propylamine-immobilized 221108-35-6DP, silica  
propylamine-immobilized 221108-36-7DP, silica  
propylamine-immobilized

(on artificial membranes; drug discovery using multiple membrane  
mimetic affinities and use of HPLC and prepn. of protected  
phospholipids useful for prepn. of immobilized artificial  
membranes)

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS  
RECORD (3 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
RE FORMAT

L48 ANSWER 24 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1998:453103 HCAPLUS Full-text

DOCUMENT NUMBER: 129:216434

ORIGINAL REFERENCE NO.: 129:43999a,44002a

TITLE: Synthesis and pharmacological evaluation of a new  
class of bicyclic phospholipids, designed as  
platelet activating factor antagonists

AUTHOR(S): Pecanha, Emerson Poley; Fraga, Carlos Alberto  
Manssour; Mauricio, Carlos; De Sant' Anna,  
Rabello; De Miranda, Ana Luisa Palhares; Barreiro,  
Eliezer Jesus

CORPORATE SOURCE: Laboratorio de Avaliacao e Sintese de Substancias  
Bioativas (LASSBio), Faculdade de Farmacia,

Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21944-970, Brazil

SOURCE: Farmaco (1998), 53(5), 327-336  
CODEN: FRMCE8; ISSN: 0014-827X

PUBLISHER: Elsevier Science S.A.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 22 Jul 1998


AB (.+-.)-3-Alkoxyethyl-(2-oxabicyclo[3.3.0]octane)-5-yl-methyl-phosphoryl-ethyl-pyridinium [alkyl = Me, CH<sub>2</sub>=CHCH<sub>2</sub>, Pr, Me(CH<sub>2</sub>)<sub>5</sub>] (I), structurally designed as conformationally restricted platelet activating factor (PAF) antagonists were synthesized in 12-26% overall yield, using Et (.+-.)-3-hydroxyethyl-5-(2-oxabicyclo[3.3.0]octane)carboxylate as key intermediate. The anti-platelet profile of I was evaluated in a PAF-induced aggregation model in rabbit platelet-rich plasma; only I [alkyl = Me(CH<sub>2</sub>)<sub>5</sub>] exhibited a modest activity.

IT 212479-12-4P  
(synthesis and platelet activating factor antagonist activity of a new class of bicyclic phospholipids)

RN 212479-12-4 HCAPLUS

CN Pyridinium, 1-[2-[[[[(2R,3aR,6aR)-hexahydro-2-[(2-propenyloxy)methyl]-3aH-cyclopenta[b]furan-3a-yl]methoxy]hydroxyphosphinyl]oxy]ethyl]-, inner salt, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



CC 26-3 (Biomolecules and Their Synthetic Analogs)  
Section cross-reference(s): 1

IT 197459-82-8P 197459-83-9P 212479-12-4P 212479-14-6P  
212479-16-8P 212479-56-6P 212479-58-8P 212479-60-2P  
(synthesis and platelet activating factor antagonist activity of a new class of bicyclic phospholipids)

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 25 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1997:532277 HCAPLUS Full-text

DOCUMENT NUMBER: 127:166876

ORIGINAL REFERENCE NO.: 127:32228h,32229a

TITLE: Copolymers having phospholipid-like structure and medical goods coated with them

INVENTOR(S): Shudo, Kenshiro; Matsuyama, Kazuo; Sakaki, Hidejiro; Kamenosono, Koji; Nakabayashi, Norio; Ishihara, Kazuhiko  
 PATENT ASSIGNEE(S): Nippon Oil and Fats Co., Ltd., Japan; Research Development Corp. of Japan; Nakabayashi, Norio; Ishihara, Kazuhiko  
 SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09183819	A	19970715	JP 1995-342470	19951228

PRIORITY APPLN. INFO.: JP 1995-342470 19951228  
 <--

ED Entered STN: 20 Aug 1997

AB Title copolymers have no.-av. mol. wt. 5000-300,000, contain structure units [CHZCR1[X(Y)mP(O)(O-)O(CH2)2N+R3R4R5]]a[CH2CR9(WSiR6R7R8)]b [R1, R9 = H, Me; R3-R5 = H, C1-6 (hydroxy)hydrocarbyl; R6 = C1-10 alkoxy, C6-14 aryloxy; R7, R8 = C1-10 (halo)alkoxy, C6-14 (halo)aryloxy, (O- or N-contg.) C1-10 alkyl; W = (CH2)k, CO2(CH2)k, CONH(CH2)k, C6H4(CH2)k, C6H4CH2NH(CH2)k; X = divalent residue; Y = C1-6 alkyleneoxy; Z = H, R2O2C; R2 = C1-10 (hydroxy)alkyl; k = 0-4; m = 0-10, a:b = (95:5)-(50:50)], and are manufd. by random or alternating polymn. of ZCH:CR1X(Y)mP(O)(O-)O(CH2)2R+R3R4R5 (R1, R3-R5, X, Y, Z, m = same as above) with CH2:CR9WSiR6R7R8 (R6-R9, W = same as above). The copolymers show high durability and biocompatibility. A monomer mixt. comprising 0.6 mol part 2-(methacryloyloxy)ethyl 2'-(trimethylammonio)ethyl phosphate and 0.4 mol part 3-(methacryloyloxypropyl)trimethoxysilane was polyemd. at 60.degree. in EtOH using t-Bu peroxyphosphate to give a copolymer (Mn 58,000), which was dissolved into EtOH and mixed with H2O and AcOH to prep. a coating. A cover glass was coated with the coating to show protein adsorption 4 ng/cm2.

IT 193684-55-8P

(durable and biocompatible copolymers having phospholipid-like structure for coatings for medical goods)


RN 193684-55-8 HCAPLUS

CN 3,5,8-Trioxa-4-phosphaundec-10-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, polymer with silicic acid (H4SiO4) ethenyl trimethyl ester (9CI) (CA INDEX NAME)

CM 1

CRN 183544-44-7

CMF C10 H22 N O5 P






CM 2

CRN 19916-97-3

CMF C5 H12 O4 Si



IPCI C08F0230-02 [ICM,6]; A61L0033-00 [ICS,6]; C08F0230-08 [ICS,6];  
C09D0143-00 [ICS,6]

IPCR A61L0033-00 [I,A]; C08F0030-02 [I,A]; C08F0030-08 [I,A]; C08F0230-02  
[I,A]; C08F0230-08 [I,A]; C09D0137-00 [I,A]; C09D0143-00 [I,A]

CC 63-8 (Pharmaceuticals)

Section cross-reference(s): 35, 42

IT 193684-52-5P ~~193684-55-8P~~ 193684-57-0P 193684-58-1P  
193684-59-2P

(durable and biocompatible copolymers having phospholipid-like  
structure for coatings for medical goods)

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS  
RECORD (4 CITINGS)

L48 ANSWER 26 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1997:411048 HCAPLUS Full-text

DOCUMENT NUMBER: 127:104339

ORIGINAL REFERENCE NO.: 127:19947a,19950a

TITLE: Stimulation of proliferation of V.gamma.2V.delta.2  
T cells by alkyl and alkenyl pyrophosphates

INVENTOR(S): Bloom, Barry R.; Tanaka, Yoshimasa; Sano,  
Shigetoshi

PATENT ASSIGNEE(S): Albert Einstein College of Medicine of Yeshiva  
University, USA

SOURCE: U.S., 25 pp., Cont.-in-part of U.S. Ser. No.  
93,528, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 5639653	A	19970617	US 1995-390881	19950217
			<--	
US 5902793	A	19990511	US 1997-877011	19970616
			<--	
PRIORITY APPLN. INFO.:			US 1993-93528	B2 19930719
			<--	
			US 1995-390881	A3 19950217

&lt;--

## ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


ED Entered STN: 03 Jul 1997

AB The proliferation of V.gamma.2V.delta.2 T cells can be stimulated by contacting V.gamma.2V.delta.2 T cells with a compd. selected from the group consisting of a monoalkyl pyrophosphate or an alkenyl pyrophosphate. Thus, 5 .mu.M monoethyl pyrophosphate or 0.3 .mu.M 3-methyl-2-hexenyl pyrophosphate are the minimal ligand concns. required for half-max. proliferative response of .gamma..delta. T cell clone 12G12.

IT 6088-04-6, Allyl pyrophosphate  
(stimulation of proliferation of V.gamma.2V.delta.2 T cells by  
alkyl and alkenyl pyrophosphates)

RN 6088-04-6 HCAPLUS

CN Diphosphoric acid, P-2-propen-1-yl ester (CA INDEX NAME)



INCL 514102000

IPCI C12N0005-02 [ICM,6]; C12N0005-06 [ICS,6]; A61K0031-66 [ICS,6];  
C07F0009-02 [ICS,6]

IPCR C07F0009-09 [I,A]; C12N0005-02 [I,A]

NCL 514/102.000; 435/375.000; 435/384.000; 514/106.000; 514/134.000;  
558/155.000; 558/156.000

CC 1-7 (Pharmacology)

IT 358-71-4, Isopentenyl pyrophosphate 358-72-5, Dimethylallyl  
pyrophosphate 372-97-4, Farnesyl pyrophosphate 763-10-0, Geranyl  
pyrophosphate 2466-09-3D, Diphosphoric acid, monoalkyl and  
monoalkenyl esters 6088-04-6, Allyl pyrophosphate  
6699-20-3, Geranylgeranyl pyrophosphate 20680-57-3, Diphosphoric  
acid, monoethyl ester 22342-44-5, Crotyl pyrophosphate 24753-22-8  
24753-28-4 52811-47-9, Diphosphoric acid, mono(butyl) ester  
56399-35-0, Diphosphoric acid, monomethyl ester 56399-36-1,  
Diphosphoric acid, mono(1-methylethyl) ester 104072-24-4,  
Diphosphoric acid Mono(Propyl) ester  
(stimulation of proliferation of V.gamma.2V.delta.2 T cells by  
alkyl and alkenyl pyrophosphates)

OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS  
RECORD (15 CITINGS)

L48 ANSWER 27 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1997:94093 HCAPLUS Full-text

DOCUMENT NUMBER: 126:104365

ORIGINAL REFERENCE NO.: 126:20149a,20152a

TITLE: Preparation of substituted liposaccharide analogs  
useful in the treatment and prevention of  
endotoxemia

INVENTOR(S): Christ, William J.; Rossignol, Daniel P.;  
Kobayashi, Seiichi; Kawata, Tsutomu

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9639411	A1	19961212	WO 1996-US9578	19960605
<--				
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
US 5681824	A	19971028	US 1995-461677	19950605
<--				
US 5750664	A	19980512	US 1995-461675	19950605
<--				
CA 2223140	A1	19961212	CA 1996-2223140	19960605
<--				
CA 2223140	C	20080805		
AU 9663802	A	19961224	AU 1996-63802	19960605
<--				
AU 707779	B2	19990722		
ZA 9604666	A	19970311	ZA 1996-4666	19960605
<--				
EP 853627	A1	19980722	EP 1996-923234	19960605
<--				
EP 853627	B1	20040121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1192216	A	19980902	CN 1996-195890	19960605
<--				
CN 1067082	C	20010613		
HU 9802662	A2	19990528	HU 1998-2662	19960605
<--				
HU 9802662	A3	19990628		
HU 221342	B1	20020928		
JP 11506793	T	19990615	JP 1997-501868	19960605
<--				
JP 4009318	B2	20071114		
RU 2170738	C2	20010720	RU 1998-100107	19960605
<--				
AT 258185	T	20040215	AT 1996-923234	19960605
<--				
PT 853627	E	20040531	PT 1996-923234	19960605
<--				
ES 2214543	T3	20040916	ES 1996-923234	19960605
<--				
IL 149971	A	20100428	IL 1996-149971	19960605
<--				
NO 9705644	A	19980204	NO 1997-5644	19971204
<--				


NO 310239	B1	20010611		
JP 2007269812	A	20071018	JP 2007-154127	20070611
			<--	
JP 4712001	B2	20110629		
JP 2011121970	A	20110623	JP 2011-18401	20110131
			<--	
PRIORITY APPLN. INFO.:			US 1995-461675	A1 19950605
			<--	
			IL 1996-122251	A3 19960605
			<--	
			JP 1997-501868	A3 19960605
			<--	
			WO 1996-US9578	W 19960605
			<--	
			JP 2007-154127	A3 20070611

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 126:104365

ED Entered STN: 10 Feb 1997

GI



AB Novel substituted liposaccharides in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia, and various forms of septic shock and methods of using these agents are provided. Also provided are method of prepg. these agents and intermediates useful therein. Thus, total prepn. of amidodeoxy oligosaccharide I is reported. I inhibited tumor-necrosis factor prodn. in vivo in mice (ED50 = 5 and 10.6 .mu.g/ mouse).

IT 185955-33-3P

(prepn. of substituted liposaccharide analogs useful in the treatment and prevention of endotoxemia)


RN 185955-33-3 HCAPLUS

CN .alpha.-D-Glucopyranose, 6-O-[4-O-[bis(2-propenyloxy)phosphinyl]-2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[ (11Z)-1-oxo-11-octadecenyl]amino]-.beta.-D-glucopyranosyl]-3-O-decyl-2-deoxy-2-[(1,3-dioxotetradecyl)amino]-, 1-(dihydrogen phosphate) 4-(2-propenyl carbonate), disodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



IPCI C07H0005-04 [ICM,6]; C07H0015-00 [ICS,6]; C07H0017-00 [ICS,6]  
 IPCR C07H0015-12 [I,A]; A61K0031-70 [I,A]; A61K0031-7028 [I,A]; A61P0031-00 [I,A]; A61P0031-04 [I,A]; C07H0003-04 [I,A]; C07H0011-00 [I,A]; C07H0011-04 [I,A]; C07H0013-06 [I,A]; C07H0015-04 [I,A]  
 CC 33-7 (Carbohydrates)  
 Section cross-reference(s): 1  
 IT 41233-29-8P 95548-26-8P 128313-03-1P 128387-27-9P 137766-83-7P  
 139629-59-7P 139686-99-0P 185954-74-9P 185954-75-0P  
 185954-76-1P 185954-77-2P 185954-78-3P 185954-79-4P

185954-80-7P	185954-81-8P	185954-82-9P	185954-83-0P
185954-84-1P	185954-85-2P	185954-86-3P	185954-87-4P
185954-88-5P	185954-89-6P	185954-90-9P	185954-91-0P
185954-92-1P	185954-93-2P	185954-94-3P	185954-95-4P
185954-96-5P	185954-97-6P	185955-11-7P	185955-12-8P
185955-13-9P	185955-14-0P	185955-15-1P	185955-16-2P
185955-17-3P	185955-18-4P	185955-19-5P	185955-20-8P
185955-21-9P	185955-22-0P	185955-23-1P	185955-24-2P
185955-25-3P	185955-26-4P	185955-28-6P	185955-29-7P
185955-30-0P	185955-31-1P	185955-32-2P	<del>185955-33-3P</del>

(prepn. of substituted liposaccharide analogs useful in the treatment and prevention of endotoxemia)

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 28 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1996:713038 HCAPLUS Full-text

DOCUMENT NUMBER: 125:330468

ORIGINAL REFERENCE NO.: 125:61899a,61902a

TITLE: Low-toxicity aqueous solution of phosphorylcholine group-bearing polymer and its manufacture

INVENTOR(S): Nakabayashi, Nobuo; Ishihara, Kazuhiko; Shuto, Kenshiro; Matsuyama, Kazuo

PATENT ASSIGNEE(S): Nof Corporation, Japan; Research Development Corporation of Japan

SOURCE: PCT Int. Appl., 46 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. -----	KIND ----	DATE -----	APPLICATION NO. -----	DATE -----
WO 9631566	A1	19961010	WO 1996-JP894	19960402
			<--	
W: KR, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 08333421	A	19961217	JP 1996-78731	19960401
			<--	
JP 3532692	B2	20040531		
EP 767212	A1	19970409	EP 1996-907752	19960402
			<--	
EP 767212	B1	20010718		
R: BE, CH, DE, FR, GB, IT, LI, NL				
US 6204324	B1	20010320	US 1996-750102	19961202
			<--	
PRIORITY APPLN. INFO.:			JP 1995-77693	A 19950403
			<--	
			JP 1996-78731	A 19960401
			<--	
			WO 1996-JP894	W 19960402

&lt;--

## ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

ED Entered STN: 05 Dec 1996

AB A process for producing a title soln. useful for skin cares, hair cares, contact lens soilproofing, etc. (no data), comprises polymg. a polymerizable compn. contg. a phosphorylcholine group-bearing monomer of  
 $ZCH:C(R_1)X(Y)mP(O)(O-)O(CH_2)_2N+R_2R_3R_4$  [X = divalent org. groups; Y = C1-6 alkylene oxide groups; Z = H; R5OCO, with R5 = C1-10 (hydroxy)alkyl; R1 = H, Me, R1-4 = H, C1-6 (hydroxy)hydrocarbyl; m = 0, 1] in the presence of a nonmetallic polymn. initiator sol. in a water-contg. medium, then purifying the resulting crude aq. soln. by a sepn. membrane. Aq. soln. produced by this process has an impurity content of .ltoreq.2000 ppm. Thus, polymg.  
 2-(methacryloyloxy)ethyl-2'-(trimethylammonio)ethyl phosphate using succinyl peroxide in water gave a polymer which was purified by a dialysis membrane.

IT 183544-45-8P

(low-toxicity aq. soln. of phosphorylcholine group-bearing polymer and manuf.)


RN 183544-45-8 HCAPLUS

CN 3,5,8-Trioxa-4-phosphaundec-10-en-1-aminium,  
 4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, homopolymer (9CI)  
 (CA INDEX NAME)

CM 1

CRN 183544-44-7

CMF C10 H22 N O5 P



IPCI C08L0043-02 [ICM,6]; C08F0006-06 [ICS,6]; C08F0030-02 [ICS,6]

IPCR C08F0006-00 [I,A]; C08F0006-06 [I,A]; C08F0030-02 [I,A]

CC 37-3 (Plastics Manufacture and Processing)

Section cross-reference(s): 62, 63

IT 67881-99-6P 125275-25-4P 148569-41-9P 150120-18-6P

183544-43-6P 183544-45-8P 183601-60-7P

(low-toxicity aq. soln. of phosphorylcholine group-bearing polymer and manuf.)

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS  
 RECORD (9 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
 RE FORMAT

L48 ANSWER 29 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1996:115532 HCAPLUS Full-text

DOCUMENT NUMBER: 124:234032


ORIGINAL REFERENCE NO.: 124:43371a,43374a

TITLE: Phosphate multivalent metal salts-modified  
 organopolysiloxanes, their manufacture, and

gelling agents  
 INVENTOR(S): Ihara, Takeshi; Yano, Shinji; Kita, Katsumi  
 PATENT ASSIGNEE(S): Kao Corp, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07316169	A	19951205	JP 1994-112945	19940526
JP 3511401	B2	20040329		
PRIORITY APPLN. INFO.:			JP 1994-112945	19940526

ED Entered STN: 24 Feb 1996  
 GI




AB Title siloxanes, useful for gelling agents of silicone oils, cosmetics, medical materials, etc., have .gtoreq.1 Si modified with title salts (I) [R1, R2 = C2-20 linear or branched alkylene; R3 = (hydroxy-substituted) C1-20 linear or branched alkyl; M = alk. earth metal or .gtoreq.2-valent transition metal; p, q = 0-200, n = metal valence no.]. Thus, 10 g phosphate Ca salt and 5.0 g 1,1,1,3,5,5,5-heptamethyltrisiloxane were mixed at 70.degree. for 4h to give a modified organopolysiloxane, which was mixed with octamethylcyclotetrasiloxane to give a gel.

IT 173787-12-7

(manuf. of phosphate metal salt-modified organopolysiloxanes useful for gelling agents of silicone oils and cosmetics and medical materials)

RN 173787-12-7 HCAPLUS

CN Phosphoric acid, monododecyl mono[9-(2-propenyloxy)nonyl] ester, calcium salt (9CI) (CA INDEX NAME)



● 1/2 Ca



IPCI C07F0009-09 [ICM,6]; C08G0077-395 [ICS,6]; C08L0083-08 [ICS,6];  
 C09K0003-00 [ICS,6]  
 IPCR C09K0003-00 [I,A]; C07F0009-09 [I,A]; C07F0019-00 [I,A]; C08G0077-38  
 [I,A]; C08G0077-395 [I,A]; C08L0083-04 [I,A]; C08L0083-08 [I,A]  
 CC 37-6 (Plastics Manufacture and Processing)  
 Section cross-reference(s): 38, 62, 63  
 IT 1873-88-7, 1,1,1,3,5,5,5-Heptamethyltrisiloxane 17066-04-5  
 173787-04-7 173787-06-9 173787-08-1 173787-12-7  
 173787-14-9  
 (manuf. of phosphate metal salt-modified organopolysiloxanes useful  
 for gelling agents of silicone oils and cosmetics and medical  
 materials)


L48 ANSWER 30 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1995:641004 HCAPLUS Full-text  
 DOCUMENT NUMBER: 123:199145  
 ORIGINAL REFERENCE NO.: 123:35573a,35576a  
 TITLE: Process for preparing phosphinyloxy propanaminium  
 inner salt derivatives  
 INVENTOR(S): Prashad, Mahavir; Kapa, Prasad K.  
 PATENT ASSIGNEE(S): Sandoz Ltd., Switz.  
 SOURCE: U.S., 20 pp. Continuation of Ser. No. US 93-73407,  
 filed on 7 Jun 1993, now abando  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 5412137	A	19950502	US 1994-197050	19940216
			<--	
PRIORITY APPLN. INFO.:			US 1993-73407	B1 19930607
			<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 123:199145  
 ED Entered STN: 28 Jun 1995  
 GI



AB The prepn. of the title compds. R1OP(:X1)(X-)OCH(CH2CO2H)CH2N+R2R3R4 where X and X1 are independently O or S; R1 is e.g., alkyl, substituted-alkyl; R2, R3, and R4 are each independently straight or branched chain (C1-4)alkyl, and pharmaceutically acceptable salts, physiol. hydrolyzable esters, and pro-drug

forms thereof, which are useful as hypoglycemic agents (test data given) are described. A representative prepd. compd. is  
(R)-3-carboxy-N,N,N-trimethyl-2-  
{[hydroxy(tetradecyloxy)phosphinyloxy]-1-propanaminium hydroxide inner salt.


IT 157244-58-1P

(prepn. of phosphinyloxy propanaminium inner salts as  
hypoglycemics)

RN 157244-58-1 HCAPLUS

CN 1-Butanaminium, 2-[[hydroxy(tetradecyloxy)phosphinyloxy]-N,N,N-trimethyl-4-oxo-4-(2-propenyloxy)-, inner salt, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



INCL 558146000

IPCI C07F0009-09 [ICM,6]; C07F0009-165 [ICS,6]

IPCR C07F0009-09 [I,A]; C07F0009-113 [I,A]; C07F0009-165 [I,A];  
C07F0009-173 [I,A]

NCL 558/146.000; 558/169.000; 558/170.000

CC 29-7 (Organometallic and Organometalloidal Compounds)

Section cross-reference(s): i

IT 157244-54-7P	157244-55-8P	157244-56-9P	157244-57-0P
<del>157244-58-1P</del>	157244-59-2P	157244-60-5P	157244-61-6P
157244-62-7P	157244-63-8P	157244-64-9P	157244-66-1P
157244-67-2P	157244-68-3P	157244-69-4P	157244-70-7P
157244-71-8P	157244-72-9P	157244-73-0P	157244-74-1P
157244-75-2P	157244-76-3P	157244-77-4P	157244-78-5P
157244-79-6P	157244-80-9P	157244-81-0P	157244-82-1P
157244-83-2P	157244-84-3P	157244-85-4P	157244-86-5P
157244-87-6P	157244-88-7P	157244-89-8P	157244-90-1P
157244-91-2P	157244-92-3P	157244-93-4P	157244-94-5P
157244-95-6P	157244-96-7P	157244-97-8P	157244-98-9P
157244-99-0P	157245-00-6P	157245-01-7P	157245-02-8P
157245-03-9P	157245-04-0P	157245-05-1P	157245-06-2P
157245-07-3P	157245-08-4P	157245-09-5P	157245-10-8P
157245-11-9P	157245-12-0P	157245-13-1P	157245-14-2P
157245-15-3P	157245-16-4P	157245-18-6P	157245-19-7P
157245-20-0P	157245-22-2P	157245-23-3P	157245-24-4P
157245-25-5P	157245-26-6P	157245-27-7P	157245-28-8P
157245-29-9P	157245-30-2P	157245-31-3P	157245-32-4P
157245-33-5P	157245-34-6P	157245-35-7P	157245-36-8P
157245-37-9P	157245-38-0P	157245-39-1P	157245-40-4P
157245-42-6P	157245-43-7P	157245-44-8P	157245-45-9P
157245-46-0P	157245-47-1P	157245-48-2P	157245-49-3P
157245-50-6P	157245-51-7P	157245-52-8P	157245-53-9P
157245-54-0P	157245-55-1P	157245-56-2P	157245-57-3P
157245-58-4P	157245-59-5P	157245-60-8P	157245-61-9P
157245-62-0P	157245-63-1P	157245-64-2P	167684-91-5P

167685-41-8P 167685-42-9P

(prepn. of phosphinyloxy propanaminium inner salts as hypoglycemics)

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L48 ANSWER 31 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1995:528833 HCAPLUS Full-text

DOCUMENT NUMBER: 123:33387

ORIGINAL REFERENCE NO.: 123:6183a,6186a

TITLE: Preparation of polymerizable phosphorylcholine derivatives with medical applications

INVENTOR(S): Suzuki, Hiroshi; Kadoma, Yoshihito; Nakabayashi, Norio; Ishihara, Kazuhiko

PATENT ASSIGNEE(S): Nippon Oils &amp; Fats Co Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO. -----	KIND ----	DATE -----	APPLICATION NO. -----	DATE -----
JP 07010892	A	19950113	JP 1993-150717	19930622
			<--	
JP 3419030	B2	20030623		
PRIORITY APPLN. INFO.:			JP 1993-150717	19930622
			<--	

OTHER SOURCE(S): MARPAT 123:33387

ED Entered STN: 06 May 1995

GI




AB The title derivs. II (R<sup>1</sup>-3 = H, C<sub>1</sub>-3 alkyl; R<sup>4</sup> = H, Me; A = linear or branched alkylene; m, n = 0, 1), useful as materials for medical appliances, e.g. catheters, artificial organs and blood vessels, contact lenses, cosmetics, water-absorbing materials, etc., are prepd. by treatment of R<sup>1</sup>R<sup>2</sup>R<sup>3</sup>N<sup>+</sup>(CH<sub>2</sub>)<sub>2</sub>OH Y<sup>-</sup> (Y<sup>-</sup> = anion) with X<sup>1</sup>X<sup>2</sup>P(O)O(A)<sub>m</sub>(O)<sub>n</sub>COCR<sup>4</sup>:CH<sub>2</sub> (I; X<sup>1</sup>-2 = halo) in the presence or absence of bases while removing hydrogen halides formed in the reaction followed by hydrolysis of the resulting products by treatment with H<sub>2</sub>O. This methods give the products without using toxic Me<sub>3</sub>N with offensive odor. CH<sub>2</sub>:CMeCO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH was treated with POCl<sub>3</sub> and Et<sub>3</sub>N in CH<sub>2</sub>Cl<sub>2</sub> at 0.degree. for 4 h to give 95% I (R<sup>4</sup> = Me, X<sup>1</sup> = X<sup>2</sup> = Cl, A = CH<sub>2</sub>CH<sub>2</sub>, m = n = 1). This was further treated with Me<sub>3</sub>N+CH<sub>2</sub>CH<sub>2</sub>OH Cl<sup>-</sup> and Et<sub>3</sub>N in CH<sub>2</sub>Cl<sub>2</sub> at 0.degree. for 2 h, and after removal of Et<sub>3</sub>N.HCl, treated with H<sub>2</sub>O at 0.degree. for 2 h to give 65% II (R<sup>1</sup> = R<sup>2</sup> = R<sup>3</sup> = R<sup>4</sup> = Me, A = CH<sub>2</sub>CH<sub>2</sub>, n = m = 1).

IT 163716-44-7P

(prepn. of (meth)acryloyloxyethyl trialkylammonioethyl phosphates as monomers for medical materials and appliances from (hydroxyethyl)trialkylammonium halides and (meth)acryloyloxyethyl dihalophosphates)

RN 163716-44-7 HCAPLUS

CN 3,5,8-Trioxa-4-phosphaundec-10-en-1-aminium, N,N,N-triethyl-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



IPCI C07F0009-09 [ICM,6]

IPCR C07F0009-09 [I,A]

CC 29-7 (Organometallic and Organometalloidal Compounds)

Section cross-reference(s): 63

IT 163716-43-6P 163716-44-7P

(prepn. of (meth)acryloyloxyethyl trialkylammonioethyl phosphates as monomers for medical materials and appliances from (hydroxyethyl)trialkylammonium halides and (meth)acryloyloxyethyl dihalophosphates)

L48 ANSWER 32 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1995:526804 HCAPLUS Full-text

DOCUMENT NUMBER: 122:291219

ORIGINAL REFERENCE NO.: 122:53107a,53110a

TITLE: Phosphonooxymethyl or methylthiomethyl ethers of taxane derivatives as antitumor agents.

INVENTOR(S): Golik, Jerzy; Kadow, John F.; Kaplan, Murray A.; Li, Wen-Sen; Perrone, Robert K.; Thottathil, John K.; Vyas, Dolatrai; Wittman, Mark D.; Wong, Henry; Wright, John J.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: Eur. Pat. Appl., 124 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 37

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 639577	A1	19950222	EP 1994-112803	19940816
			<--	
EP 639577	B1	20020515		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
IL 122990	A	20020523	IL 1993-122990	19931223
			<--	
IL 148029	A	20050517	IL 1993-148029	19931223
			<--	

10/596,747

CA 2129288	A1	19950218	CA 1994-2129288	19940802
			<--	
CA 2129288	C	20000516		
HU 67742	A2	19950428	HU 1994-2342	19940812
			<--	
JP 07149779	A	19950613	JP 1994-250219	19940812
			<--	
JP 3062986	B2	20000712		
FI 9403749	A	19950218	FI 1994-3749	19940815
			<--	
FI 113271	B1	20040331		
NO 9403002	A	19950220	NO 1994-3002	19940815
			<--	
NO 309093	B1	20001211		
AU 9470267	A	19950302	AU 1994-70267	19940815
			<--	
AU 694941	B2	19980806		
CN 1111637	A	19951115	CN 1994-109468	19940815
			<--	
CN 1051315	C	20000412		
RU 2128661	C1	19990410	RU 1994-29662	19940815
			<--	
ZA 9406180	A	19950216	ZA 1994-6180	19940816
			<--	
PL 179636	B1	20001031	PL 1994-304649	19940816
			<--	
AT 217629	T	20020615	AT 1994-112803	19940816
			<--	
PT 639577	E	20021031	PT 1994-112803	19940816
			<--	
ES 2176212	T3	20021201	ES 1994-112803	19940816
			<--	
US 5646176	A	19970708	US 1995-445360	19950519
			<--	
US 6066747	A	20000523	US 1995-522307	19951030
			<--	
US 20010023255	A1	20010920	US 1997-870794	19970606
			<--	
US 6455575	B2	20020924		
AU 9891356	A	19990114	AU 1998-91356	19981106
			<--	
AU 706511	B2	19990617		
CN 1237580	A	19991208	CN 1999-105343	19990429
			<--	
CN 1100771	C	20030205		
US 20030027855	A1	20030206	US 2002-208418	20020730
			<--	
US 6710191	B2	20040323		
PRIORITY APPLN. INFO.:			US 1993-108015	A 19930817
			<--	
			US 1993-154840	A 19931124
			<--	
			US 1994-245119	A 19940517
			<--	
			US 1992-996455	B2 19921224
			<--	

IL 1993-108161	A3 19931223
<--	
IL 1993-122990	A3 19931223
<--	
WO 1994-US2382	W 19940304
<--	
AU 1994-70267	A3 19940815
<--	
US 1995-427502	B1 19950424
<--	
US 2000-566970	A1 20000509
<--	

OTHER SOURCE(S): MARPAT 122:291219

ED Entered STN: 05 May 1995

AB Taxane derivs. T-[OCH<sub>2</sub>(OCH<sub>2</sub>)<sub>m</sub>OP(O)(OH)<sub>2</sub>]<sub>n</sub> [T = taxane substituted at C-13 by 3-amino-2-hydroxypropanoyloxy; m = 0-6; n = 1-3] were prepd. from paclitaxel or baccatin III via T'-[OCH<sub>2</sub>(OCH<sub>2</sub>)<sub>m</sub>SMethyl]<sub>n</sub> [T' = protected T] for use as antitumor agents. Thus, paclitaxel was converted to its 7-O-methylthiomethyl deriv., treated with dibenzyl phosphate, followed by hydrogenolysis to give 7-O-phosphonooxymethylpaclitaxel. This compd. had an IC<sub>50</sub> against HCT-116 human carcinoma of 0.0158 .mu.M. Some of the methylthiomethyl derivs. also have antitumor activity.


IT 1242672-84-9

(Phosphonooxymethyl or methylthiomethyl ethers of taxane derivatives as antitumor agents.)

RN 1242672-84-9 HCAPLUS

CN 2-Furanpropanoic acid, .beta.-[[ (1,1-dimethylethoxy)carbonyl]amino]-.alpha.-[[ (2-propen-1-yloxy)carbonyl]oxy]-, (2aR,4S,4aS,6R,9S,11S,12R,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-4-[[ (phosphonooxy)methoxy]methoxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.R)- (CA INDEX NAME)

Absolute stereochemistry.



IPCI C07F0009-655 [ICM,6]; A61K0031-66 [ICS,6]; A61K0031-335 [ICS,6];  
 C07D0305-14 [ICS,6]; C07D0407-12 [ICS,6]; C07F0009-6558 [ICS,6]  
 IPCR A61K0031-665 [I,A]; A61K0031-00 [I,A]; A61K0031-335 [I,A]; A61P0035-00  
 [I,A]; C07C0323-13 [I,A]; C07D [I,S]; C07D0305-14 [I,A]; C07D0407-12  
 [I,A]; C07D0409-12 [I,A]; C07F0007-18 [I,A]; C07F0009-09 [I,A];

C07F0009-655 [I,A]; C07F0009-6558 [I,A]; H01L0021-48 [I,A]

CC 30-20 (Terpenes and Terpenoids)

Section cross-reference(s): i

IT

1242672-58-7	1242672-59-8	1242672-60-1	1242672-61-2
1242672-62-3	1242672-63-4	1242672-64-5	1242672-65-6
1242672-66-7	1242672-67-8	1242672-68-9	1242672-69-0
1242672-70-3	1242672-71-4	1242672-72-5	1242672-73-6
1242672-74-7	1242672-75-8	1242672-76-9	1242672-77-0
1242672-78-1	1242672-79-2	1242672-81-6	1242672-82-7
1242672-83-8	<del>1242672-84-9</del>	1242672-85-0	1242672-86-1
1242672-87-2	1242672-88-3	1242672-89-4	1242672-90-7
1242672-91-8	1242672-92-9	1242672-93-0	1242672-94-1
1242672-95-2	1242672-96-3	1242672-97-4	1242672-98-5
1242672-99-6	1242673-00-2	1242673-01-3	1242673-02-4
1242673-03-5	1242673-04-6	1242673-05-7	1242673-06-8
1242673-07-9	1242673-08-0	1242673-09-1	1242673-10-4
1242673-11-5	1242673-12-6	1242673-13-7	1242673-14-8
1242673-15-9	1242673-20-6	1242673-28-4	1242673-30-8
1242673-31-9	1242673-32-0	1242673-33-1	1242673-34-2
1242673-35-3	1242673-36-4	1242673-37-5	1242673-38-6
1242673-39-7	1242673-40-0	1242673-41-1	1242673-42-2
1242673-43-3	1242673-44-4	1242673-47-7	1242673-48-8
1242673-49-9	1242673-50-2	1242673-51-3	1242673-52-4
1242673-53-5	1242673-54-6	1242673-56-8	1242673-57-9
1242673-58-0	1242673-59-1	1242673-60-4	1242673-61-5
1242673-62-6	1242673-63-7	1242673-64-8	1242673-65-9
1242673-66-0	1242673-67-1	1242673-68-2	1242673-69-3
1242673-70-6	1242673-71-7	1242673-72-8	1242673-73-9
1242673-74-0	1242673-75-1	1242673-77-3	1242673-78-4
1242673-79-5	1242673-80-8	1242673-81-9	1242673-82-0
1242673-83-1	1242673-84-2	1242673-87-5	1242673-88-6
1242673-89-7	1242673-90-0	1242673-91-1	1242673-92-2
1242674-07-2	1242674-08-3	1242674-09-4	1242674-10-7
1242674-11-8	1242674-12-9	1242674-13-0	1242674-14-1
1242674-15-2	1242674-17-4	1242674-23-2	1242674-24-3
1242674-25-4	1242674-26-5	1242674-27-6	1242674-28-7
1242674-29-8	1242674-30-1	1242674-31-2	1242674-32-3
1242674-33-4	1242674-34-5	1242674-35-6	1242674-36-7
1242674-37-8	1242674-40-3	1242674-41-4	1242674-42-5
1242674-43-6	1242674-44-7	1242674-45-8	1242674-46-9
1242674-47-0	1242674-50-5	1242674-51-6	1242674-56-1
1242674-57-2	1242674-58-3	1242674-59-4	1242674-71-0
1242674-72-1	1242674-73-2	1242674-74-3	1242674-75-4
1242674-76-5	1242674-77-6	1242674-78-7	1242674-79-8
1242674-80-1	1242674-81-2	1242674-82-3	1242674-83-4
1242674-84-5	1242674-85-6	1242675-16-6	1242675-17-7
1242675-18-8	1242675-19-9	1242675-20-2	1242675-21-3
1242675-22-4	1242675-23-5	1242675-24-6	1242675-25-7
1242675-26-8	1242675-27-9	1242675-28-0	1242675-29-1
1242675-30-4	1242675-31-5	1242675-32-6	1242675-33-7
1242675-34-8	1242675-35-9	1242675-36-0	1242675-37-1
1242675-38-2	1242675-39-3	1242675-40-6	1242675-41-7
1242675-42-8	1242675-43-9	1242675-44-0	1242675-45-1
1242675-46-2	1242675-47-3	1242675-48-4	1242675-49-5
1242675-50-8	1242675-51-9	1242675-52-0	1242675-53-1
1242675-54-2	1242675-55-3	1242675-56-4	1242675-57-5

1242675-58-6	1242675-59-7	1242675-60-0	1242675-61-1
1242675-62-2	1242675-63-3	1242675-64-4	1242675-65-5
<del>1242675-67-7</del>	1242675-79-1	1242675-80-4	1242675-81-5
1242675-82-6	1242675-84-8	1242675-85-9	1242675-86-0
1242675-87-1	1242675-90-6	1242676-00-1	1242676-02-3
1242676-03-4	1242676-04-5	1242676-05-6	1242676-06-7
1242676-07-8	1242676-08-9	<del>1242676-09-0</del>	

(Phosphonooxymethyl or methylthiomethyl ethers of taxane derivatives as antitumor agents.)

IT	<del>1242676-10-3</del>	1242676-12-5	1242676-24-9	1242676-25-0
	1242676-26-1	1242676-27-2	1242676-28-3	1242676-29-4
	1242676-30-7	1242676-31-8	1242676-32-9	1242676-33-0
	1242676-34-1	1242676-35-2	1242676-36-3	1242676-37-4
	1242676-38-5	1242676-39-6	1242676-40-9	1242676-41-0
	1242676-42-1	1242676-43-2	1242676-44-3	1242676-45-4
	1242676-46-5	1242676-47-6	1242676-48-7	<del>1242676-49-8</del>
	1242676-50-1	1242676-51-2	1242676-52-3	1242676-53-4
	1242676-54-5	1242676-55-6	1242676-56-7	1242676-57-8
	1242676-59-0	1242676-65-8	1242676-71-6	1242676-72-7
	1242676-73-8	1242676-74-9	<del>1242676-75-0</del>	1242676-76-1
	1242676-78-3	1242676-79-4	1242676-80-7	1242676-81-8
	1242676-82-9	1242676-83-0	1242676-88-5	1242676-95-4
	1242677-03-7	1242677-04-8	1242677-05-9	1242677-06-0
	1242677-07-1	1242677-08-2	1242677-09-3	1242677-10-6
	1242677-12-8	1242677-24-2	1242677-34-4	1242677-47-9
	1242677-59-3	1242677-70-8	1242677-79-7	1242677-88-8
	1242677-98-0	1242678-09-6	1242679-22-6	1242679-49-7
	1242679-60-2	1242679-71-5	1242679-82-8	1242679-94-2
	<del>1242680-05-2</del>	1242680-31-4	1242680-42-7	1242680-55-2
	1242680-66-5	1242680-79-0	1242680-89-2	1242680-99-4
	1242681-09-9	1242681-20-4	1242681-29-3	1242681-38-4
	1242681-48-6	1242681-60-2	1242681-74-8	1242682-00-3
	1242682-10-5	1242682-19-4	1242682-28-5	1242682-37-6
	<del>1242682-53-6</del>	1242682-65-0	1242682-70-7	1242682-78-5
	1242682-85-4	1242682-92-3	1242682-98-9	1242683-05-1
	1242683-19-7	1242683-25-5	1242683-40-4	1242683-55-1
	1242683-67-5	<del>1242683-77-7</del>	1242684-10-1	1242684-29-2
	1242684-57-6	1242684-84-9	1242684-96-3	1242685-09-1
	1242685-30-8	1242685-48-8	1242685-97-7	1242686-13-0
	1242686-15-2	1242686-26-5	1242686-28-7	1242686-30-1
	1242686-31-2	1242686-32-3	1242686-33-4	1242686-34-5
	1242686-35-6	1242686-36-7	1242686-37-8	1242686-38-9
	1242686-39-0	1242686-40-3	1242686-41-4	1242686-42-5
	1242686-43-6	1242686-44-7	1242686-45-8	1242686-46-9
	1242686-47-0	1242686-48-1	1242686-49-2	1242686-50-5
	1242686-51-6	1242686-54-9	1242686-55-0	1242686-56-1
	1242686-57-2	1242686-58-3	1242686-59-4	1242686-60-7
	1242686-61-8	1242686-62-9	1242686-63-0	1242686-64-1
	1242686-65-2	1242686-66-3	1242686-67-4	1242686-68-5
	1242686-69-6	1242686-70-9	1242686-71-0	1242686-72-1
	1242686-73-2	1242686-74-3	1242686-75-4	1242686-76-5
	1242686-77-6	1242686-79-8	1242686-80-1	1242686-81-2
	1242686-83-4	1242686-85-6	1242686-86-7	1242686-87-8
	1242686-88-9	1242686-89-0	1242686-90-3	1242686-91-4
	1242686-92-5	1242686-93-6	1242686-94-7	1242686-96-9

(Phosphonooxymethyl or methylthiomethyl ethers of taxane derivatives as antitumor agents.)



derivatives as antitumor agents.)

OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS  
RECORD (26 CITINGS)

L48 ANSWER 33 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN  
ACCESSION NUMBER: 1995:297487 HCAPLUS Full-text  
DOCUMENT NUMBER: 122:81691  
ORIGINAL REFERENCE NO.: 122:15531a,15534a  
TITLE: Preparation of phosphonooxymethyl taxane ethers as  
neoplasm inhibitors  
INVENTOR(S): Golik, Jerzy; Vyas, Dolatrai; Wrigth, John J. Kim;  
Wong, Henry; Kadow, John F.; Thotathil, John K.;  
Li, Wen-Sen; Kaplan, Murray A.; Perrone, Robert K.  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA  
SOURCE: Eur. Pat. Appl., 96 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 37  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 604910	A1	19940706	EP 1993-120801	19931223
			<--	
EP 604910	B1	20000614		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
IL 129059	A	20010724	IL 1993-129059	19930722
			<--	
ZA 9309290	A	19940610	ZA 1993-9290	19931210
			<--	
CA 2111527	A1	19940625	CA 1993-2111527	19931215
			<--	
CA 2111527	C	20000718		
NO 9304614	A	19940627	NO 1993-4614	19931215
			<--	
NO 310238	B1	20010611		
AU 9352609	A	19940707	AU 1993-52609	19931221
			<--	
AU 660570	B2	19950629		
CZ 289871	B6	20020417	CZ 1993-2855	19931221
			<--	
IL 108111	A	20020912	IL 1993-108111	19931221
			<--	
PL 175014	B1	19981030	PL 1993-301610	19931222
			<--	
FI 9305821	A	19940625	FI 1993-5821	19931223
			<--	
FI 111724	B1	20030915		
HU 65547	A2	19940628	HU 1993-3739	19931223
			<--	
RU 2136673	C1	19990910	RU 1993-56641	19931223
			<--	
AT 193891	T	20000615	AT 1993-120801	19931223
			<--	

10/596,747

PT 604910	E	20000929	PT 1993-120801	19931223
			<--	
ES 2147739	T3	20001001	ES 1993-120801	19931223
			<--	
IL 122990	A	20020523	IL 1993-122990	19931223
			<--	
IL 148029	A	20050517	IL 1993-148029	19931223
			<--	
CN 1093369	A	19941012	CN 1993-121100	19931224
			<--	
CN 1037774	C	19980318		
JP 07002885	A	19950106	JP 1993-354778	19931224
			<--	
JP 3189140	B2	20010716		
TW 410228	B	20001101	TW 1993-110985	19931224
			<--	
ZA 9406180	A	19950216	ZA 1994-6180	19940816
			<--	
US 6066747	A	20000523	US 1995-522307	19951030
			<--	
US 20010023255	A1	20010920	US 1997-870794	19970606
			<--	
US 6455575	B2	20020924		
CN 1174838	A	19980304	CN 1997-114773	19970730
			<--	
CN 1184219	C	20050112		
AU 9891356	A	19990114	AU 1998-91356	19981106
			<--	
AU 706511	B2	19990617		
GR 3034312	T3	20001229	GR 2000-401999	20000831
			<--	
US 20030027855	A1	20030206	US 2002-208418	20020730
			<--	
US 6710191	B2	20040323		
PRIORITY APPLN. INFO.:			US 1992-996455	A 19921224
			<--	
			US 1993-108015	A 19930817
			<--	
			US 1993-154840	A 19931124
			<--	
			US 1992-955008	A 19921001
			<--	
			US 1992-981151	A 19921124
			<--	
			US 1992-995443	A 19921223
			<--	
			US 1993-80704	A 19930628
			<--	
			IL 1993-106453	A3 19930722
			<--	
			IL 1993-108161	A3 19931223
			<--	
			IL 1993-122990	A3 19931223
			<--	
			WO 1994-US2382	W 19940304
			<--	

10/596,747


US 1994-245119	B3 19940517
<--	
AU 1994-70267	A3 19940815
<--	
US 1995-427502	B1 19950424
<--	
US 2000-566970	A1 20000509
<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 122:81691

ED Entered STN: 18 Jan 1995

GI



AB T[OCH<sub>2</sub>(OCH<sub>2</sub>)<sub>m</sub>OP(O)(OH)<sub>2</sub>]<sub>n</sub> [T = a taxane moiety bearing on the C-13 C atom a substituted 3-amino-2-hydroxypropanoyloxy group (sic); m = 0-6; n = 1-3] were prepd. Thus, paclitaxel was converted in 5 steps to 7-O-phosphonooxymethylpaclitaxel triethanolamine salt which gave survival of M109 lung carcinoma-implanted mice 160% that of controls at 24mg/kg i.v. on days 5,6,7,8, and 9 post tumor implant.


IT 1242690-20-5

(Preparation of phosphonooxymethyl taxane ethers as neoplasm inhibitors)

RN 1242690-20-5 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



IPCI C07F0009-655 [ICM,5]; A61K0031-675 [ICS,5]; C07F0009-6558 [ICS,5];  
 C07D0305-14 [ICS,5]; C07D0407-12 [ICS,5]; C07F0007-18 [ICS,5]  
 IPCR A61K0031-665 [I,A]; A61P0035-00 [I,A]; C07D0305-14 [I,A]; C07D0407-12  
 [I,A]; C07D0409-12 [I,A]; C07F0007-18 [I,A]; C07F0009-655 [I,A];  
 C07F0009-6558 [I,A]; H01L0021-48 [I,A]  
 CC 30-20 (Terpenes and Terpenoids)  
 Section cross-reference(s): 1.  
 IT 162785-24-2 162785-27-5 162785-30-0 ~~1242690-20-5~~  
 1242690-45-4 1242690-61-4 1242690-72-7 1242690-82-9  
 1242690-94-3 1242691-04-8 1242691-16-2 1242691-26-4  
 1242691-46-8 1242691-57-1 1242691-68-4 1242701-04-7  
 1242701-06-9 1242701-08-1 1242701-26-3 1242701-46-7  
 1242701-64-9 1242701-76-3 1242701-88-7 1242702-06-2  
 1242702-20-0 1242702-21-1 1242702-22-2 1242702-23-3  
 1242702-24-4 1242702-25-5 1242702-26-6 1242702-27-7  
 1242702-28-8 1242702-29-9 1242702-30-2 1242702-31-3  
 1242702-32-4 1242702-33-5 1242702-34-6 1242702-35-7  
 1242702-36-8 1242702-37-9 1242702-38-0 1242702-39-1  
 1242702-40-4 1242702-41-5 1242702-42-6 1242702-43-7  
 1242702-44-8 1242702-45-9 1242702-46-0 1242702-47-1  
 1242702-48-2 1242702-49-3 1242702-50-6 1242702-54-0  
 1242702-55-1 1242702-56-2 1242702-57-3 1242702-58-4  
 1242702-59-5 1242702-60-8 1242702-61-9 1242702-62-0  
 1242702-63-1 1242702-64-2 1242702-65-3 1242702-66-4  
 1242702-67-5 1242702-68-6 1242702-69-7 1242702-70-0  
 1242702-71-1 1242702-72-2 1242702-74-4 1242702-83-5  
 1242702-93-7 1242703-03-2 1242703-26-9 1242703-42-9  
 1242703-52-1 1242703-62-3 1242703-72-5 1242703-82-7  
 1242703-92-9 1242704-11-5 1242704-21-7 1242704-34-2  
 1242704-54-6 1242704-68-2 1242704-88-6 1242705-03-8  
 1242705-14-1 1242705-25-4 1242705-36-7 1242705-53-8  
 1242705-73-2 1242705-83-4 1242705-93-6 1242706-03-1  
 1242706-13-3 1242706-23-5 1242706-38-2 1242706-48-4  
 1242706-60-0 ~~1242706-84-8~~ 1242706-94-0 1242707-04-5  
 1242707-13-6 1242707-22-7 1242707-32-9 1242707-40-9  
 1242707-58-9 1242707-67-0 1242707-86-3 1242707-95-4  
 1242708-05-9 1242708-14-0 1242708-24-2 1242708-39-9  
~~1242708-58-2~~ 1242708-68-4 1242708-82-2 1242708-95-7  
 1242709-09-6 1242709-19-8 1242709-28-9 1242709-38-1  
 1242709-48-3 1242709-59-6 1242709-68-7 1242709-81-4  
 1242710-01-5 1242710-13-9 1242710-24-2 1242710-34-4  
 1242710-44-6 1242710-54-8 1242710-64-0 1242710-73-1  
 1242710-82-2 1242711-02-9 1242711-68-7 1242711-88-1  
 1242711-98-3 1242712-02-2 1242712-03-3 1242712-04-4  
~~1242712-05-5~~ 1242712-06-6 1242712-07-7 1242712-08-8  
 1242712-09-9 1242712-10-2 1242712-11-3 1242712-12-4  
 1242712-13-5 1242712-14-6 1242712-15-7 1242712-16-8  
 1242712-17-9 1242712-18-0 1242712-19-1 1242712-20-4  
 1242712-21-5 1242712-22-6 1242712-23-7 1242712-24-8  
 1242712-25-9 1242712-26-0 1242712-27-1 1242712-31-7  
~~1242712-32-8~~ 1242712-33-9 1242712-34-0 1242712-35-1  
 1242712-36-2 1242712-37-3 1242712-38-4 1242712-39-5  
 1242712-40-8 1242712-41-9 1242712-42-0 1242712-43-1

1242712-44-2	1242712-45-3	1242712-46-4	1242712-47-5
1242712-48-6	1242712-49-7	1242712-50-0	1242712-51-1
1242712-52-2	1242712-53-3	1242712-54-4	1242712-55-5
1242712-58-8	1242712-59-9	1242712-60-2	1242712-61-3
1242712-62-4	1242712-63-5	1242712-64-6	1242712-65-7
1242712-66-8	1242712-67-9	1242712-68-0	1242712-69-1
1242712-70-4	1242712-71-5	<del>1242712-72-6</del>	1242712-73-7
1242712-74-8	1242712-75-9	1242712-76-0	1242712-77-1
1242712-78-2	1242712-79-3	1242712-80-6	1242712-81-7
1242712-82-8	1242712-83-9	1242712-86-2	1242712-87-3
1242712-88-4	1242712-89-5	1242712-90-8	1242712-91-9
1242712-92-0	1242712-94-2	1242713-08-1	1242713-30-9
1242713-41-2	1242713-53-6	1242713-61-6	1242713-69-4
1242713-84-3	1242713-93-4	1242714-01-7	

(Preparation of phosphonooxymethyl taxane ethers as neoplasm inhibitors)

IT	1242714-11-9	1242714-20-0	1242714-30-2	1242714-43-7
	1242714-67-5	1242714-80-2	1242714-90-4	1242714-99-3
	1242715-07-6	1242715-18-9	1242715-27-0	1242715-37-2
	1242715-47-4	1242715-58-7	1242715-67-8	1242715-80-5
	1242715-90-7	1242716-10-4	1242716-21-7	1242716-32-0
	1242716-43-3	1242716-53-5	1242716-64-8	1242716-84-2
	1242716-93-3	1242717-04-9	1242717-13-0	<del>1242717-32-3</del>
	1242717-45-8	1242717-59-4	1242717-68-5	1242717-91-4
	1242718-25-7	1242718-35-9	1242718-47-3	1242718-57-5
	1242718-67-7	1242718-79-1	1242718-97-3	1242719-08-9
	1242719-19-2	1242719-30-7	1242719-40-9	1242719-50-1
	1242719-60-3	1242719-72-7	1242719-83-0	1242719-96-5
	1242720-07-5	1242720-25-7	1242720-62-2	1242720-73-5
	1242720-97-3	1242721-08-9	1242721-19-2	1242721-30-7
	1242721-40-9	1242721-52-3	1242721-63-6	1242721-73-8
	1242721-84-1	1242721-92-1	1242722-05-9	1242722-16-2
	1242722-33-3	1242722-45-7	1242722-51-5	1242722-52-6
	1242722-53-7	1242722-54-8	1242722-55-9	1242722-56-0
	1242722-57-1	1242722-58-2	1242722-59-3	1242722-60-6
	1242722-61-7	1242722-62-8	1242722-63-9	1242722-64-0
	1242722-65-1	1242722-66-2	1242722-67-3	1242722-68-4
	1242722-69-5	1242722-70-8	1242722-71-9	1242722-72-0
	1242722-73-1	1242722-74-2	1242722-75-3	<del>1242722-76-4</del>
	1242722-77-5	1242722-78-6	1242722-79-7	1242722-80-0
	1242722-81-1	1242722-82-2	1242722-83-3	1242722-84-4
	1242722-85-5	1242722-86-6	1242722-87-7	1242722-88-8
	1242722-89-9	1242722-90-2	1242722-91-3	1242722-92-4
	1242722-93-5	1242722-94-6	1242722-95-7	1242722-97-9
	1242723-07-4	1242723-09-6	1242723-10-9	1242723-11-0
	1242723-12-1	1242723-13-2	1242723-14-3	1242723-15-4
	1242723-16-5	1242723-18-7	1242723-19-8	1242723-20-1
	1242723-22-3	<del>1242723-25-6</del>	1242723-26-7	1242723-27-8
	1242723-28-9	1242723-29-0	1242723-30-3	1242723-39-2
	1242723-44-9	1242723-45-0	1242723-46-1	1242723-47-2
	1242723-48-3	1242723-49-4	1242723-50-7	1242723-51-8
	1242723-52-9	1242723-53-0	1242723-54-1	1242723-55-2
	1242723-58-5	1242723-70-1	1242723-87-0	1242723-99-4
	1242724-10-2	1242724-20-4	1242726-65-3	

(Preparation of phosphonooxymethyl taxane ethers as neoplasm inhibitors)

OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS  
RECORD (11 CITINGS)


L48 ANSWER 34 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 1994:534463 HCAPLUS Full-text  
 DOCUMENT NUMBER: 121:134463  
 ORIGINAL REFERENCE NO.: 121:24325a,24328a  
 TITLE: Phosphinyloxy propanaminium inner salt derivatives  
 with hypoglycemic activity  
 INVENTOR(S): Anderson, Robert Charles; Bebernitz, Gregory R.;  
 Fraser, James D.; Hughes, Jeffrey W.; Kapa, Prasad  
 K.; Prashad, Mahavir; Smith, Howard C.; Willhauer,  
 Edwin B.  
 PATENT ASSIGNEE(S): Sandoz Ltd., Switz.; Sandoz-Patent-G.m.b.H.;  
 Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H.  
 SOURCE: Eur. Pat. Appl., 26 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO. -----	KIND ----	DATE -----	APPLICATION NO. -----	DATE -----
EP 574355	A1	19931215	EP 1993-810406	19930607
			<--	
EP 574355	B1	19970813		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
HU 65327	A2	19940502	HU 1993-1587	19930528
			<--	
AT 156828	T	19970815	AT 1993-810406	19930607
			<--	
ES 2105194	T3	19971016	ES 1993-810406	19930607
			<--	
NO 9302096	A	19931213	NO 1993-2096	19930609
			<--	
AU 9340115	A	19931216	AU 1993-40115	19930609
			<--	
AU 667537	B2	19960328		
IL 105965	A	19970318	IL 1993-105965	19930609
			<--	
CA 2098133	A1	19931212	CA 1993-2098133	19930610
			<--	
JP 06073077	A	19940315	JP 1993-163868	19930610
			<--	
CN 1086217	A	19940504	CN 1993-108729	19930610
			<--	
CN 1039326	C	19980729		
ZA 9304157	A	19940905	ZA 1993-4157	19930611
			<--	
US 5516767	A	19960514	US 1995-373802	19950117
			<--	
PRIORITY APPLN. INFO.:			US 1992-897210	A 19920611
			<--	
			US 1993-72804	B1 19930607
			<--	

OTHER SOURCE(S): CASREACT 121:134463; MARPAT 121:134463

ED Entered STN: 17 Sep 1994

GI



AB Title compds. ROP(:X1) (X-)OCH(CH<sub>2</sub>CO<sub>2</sub>H)CH<sub>2</sub>N+R<sub>1</sub>R<sub>2</sub>R<sub>3</sub> (X, X<sub>1</sub> = O, S; R = organyl e.g., tetradecyl; R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> = C1-4-alkyl) were prepd. in free acid form or in salt, physiolo. hydrolyzable ester or pro-drug form. They can be prepd. by various procedures, e.g. coupling accompanied by oxidn. or thiolation and hydrolysis or thiolysis, or by redn. to amino of a nitro substituent on an arom. ring. They possess hypoglycemic activity and are thus indicated for use in the treatment of diabetes.


IT 157244-58-1

(prepn. as hypoglycemics)

RN 157244-58-1 HCAPLUS

CN 1-Butanaminium, 2-[[hydroxy(tetradecyloxy)phosphinyl]oxy]-N,N,N-trimethyl-4-oxo-4-(2-propenyloxy)-, inner salt, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IPCI C07F0009-09 [ICM,5]; A61K0031-66 [ICS,5]; C07F0009-165 [ICS,5];  
C07F0009-113 [ICS,5]

IPCR A61K0031-66 [I,A]; A61P0003-08 [I,A]; A61P0003-10 [I,A]; C07C0211-63  
[I,A]; C07F0009-06 [I,A]; C07F0009-09 [I,A]; C07F0009-113 [I,A];  
C07F0009-165 [I,A]

CC 29-7 (Organometallic and Organometalloidal Compounds)

Section cross-reference(s): i

IT	157244-53-6	157244-54-7	157244-55-8	157244-56-9	157244-57-0
	<del>157244-58-1</del>	157244-59-2	157244-60-5	157244-61-6	
	157244-62-7	157244-63-8	157244-64-9	157244-65-0	157244-66-1
	157244-67-2	157244-68-3	157244-69-4	157244-70-7	157244-71-8
	157244-72-9	157244-73-0	157244-74-1	157244-75-2	157244-76-3
	157244-77-4	157244-78-5	157244-79-6	157244-80-9	157244-81-0
	157244-82-1	157244-83-2	157244-84-3	157244-85-4	157244-86-5
	157244-87-6	157244-88-7	157244-89-8	157244-90-1	157244-91-2
	157244-92-3	157244-93-4	157244-94-5	157244-95-6	157244-96-7

157244-97-8	157244-98-9	157244-99-0	157245-00-6	157245-01-7
157245-02-8	157245-03-9	157245-04-0	157245-05-1	157245-06-2
157245-07-3	157245-08-4	157245-09-5	157245-10-8	157245-11-9
157245-12-0	157245-13-1	157245-14-2	157245-15-3	157245-16-4
157245-17-5	157245-18-6	157245-19-7	157245-20-0	157245-21-1
157245-22-2	157245-23-3	157245-24-4	157245-25-5	157245-26-6
157245-27-7	157245-28-8	157245-29-9	157245-30-2	157245-31-3
157245-32-4	157245-33-5	157245-34-6	157245-35-7	157245-36-8
157245-37-9	157245-38-0	157245-39-1	157245-40-4	157245-41-5
157245-42-6	157245-43-7	157245-44-8	157245-45-9	157245-46-0
157245-47-1	157245-48-2	157245-49-3	157245-50-6	157245-51-7
157245-52-8	157245-53-9	157245-54-0	157245-55-1	157245-56-2
157245-57-3				

(prepn. as hypoglycemics)

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS  
RECORD (5 CITINGS)

L48 ANSWER 35 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1994:517786 HCAPLUS Full-text

DOCUMENT NUMBER: 121:117786

ORIGINAL REFERENCE NO.: 121:21093a,21096a

TITLE: Diester monomer, its polymer, water-containing  
soft contact lens, and processing solution for  
contact lens

INVENTOR(S): Koinuma, Yasumi; Matsumoto, Takeo; Nakada,  
Nobuharu; Nakabayashi, Nobuo; Ishihara, Kazuhiko

PATENT ASSIGNEE(S): NOF Corp., Japan

SOURCE: Eur. Pat. Appl., 26 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 580435	A1	19940126	EP 1993-305795	19930722
			<--	
EP 580435	B1	19980916		
R: BE, CH, DE, FR, GB, IT, LI, NL				
JP 06041156	A	19940215	JP 1992-197235	19920723
			<--	
JP 3240695	B2	20011217		
JP 06041157	A	19940215	JP 1992-197238	19920723
			<--	
JP 3240696	B2	20011217		
JP 06043407	A	19940218	JP 1992-197236	19920723
			<--	
JP 3206117	B2	20010904		
JP 06043408	A	19940218	JP 1992-197237	19920723
			<--	
JP 3206118	B2	20010904		
JP 06043400	A	19940218	JP 1992-198633	19920724
			<--	
JP 3227810	B2	20011112		
JP 06043401	A	19940218	JP 1992-198634	19920724



<--

JP 3227811	B2	20011112		
US 5466853	A	19951114	US 1993-94293	19930719
			<--	
PRIORITY APPLN. INFO.:			JP 1992-197235	A 19920723
			<--	
			JP 1992-197236	A 19920723
			<--	
			JP 1992-197237	A 19920723
			<--	
			JP 1992-197238	A 19920723
			<--	
			JP 1992-198633	A 19920724
			<--	
			JP 1992-198634	A 19920724
			<--	

## ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 121:117786

ED Entered STN: 03 Sep 1994

AB A diester monomer is represented by the formula  $\text{HR}_1\text{C:CR}_3(\text{CH}_2)_m\text{R}_2$  (I), wherein  $\text{R}_1$ ,  $\text{R}_2$ , and  $\text{R}_3$  represent a halogen atom, an alkoxy, an alkenyloxy, a hydroxyalkyloxycarbonyl, or a phosphorylcholine deriv. group. A polymer and a water-contg. contact lens are obtained by polymg. a starting component material including the above-mentioned diester monomer of the formula I. A contact lens processing soln. includes the polymer and a solvent for dissolving the polymer. The polymers provide a soft contact lens with an improved water content and O permeability. For example, .alpha.-isopropyl-.beta.-[(2'-trimethylammonio)ethyl Et phosphate]itaconate-allyl methacrylate copolymer was prepd. and showed a higher water content and O permeation coeff., compared to those of 2-hydroxyethyl methacrylate-ethylene glycol dimethacrylate copolymer.

IT 156526-61-3P

(prepn. of, for manuf. of soft contact lenses)

RN 156526-61-3 HCAPLUS


CN 3,5,10,15-Tetraoxa-4-phosphaoctadeca-12,17-dien-1-aminium, 4-hydroxy-N,N,N-trimethyl-11,14-dioxo-, inner salt, 4-oxide, (E)-, polymer with 1,2-ethanediyl bis(2-methyl-2-propenoate) and 2-hydroxyethyl 2-propenoate (9CI) (CA INDEX NAME)

CM 1

CRN 156526-60-2


CMF C16 H28 N O8 P

Double bond geometry as shown.




CM 2

CRN 818-61-1  
CMF C5 H8 O3



CM 3

CRN 97-90-5  
CMF C10 H14 O4



IPCI C07F0009-10 [ICM,5]; C08F0030-02 [ICS,5]; G02C0007-04 [ICS,5]

IPCR C07F0009-09 [I,A]; C08F0030-02 [I,A]; G02B0001-04 [I,A]

CC 63-7 (Pharmaceuticals)

Section cross-reference(s): 35

IT	156526-57-7P	156526-59-9P	<del>156526-61-3P</del>	156526-68-0P
	156549-95-0P	156549-97-2P	156608-05-8P	156608-07-0P
	156608-08-1P	156608-09-2P	156608-11-6P	156608-12-7P
	156608-13-8P	156608-14-9P	156608-15-0P	156608-16-1P
	156608-17-2P	156608-18-3P	156608-19-4P	156608-20-7P
	156608-21-8P	156608-22-9P	156608-24-1P	156608-26-3P
	156608-27-4P	156646-89-8P	156646-90-1P	156646-91-2P
	156646-93-4P	156978-35-7P		

(prepn. of, for manuf. of soft contact lenses)

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS  
RECORD (6 CITINGS)

L48 ANSWER 36 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1994:77596 HCAPLUS Full-text

DOCUMENT NUMBER: 120:77596

ORIGINAL REFERENCE NO.: 120:13977a,13980a

TITLE: Preparation and antitumor activity of  
anti-endotoxin lipid A analogs

INVENTOR(S): Christ, William J.; Kawata, Tsutomu; Hawkins, Lynn  
D.; Kobayashi, Seiichi; Asano, Osamu; Rossignol,  
Daniel P.

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 213 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 536969	A2	19930414	EP 1992-309057	19921005
<--				
EP 536969	A3	19940518		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5530113	A	19960625	US 1992-935050	19920825
<--				
PRIORITY APPLN. INFO.:			US 1991-776100	A 19911011
<--				
			US 1992-935050	A 19920825
<--				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 120:77596

ED Entered STN: 19 Feb 1994

GI



AB Title compds. I [R1-R4 = acyl, alkenylcarboxy, alkynylcarboxy; A1, A2 = H, OH, OMe, (CH2)<sub>n</sub>CO<sub>2</sub>H, O(CH2)<sub>n</sub>CO<sub>2</sub>H, O(CH2)<sub>n</sub>PO<sub>3</sub>H<sub>2</sub>, (CH2)<sub>n</sub>OPO<sub>3</sub>H<sub>2</sub>, n = 0-5; X = H, alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, (CH2)<sub>m</sub>OPO<sub>3</sub>H<sub>2</sub>, (CH2)<sub>m</sub>OR<sub>5</sub>, m = 0-14, R<sub>5</sub> = R1-R4; Y = H, OH, halo, OZ(CH2)<sub>m</sub>Me, Z = bond, CO, CO<sub>2</sub>], were prepd. as virucides. Thus, compd. II was prepd. and effectively inhibited in vivo LPS-induced prodn. of tumor necrosis factor (TNF) in mice (ED<sub>50</sub> = 16.2 .mu.g/mouse).

IT 151663-32-0


(prepn. as intermediate in prepn. of disaccharide lipid A analogs as neoplasm inhibitors)

RN 151663-32-0 HCAPLUS

CN .alpha.-D-Glucopyranoside, 2-(phosphonoxy)ethyl 2-deoxy-6-O-[2-deoxy-2-[(1,3-dioxotetradecyl)amino]-3-O-[1-oxo-3-[(1-oxo-5-dodecenyl)oxy]decyl]-4-O-phosphono-.beta.-D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-, 3-(3-hydroxydecanoate) 4-(2-propenyl

carbonate), [3(R),6(R(Z))]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CH=CH—(CH<sub>2</sub>)<sub>5</sub>—Me

IPCI C07H0013-06 [ICM,5]; C07H0017-04 [ICS,5]; C07H0015-04 [ICS,5];  
 C07H0015-06 [ICS,5]; C07H0015-10 [ICS,5]; C07H0015-18 [ICS,5];  
 A61K0031-70 [ICS,5]; C07H0013-04 [ICS,5]  
 IPCR A61K0031-35 [I,A]; A61K0031-351 [I,A]; A61K0031-739 [I,A]; A61P0031-04  
 [I,A]; A61P0031-12 [I,A]; C07D0309-10 [I,A]; C07H0003-04 [I,A];  
 C07H0005-04 [I,A]; C07H0005-06 [I,A]; C07H0007-02 [I,A]; C07H0011-04  
 [I,A]; C07H0013-06 [I,A]; C07H0015-10 [I,A]  
 CC 33-4 (Carbohydrates)  
 Section cross-reference(s): 3, 6, 34  
 IT 2430-94-6 13195-66-9 16383-57-6 19307-20-1, 5-Dodecynoic acid  
 22348-96-5 25941-03-1 26817-68-5 35087-25-3 38972-51-9  
 38972-58-6 38972-73-5 51450-36-3 51721-40-5 51721-41-6  
 56618-58-7 67587-21-7 74124-22-4 76062-98-1 76690-01-2  
 87357-65-1 88222-72-4 97747-17-6 99049-68-0 119471-50-0  
 121524-01-4 126761-03-3, 5-Dodecynenitrile 128313-03-1  
 128387-27-9 130322-00-8 151662-55-4 151662-56-5 151662-57-6  
 151662-58-7 151662-59-8 151662-60-1 151662-61-2 151662-62-3  
 151662-63-4 151662-64-5 151662-65-6 151662-66-7 151662-67-8  
 151662-68-9 151662-69-0 151662-70-3 151662-71-4 151662-72-5  
 151662-73-6 151662-74-7 151662-75-8 151662-76-9 151662-77-0  
 151662-78-1 151662-79-2 151662-80-5 151662-81-6 151662-82-7  
 151662-83-8 151662-84-9 151662-85-0 151662-86-1 151662-87-2  
 151662-88-3 151662-89-4 151662-90-7 151662-91-8 151662-92-9  
 151662-93-0 151662-94-1 151662-95-2 151662-96-3 151662-97-4  
 151662-98-5 151662-99-6 151663-00-2 151663-01-3 151663-02-4  
 151663-03-5 151663-04-6 151663-05-7 151663-06-8 151663-07-9  
 151663-08-0 151663-09-1 151663-10-4 151663-11-5 151663-12-6

151663-13-7	151663-14-8	151663-15-9	151663-16-0	151663-17-1
151663-18-2	151663-19-3	151663-20-6	151663-21-7	151663-22-8
151663-23-9	151663-24-0	151663-25-1	151663-26-2	151663-27-3
151663-28-4	151663-29-5	151663-30-8	151663-31-9	
<del>151663-32-0</del>	151663-33-1	151663-34-2	151663-35-3	
151663-36-4	151663-37-5	151663-38-6	151663-39-7	151663-40-0
151663-41-1	151663-42-2	151663-43-3	151663-44-4	151663-45-5
151663-46-6	151663-47-7	151663-48-8	151663-49-9	151663-50-2
151663-51-3	151663-52-4	151663-53-5	151663-54-6	151663-55-7
151663-56-8	151663-57-9	151663-58-0	151663-59-1	151663-60-4
151663-61-5	151663-62-6	151663-63-7	151663-64-8	151663-65-9
151663-66-0	151663-68-2	151663-69-3	151663-70-6	151663-71-7
151663-72-8	151663-73-9	151663-74-0	151663-75-1	151663-76-2
151663-77-3	151663-78-4	151663-79-5	151663-80-8	151663-81-9
151663-82-0	151663-83-1	151663-84-2	151663-85-3	151663-86-4
151663-87-5	151663-88-6	151663-89-7	151663-90-0	151663-91-1
151663-92-2	151663-93-3	151663-94-4	151663-95-5	151663-96-6
151663-97-7	151663-98-8	151663-99-9	151664-00-5	151664-01-6
151664-02-7	151664-03-8	151763-69-8	151763-70-1	151763-71-2
151763-72-3	151763-73-4	151763-74-5	151763-75-6	151763-76-7
151763-77-8	151763-78-9	151763-79-0	152197-31-4	152219-14-2
152219-16-4	152219-18-6	152219-20-0	152276-35-2	152276-37-4
152276-39-6	152276-41-0	152276-43-2	152276-45-4	152276-47-6
152276-49-8	152276-51-2	152276-53-4	152276-55-6	152276-57-8
152276-59-0	152276-61-4	152308-06-0	152308-08-2	152308-10-6
152308-12-8	152308-14-0	152308-16-2	152308-18-4	152308-20-8
152375-80-9	152375-82-1	152376-87-9	152376-89-1	179893-85-7

(prepn. as intermediate in prepn. of disaccharide lipid A analogs  
as neoplasm inhibitors)

OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS  
RECORD (10 CITINGS)

L48 ANSWER 37 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1990:514809 HCAPLUS Full-text

DOCUMENT NUMBER: 113:114809

ORIGINAL REFERENCE NO.: 113:19439a,19442a

TITLE: Phenol derivatives as platelet activating factor  
inhibitors

INVENTOR(S): Wissner, Allan; Schaub, Robert E.; Sum, Phaik Eng

PATENT ASSIGNEE(S): American Cyanamid Co., USA

SOURCE: Eur. Pat. Appl., 88 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 336142	A2	19891011	EP 1989-104429	19890313
			<--	
EP 336142	A3	19910424		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
NO 8901376	A	19891005	NO 1989-1376	19890331
			<--	
AU 8932394	A	19891005	AU 1989-32394	19890403


			<--	
AU 626844	B2	19920813		
DK 8901600	A	19891005	DK 1989-1600	19890403
			<--	
FI 8901583	A	19891005	FI 1989-1583	19890403
			<--	
ZA 8902447	A	19891227	ZA 1989-2447	19890403
			<--	
JP 02006470	A	19900110	JP 1989-81640	19890403
			<--	
US 5215975	A	19930601	US 1991-763716	19910923
			<--	
US 5234918	A	19930810	US 1991-763714	19910923
			<--	
AU 9228337	A	19930211	AU 1992-28337	19921112
			<--	
US 5411983	A	19950502	US 1993-99037	19930728
			<--	
PRIORITY APPLN. INFO.:			US 1988-177299	A 19880404
			<--	
			US 1989-316721	B1 19890303
			<--	
			US 1991-763714	A3 19910923
			<--	
			US 1991-763716	A1 19910923
			<--	
OTHER SOURCE(S):	MARPAT	113:114809		
ED	Entered STN:	29 Sep 1990		
GI				



AB Title compds. I [X = alkyl, PhO, Ph, alkoxy, etc.; i = 1-3; j = 1-6; Q = RO, ROCOCH2O, RCO2 (R = H, alkyl, alkenyl); Y = OCO, OCH2, OP(O)(O-)O; R1 = alkyl, alkoxy, halo; n = 1-4; A = 5- to 7-membered arom. heterocyclcyl contg. .gtoreq.1N (and which may contain S), (R2)2S+, (R3)3P+; R2 = alkyl; R3 = alkyl, (substituted) Ph] are prepd. Thiazolium phosphate internal salt II (prepd. from PhCHO and glycerol with 7 steps) showed 61.8% inhibition of PAF-induced vascular permeability in guinea pig skin.

IT 127164-65-2P  
(prepn. and reaction of, in prepn. of platelet activating factor inhibitors)

RN 127164-65-2 HCAPLUS  
 CN Phosphoric acid, mono[3-(bromomethyl)phenyl]  
 mono[3-(hexadecyloxy)-2-[(2-methyl-2-propen-1-yl)oxy]propyl] ester  
 (CA INDEX NAME)



IPCI C07F0009-12 [ICM,4]; C07F0009-54 [ICS,4]; C07F0009-65 [ICS,4];  
 C07C0149-46 [ICS,4]; A61K0031-66 [ICS,4]; A61K0031-095 [ICS,4]  
 IPCR A61K0031-095 [I,A]; A61K0031-215 [I,A]; A61K0031-415 [I,A];  
 A61K0031-425 [I,A]; A61K0031-426 [I,A]; A61K0031-44 [I,A];  
 A61K0031-4418 [I,A]; A61K0031-4425 [I,A]; A61K0031-47 [I,A];  
 A61K0031-472 [I,A]; A61K0031-495 [I,A]; A61K0031-50 [I,A];  
 A61K0031-505 [I,A]; A61K0031-685 [I,A]; A61P0001-04 [I,A]; A61P0007-00  
 [I,A]; A61P0007-02 [I,A]; A61P0009-06 [I,A]; A61P0011-00 [I,A];  
 A61P0011-08 [I,A]; A61P0011-16 [I,A]; A61P0017-00 [I,A]; A61P0035-00  
 [I,A]; A61P0037-08 [I,A]; C07C0043-174 [I,A]; C07C0043-178 [I,A];  
 C07C0059-125 [I,A]; C07C0309-73 [I,A]; C07C0381-00 [I,A]; C07C0381-12  
 [I,A]; C07D0213-20 [I,A]; C07D0215-10 [I,A]; C07D0217-10 [I,A];  
 C07D0233-60 [I,A]; C07D0233-68 [I,A]; C07D0233-70 [I,A]; C07D0237-08  
 [I,A]; C07D0239-20 [I,A]; C07D0239-26 [I,A]; C07D0241-12 [I,A];  
 C07D0277-22 [I,A]; C07D0295-04 [I,A]; C07D0521-00 [I,A]; C07F0009-12  
 [I,A]; C07F0009-54 [I,A]; C07F0009-58 [I,A]; C07F0009-60 [I,A];  
 C07F0009-62 [I,A]; C07F0009-6509 [I,A]; C07F0009-6539 [I,A]  
 CC 25-10 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)  
 Section cross-reference(s): 1, 27, 28, 29  
 IT 1708-40-3P 27079-92-1P 54267-06-0P 80350-03-4P 99884-78-3P  
 104216-84-4P 111841-39-5P 111841-45-3P 111841-68-0P  
 121348-74-1P 127164-51-6P 127164-52-7P 127164-53-8P  
 127164-54-9P 127164-55-0P 127164-56-1P 127164-57-2P  
 127164-58-3P 127164-59-4P 127164-60-7P 127164-61-8P  
 127164-62-9P 127164-63-0P 127164-64-1P 127164-65-2P  
 127164-66-3P 127164-67-4P 127164-68-5P 127164-69-6P  
 127164-70-9P, 8-Hydroxy-7-methoxy-1-octene 127164-71-0P  
 127164-72-1P 127164-73-2P 127164-74-3P  
 (prepn. and reaction of, in prepn. of platelet activating factor  
 inhibitors)  
 IT 127164-07-2P 127164-08-3P 127164-09-4P 127164-10-7P  
 127164-11-8P 127164-12-9P 127164-13-0P 127164-14-1P  
 127164-15-2P 127164-16-3P 127164-17-4P 127164-18-5P  
 127164-19-6P 127164-20-9P 127164-21-0P 127164-22-1P  
 127164-23-2P 127164-24-3P 127164-25-4P 127164-26-5P  
 127164-27-6P 127164-28-7P 127164-29-8P 127164-30-1P  
 127164-31-2P 127164-32-3P 127164-33-4P 127164-34-5P  
 127164-35-6P 127164-36-7P 127164-37-8P 127164-38-9P  
 127164-39-0P 127164-40-3P 127164-41-4P 127164-42-5P  
 127164-43-6P 127164-44-7P 127164-45-8P 127164-46-9P  
 127164-47-0P 127164-48-1P 127164-49-2P 127164-50-5P

127190-20-9P 127190-21-0P 127190-22-1P 129008-01-1P  
 (prepn. of, as platelet activating factor inhibitor)  
 OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS  
 RECORD (2 CITINGS)

L48 ANSWER 38 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN  
 ACCESSION NUMBER: 1989:57664 HCAPLUS Full-text  
 DOCUMENT NUMBER: 110:57664  
 ORIGINAL REFERENCE NO.: 110:9549a,9552a  
 TITLE: (Pyridinylmethyl)sulfinylbenzimidazole derivatives  
 as antiulcer agents, their preparation and  
 formulations containing them  
 INVENTOR(S): Alminger, Tomas Boerje; Bergman, Rolf Axel;  
 Bundgaard, Hans; Lindberg, Per Lennart; Sundén,  
 Gunnel Elisabeth  
 PATENT ASSIGNEE(S): Aktiebolag Haessle, Swed.  
 SOURCE: PCT Int. Appl., 96 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8803921	A1	19880602	WO 1987-SE546	19871120
<--				
W: AT, AU, BB, BG, BR, CH, DE, DK, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU, US				
RW: AT, BE, BJ, CF, CG, CH, CM, DE, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
ZA 8708263	A	19880727	ZA 1987-8263	19871103
<--				
IL 84504	A	19941007	IL 1987-84504	19871117
<--				
AU 8783302	A	19880616	AU 1987-83302	19871120
<--				
AU 612129	B2	19910704		
EP 279149	A2	19880824	EP 1987-850362	19871120
<--				
EP 279149	A3	19880831		
EP 279149	B1	19921230		
R: ES, GR				
DD 270531	A5	19890802	DD 1987-309270	19871120
<--				
EP 332647	A1	19890920	EP 1987-908006	19871120
<--				
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 02500744	T	19900315	JP 1988-500255	19871120
<--				
HU 51269	A2	19900428	HU 1987-6196	19871120
<--				
HU 204814	B	19920228		
EP 510719	A1	19921028	EP 1992-108817	19871120
<--				
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				



10/596,747

AT 84032	T	19930115	AT 1987-850362	19871120
			<--	
ES 2052603	T3	19940716	ES 1987-850362	19871120
			<--	
RU 2062778	C1	19960627	RU 1987-4614294	19871120
			<--	
CN 87107309	A	19880824	CN 1987-107309	19871121
			<--	
CN 1023226	C	19931222		
PL 157655	B1	19920630	PL 1987-268927	19871121
			<--	
DK 8803654	A	19880701	DK 1988-3654	19880701
			<--	
NO 8803229	A	19880916	NO 1988-3229	19880720
			<--	
NO 173998	B	19931122		
NO 173998	C	19940302		
FI 8902454	A	19890519	FI 1989-2454	19890519
			<--	
US 5215974	A	19930601	US 1991-654394	19910208
			<--	
LV 10954	B	19960820	LV 1993-1371	19931223
			<--	
LT 3810	B	19960325	LT 1993-1685	19931228
			<--	
PRIORITY APPLN. INFO.:			SE 1986-4998	A 19861121
			<--	
			SE 1986-5551	A 19861223
			<--	
			SE 1987-4049	A 19871016
			<--	
			EP 1987-850362	A 19871120
			<--	
			WO 1987-SE546	A 19871120
			<--	
			US 1988-199263	B2 19880518
			<--	
			US 1989-297606	B1 19890113
			<--	
			US 1989-380040	B1 19891010
			<--	

OTHER SOURCE(S): CASREACT 110:57664; MARPAT 110:57664  
 ED Entered STN: 17 Feb 1989  
 GI




AB The title compds. I [X = S, SO; R1 - R4 = H, C1-8 alkyl, C1-8 alkoxy, alkoxyalkyl, halo, CN, CF3, NO2, etc.; R1R2, R2R3, R3R4 may form (satd. substituted heteroatom-contg. rings); R5 = H, C1-4 alkyl, R6 = H, C1-8 alkyl, C1-8 alkoxy, halo; R7 = H, C1-7 alkyl, C1-7 alkoxy; etc.; R8 = H, C1-8 alkyl, C1-8 alkoxy, halo, etc.; or R6R7 or R7R8 together with the adjacent C atoms in the pyridine ring may form a (satd. O, S, N-contg. ring); Z = OP(:O)(OH)OnR9, OP(:O)(OH)OP(:O)(OH)OnR9, etc.; n = 0 or 1; R9 = H, C1-6 alkyl, etc.], useful as antiulcer agents, were prepd. Pure 1-chloromethyl-6-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and the mono-triethylammonium salt of phosphoric acid monoethyl ester in CH2Cl2 contg. Et3N were mixed together. The solvent was evapd. and the residue was heated at 60.degree. for 5 min. CH2Cl2 was added, distd. off, and the product heated again at 60.degree.. This procedure was repeated 4 times until the reaction was completed. The crude product was purified to give 26% I [X = SO, R1, R2, R4, R5 = H, R3 = R7 = OMe, R6 = R8 = Me, Z = OP(:O)(ONa)OEt] (II). At 1 .mu.mol/kg (administered via the duodenal fistula), II inhibited histamine-induced gastric secretion in dogs by 97%. A syrup contg. sucrose 30, saccharin 0.6, EtOH 5, and II 1, flavoring material 0.05 g, and H2O to 100 mL was prepd.

IT 118381-67-2P

(prepn. of, as antiulcer agent)

RN 118381-67-2 HCAPLUS

CN 1H-Benzimidazole-1-methanol, 6-bromo-2-[[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl)methyl]sulfinyl]-, dihydrogen phosphate (ester), sodium salt (9CI) (CA INDEX NAME)



●x Na

IPCI C07D0401-12 [ICM,4]; A61K0031-415 [ICS,4]

IPCR C07D0401-12 [I,A]; A61K0031-415 [I,A]; A61K0031-4184 [I,A];

A61K0031-44 [I,A]; A61K0031-4427 [I,A]; A61K0031-675 [I,A];

A61P0001-04 [I,A]; A61P0043-00 [I,A]; C07D0401-14 [I,A]; C07D0453-02

[I,A]; C07F0009-6558 [I,A]

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT	118293-04-2P	118293-30-4P	118293-38-2P	118308-64-8P
	118308-65-9P	118308-66-0P	118308-67-1P	118308-68-2P
	118308-69-3P	118308-70-6P	118308-73-9P	118308-74-0P
	118308-75-1P	118308-76-2P	118308-77-3P	118308-78-4P
	118308-79-5P	118381-57-0P	118381-58-1P	118381-59-2P
	118381-60-5P	118381-61-6P	118381-62-7P	118381-63-8P
	118381-64-9P	118381-65-0P	118381-66-1P	118381-67-2P
	118381-68-3P	118381-69-4P	118381-70-7P	118381-71-8P
	118381-72-9P	118381-73-0P	118381-74-1P	118381-75-2P
	118381-76-3P	118381-77-4P	118381-78-5P	118381-79-6P

118381-80-9P 118381-81-0P 118381-82-1P 118381-83-2P  
 118381-84-3P 118381-86-5P 118381-87-6P ~~118381-88-7P~~  
~~118381-89-8P~~ 118381-90-1P 118381-91-2P 118381-92-3P  
 118381-93-4P 118381-94-5P 118381-95-6P 118381-96-7P  
 118381-97-8P 118381-98-9P 118381-99-0P 118382-00-6P  
 118382-01-7P 118382-02-8P 118382-03-9P 118382-04-0P  
 118402-37-2P 118402-38-3P 118402-39-4P 118402-40-7P  
 118402-41-8P

(prepn. of, as antiulcer agent)

OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS  
 RECORD (51 CITINGS)  
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
 RE FORMAT

L48 ANSWER 39 OF 39 HCAPLUS COPYRIGHT 2012 ACS on STN

ACCESSION NUMBER: 1981:90388 HCAPLUS Full-text

DOCUMENT NUMBER: 94:90388

ORIGINAL REFERENCE NO.: 94:14641a,14644a

TITLE: Dental cements

PATENT ASSIGNEE(S): Lion Corp., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 55139311	A	19801031	JP 1979-47074	19790417
			<--	
JP 62057601	B	19871202		
PRIORITY APPLN. INFO.:			JP 1979-47074	A 19790417
			<--	

ED Entered STN: 12 May 1984

GI



AB Dental cements comprise: (1) reagent A contg. phytic acid [83-86-3] or derivs. (I) (R1, R2, R3, R4 = substituted or nonsubstituted C1-12 alkyl and allyl, or H) and, (2) reagent B contg. alkali metal salts. Reagent A and reagent B are mixed in the presence of H2O for hardening. The cements can be used as fillings. For example, reagent A contg. 50% phytic acid and 40% penta-Na phytate [62989-51-9]


and reagent B contg. silica 30, alumina 18, CaF<sub>2</sub> 34, AlF<sub>3</sub> 6 and AlPO<sub>4</sub> 12 parts were prepd.

IT 76653-86-6

(dental cements contg. alkali metal salts and)

RN 76653-86-6 HCAPLUS

CN D-myo-Inositol, 1,2,4,5,6-pentakis(dihydrogen phosphate) 3-(2-propenyl hydrogen phosphate) (9CI) (CA INDEX NAME)



IPCI A61K0006-08

IPCR A61K0006-06 [I,A]; A61K0006-08 [I,A]

CC 63-7 (Pharmaceuticals)

IT 83-86-3 62989-51-9 76653-86-6

(dental cements contg. alkali metal salts and)

=> d his nofile

(FILE 'HOME' ENTERED AT 08:35:19 ON 13 APR 2012)

FILE 'HCAPLUS' ENTERED AT 08:35:32 ON 13 APR 2012

L1 1 SEA SPE=ON ABB=ON PLU=ON US20070293642/PN  
SEL RN

FILE 'REGISTRY' ENTERED AT 08:35:53 ON 13 APR 2012

L2 12 SEA SPE=ON ABB=ON PLU=ON (10025-87-3/BI OR 10029-04-6/BI  
OR 107-21-1/BI OR 112-47-0/BI OR 17435-77-7/BI OR  
752234-97-2/BI OR 752234-98-3/BI OR 752234-99-4/BI OR  
752235-00-0/BI OR 855894-56-3/BI OR 855894-57-4/BI OR  
855894-58-5/BI)

L3 STR

L4 50 SEA SSS SAM L3

L5 STR L3

L6 50 SEA SSS SAM L5

L7 28963 SEA SSS FUL L5

L8 5 SEA SPE=ON ABB=ON PLU=ON L7 AND L2

L9 7 SEA SPE=ON ABB=ON PLU=ON L2 NOT L8

SAV L7 TEMP SAS747/A

L10 STR

L11 32 SEA SUB=L7 SSS SAM L10

L12 797 SEA SUB=L7 SSS FUL L10

L13 244 SEA SPE=ON ABB=ON PLU=ON L12 AND PMS/CI

L14 2 SEA SPE=ON ABB=ON PLU=ON L13 AND L2

L15 5 SEA SPE=ON ABB=ON PLU=ON L12 AND L2

SAV L12 TEMP SAS747A/A

L16 STR

L17 50 SEA SUB=L7 SSS SAM L16

L18 13442 SEA SUB=L7 SSS FUL L16

L19 2 SEA SPE=ON ABB=ON PLU=ON L18 AND L2

SAV L18 TEMP SAS747B/A

L20 14 SEA SPE=ON ABB=ON PLU=ON L12 AND L18

FILE 'HCAPLUS' ENTERED AT 10:08:13 ON 13 APR 2012

L21 8 SEA SPE=ON ABB=ON PLU=ON L20

L22 400 SEA SPE=ON ABB=ON PLU=ON L12

L23 13991 SEA SPE=ON ABB=ON PLU=ON L18

L24 1 SEA SPE=ON ABB=ON PLU=ON L22 AND L1

L25 58 SEA SPE=ON ABB=ON PLU=ON L22 AND PHARM?/SC, SX

L26 44 SEA SPE=ON ABB=ON PLU=ON L25 AND (1802-2003)/PRY,AY,PY

L27 37 SEA SPE=ON ABB=ON PLU=ON L22 AND L23

L28 20 SEA SPE=ON ABB=ON PLU=ON L27 AND (1802-2003)/PRY,AY,PY

L29 2 SEA SPE=ON ABB=ON PLU=ON L21 AND (1802-2003)/PRY,AY,PY

L30 20 SEA SPE=ON ABB=ON PLU=ON L28 OR L29

L31 QUE SPE=ON ABB=ON PLU=ON DENTAL? (5A) (ADHES? OR SEAL? OR  
MATERIAL? OR GLUE? OR BOND)

L32 80 SEA SPE=ON ABB=ON PLU=ON L23 AND L31

FILE 'REGISTRY' ENTERED AT 10:26:55 ON 13 APR 2012

L33 STR L10

L34 0 SEA SUB=L12 SSS SAM L33

10/596,747

L35           24 SEA SUB=L12 SSS FUL L33  
L36           5 SEA SPE=ON ABB=ON PLU=ON L35 AND L2  
              SAV L35 SAS747C/A

FILE 'HCAPLUS' ENTERED AT 10:30:25 ON 13 APR 2012

L37           8 SEA SPE=ON ABB=ON PLU=ON L35  
L38           3 SEA SPE=ON ABB=ON PLU=ON L37 AND (1802-2003)/PRY,AY,PY  
L39           19 SEA SPE=ON ABB=ON PLU=ON L30 NOT L38

FILE 'REGISTRY' ENTERED AT 10:59:55 ON 13 APR 2012

L40           STR L33  
L41           4 SEA SUB=L12 SSS SAM L40  
L42           112 SEA SUB=L12 SSS FUL L40  
              SAV L42 TEMP SAS747D/A

FILE 'HCAPLUS' ENTERED AT 11:01:34 ON 13 APR 2012

L43           30 SEA SPE=ON ABB=ON PLU=ON L42  
L44           5 SEA SPE=ON ABB=ON PLU=ON L43 AND L26  
L45           15 SEA SPE=ON ABB=ON PLU=ON L43 AND (1802-2003)/PRY,AY,PY  
L46           54 SEA SPE=ON ABB=ON PLU=ON L45 OR L26  
L47           48 SEA SPE=ON ABB=ON PLU=ON L46 NOT (38 OR L39)  
L48           39 SEA SPE=ON ABB=ON PLU=ON L47 AND PHARM?/SC,SX

=>